Janssen Research & Development *

Statistical Analysis Plan

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis

Protocol CNTO1959PSA3002; Phase 3
Amendment 3
CNTO1959 (guselkumab)

Status: Approved
Date: 21 March 2019
Prepared by: Janssen Research & Development, LLC
Document No.: EDMS-ERI-146207739

Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP).

Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential.
TABLE OF CONTENTS

TABLE OF CONTENTS ..................................................................................................................... 2

ABBREVIATIONS .......................................................................................................................... 6

SUMMARY OF CHANGES IN AMENDMENT 1 TO THE SAP (APPROVAL DATE: MAY 24, 2018) .................................................................................................................. 8

SUMMARY OF CHANGES IN AMENDMENT 2 TO THE SAP ..................................................... 11

SUMMARY OF CHANGES IN AMENDMENT 3 TO THE SAP ..................................................... 13

1. INTRODUCTION ......................................................................................................................... 18
   1.1. Trial Objectives .................................................................................................................. 18
   1.2. Trial Design ...................................................................................................................... 18
   1.3. Statistical Hypotheses for Trial Objectives ....................................................................... 21
   1.4. Sample Size Justification .................................................................................................. 22
   1.4.1. Primary Endpoint – ACR 20 Response at Week 24 ..................................................... 22
   1.4.2. Major Secondary Endpoint – Change from Baseline in Modified vdH-S Score at Week 24 ......................................................................................................................... 23
   1.5. Randomization and Blinding .............................................................................................. 24
   1.5.1. Randomization ............................................................................................................. 24
   1.5.2. Maintenance of the Blind ............................................................................................ 25
   1.6. Radiographic Image Reading and Scoring ......................................................................... 27

2. GENERAL ANALYSIS DEFINITIONS .................................................................................. 28
   2.1. Visit Windows .................................................................................................................... 28
   2.1.1. Visit Windows for Dosing and PK Analysis ................................................................. 28
   2.1.2. Visit Windows for Radiographic Assessments and Analyses ....................................... 28
   2.2. Pooling Algorithm for Analysis ....................................................................................... 28
   2.3. Analysis Sets .................................................................................................................... 28
   2.3.1. Efficacy Analysis Set(s) ............................................................................................... 28
   2.3.1.1. Full Analysis Set 1 (Week 0 – Week 24) ................................................................ 28
   2.3.1.2. Full Analysis Set 2 (Week 24 – Week 52) ............................................................... 28
   2.3.1.3. Full Analysis Set 3 (Week 52 – Week 100) ............................................................... 28
   2.3.1.4. Full Analysis Set 1 for Structural Damage (Read Campaign 1) .............................. 29
   2.3.1.5. Full Analysis Set 2 for Structural Damage (Read Campaign 2) .............................. 29
   2.3.1.6. Full Analysis Set 3 for Structural Damage (Read Campaign 3) .............................. 29
   2.3.1.7. Per-Protocol Analysis Set (Week 0 – Week 24) ....................................................... 29
   2.3.2. Safety Analysis Set ...................................................................................................... 29
   2.3.3. PK Analysis Set ........................................................................................................... 29
   2.3.4. Immunogenicity Analysis Set ....................................................................................... 30
   2.3.5. Pharmacodynamics Analysis Set ............................................................................... 30
   2.4. Definition of Subgroups ................................................................................................... 30
   2.5. Treatment Failure ............................................................................................................ 31

3. INTERIM ANALYSIS AND DATA MONITORING COMMITTEE REVIEW ..................... 31
   3.1. Interim Analysis ................................................................................................................ 31
   3.2. Data Monitoring Committee ........................................................................................... 31

4. SUBJECT INFORMATION ....................................................................................................... 32
   4.1. Demographics and Baseline Characteristics ................................................................. 32
   4.2. Disposition Information ................................................................................................... 33
   4.3. Treatment Compliance .................................................................................................... 33
   4.4. Treatment Exposure and Study follow-up ...................................................................... 33
   4.5. Protocol Deviations ........................................................................................................ 33
   4.6. Prior and Concomitant Medications ............................................................................... 34

Approved, Date: 21 March 2019
5. Efficacy ................................................................. 34
5.1. General Method of Analysis................................................................. 34
5.2. Analysis Specifications........................................................................ 36
5.2.1. Level of Significance................................................................... 36
5.2.2. Multiplicity Adjustment for Testing Procedures......................... 36
5.2.2.1. US-Specific Multiplicity Adjustment for Testing Procedures...... 37
5.2.2.2. Global(Ex-US) Multiplicity Adjustment for Testing Procedures... 39
5.2.3. Data Handling Rules................................................................. 41
5.2.3.1. Missing Data Non-Responder Imputation (NRI).......................... 41
5.2.3.2. Missing Data Exhaustive Scenario Imputation......................... 41
5.2.3.3. Multiple Imputation (MI).......................................................... 41
5.2.3.3.1. MI Using FCS Regression..................................................... 41
5.2.3.3.2. MI for Binary Endpoints for Tipping Point Sensitivity Analysis of MAR Assumption... 42
5.2.3.3.3. Missing Data Handling for Tipping Point Sensitivity Analysis for Continuous Endpoints...... 42
5.2.3.3.4. 2-Step MI (for X-ray Imaging Data)........................................ 42
5.2.3.4. Missing Data Linear Extrapolation (LEXT)................................. 43
5.2.3.5. Missing Data Last Observation Carried Forward (LOCF)........... 43
5.2.3.6. Missing Data as Missing for Continuous Endpoints.................. 43
5.2.3.6.1. Missing Data Handling for Tipping Point Analysis Evaluating the Assumption of MCAR for Continuous Endpoints... 43
5.2.4. Estimands ................................................................................. 44
5.2.4.1. Composite Strategy............................................................... 44
5.2.4.2. Alternative Composite Strategy................................................ 45
5.2.4.3. Treatment Policy Strategy...................................................... 45
5.2.4.4. Per-Protocol Strategy............................................................. 45
5.3. Primary Efficacy Endpoint(s)......................................................... 46
5.3.1. Definition.................................................................................. 46
5.3.2. Analysis Methods........................................................................ 47
5.3.2.1. Sensitivity and Supplementary Analyses................................. 48
5.3.2.2. Subgroup Analyses................................................................. 49
5.3.2.3. Summary of Analyses Related to the Primary Endpoint of ACR 20 Response at Week 24.......................... 49
5.4. Major Secondary Endpoints......................................................... 51
5.4.1. Change from Baseline in HAQ-DI Score at Week 24....................... 52
5.4.1.1. Definition............................................................................. 52
5.4.1.2. Analysis Methods................................................................. 52
5.4.2. Proportion of Subjects with ACR 50 Response at Week 24, Proportion of Subjects with ACR 50 Response at Week 16, Proportion of Subjects with ACR 20 Response at Week 16, and Proportion of Subjects with ACR 70 Response at Week 24.............................. 53
5.4.2.1. Definition............................................................................. 53
5.4.2.2. Analysis Methods................................................................. 53
5.4.3. Proportion of Subjects who Achieve a Psoriasis IGA Response at Week 24 Among the Subjects with ≥3% BSA Psoriatic Involvement and an IGA Score of ≥2 (mild) at Baseline................................................................. 53
5.4.3.1. Definition............................................................................. 53
5.4.3.2. Analysis Methods................................................................. 53
5.4.4. Change from Baseline in Modified vdH-S Score at Week 24........... 54
5.4.4.1. Definition............................................................................. 54
5.4.4.2. Analysis Methods................................................................. 55
5.4.4.2.1. Sensitivity Analysis............................................................. 55
5.4.4.2.2. Subgroup Analysis............................................................. 57
5.4.5. Change from Baseline in Enthesitis Score at Week 24 and Proportion of subjects with Resolution of Enthesitis at Week 24 in Subjects with Enthesitis at Baseline.............................. 58
5.4.5.1. Definition............................................................................. 58
5.4.5.2. Analysis Methods................................................................. 58
5.4.6. Change from Baseline in Dactylitis Scores at Week 24 and Proportion of subjects with Resolution of Dactylitis at Week 24 in Subjects with Dactylitis at Baseline.............................. 59
5.4.6.1. Definition.........................................................................................................................59
5.4.6.2. Analysis Methods...............................................................................................................59
5.4.7. Change from Baseline in SF-36 PCS Score at Week 24 and Change from Baseline in SF-36 MCS score at Week 24..............................................................................................................60
5.4.7.1. Definition...........................................................................................................................60
5.4.7.2. Analysis Methods...............................................................................................................60
5.4.8. Change from Baseline in DAS28 (CRP) at Week 24............................................................61
5.4.8.1. Definition...........................................................................................................................61
5.4.8.2. Analysis Methods...............................................................................................................61
5.4.9. Summary of Analyses Related to Major Secondary Endpoints............................................62
5.4.10. Additional Tipping Point Analyses.......................................................................................63
5.5. Other Efficacy Variable(s).......................................................................................................64
5.5.1. Efficacy Endpoints Related to Reduction of Signs and Symptoms and Physical Function..................................................................................................................................................65
5.5.1.1. Definition...........................................................................................................................65
5.5.1.1.1. ACR Related Endpoints ..................................................................................................65
5.5.1.1.2. HAQ-DI Related Endpoints ..........................................................................................65
5.5.1.1.3. DAS28 Related Endpoints ...........................................................................................66
5.5.1.1.4. Responders Based on Modified Psoriatic Arthritis Responder Criteria (PsARC)...........66
5.5.1.1.5. Enthesitis Related Endpoints .........................................................................................66
5.5.1.1.6. Dactylitis Related Endpoints .........................................................................................67
5.5.1.1.7. PASDAS Related Endpoints...........................................................................................67
5.5.1.1.8. GRACE Related Endpoints ...........................................................................................68
5.5.1.1.9. mCOPDAI Related Endpoints .........................................................................................69
5.5.1.1.10. DAPSA Related Endpoints...........................................................................................69
5.5.1.1.11. Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA)....................70
5.5.1.1.12. BASDAI Related Endpoints...........................................................................................70
5.5.1.2. Analysis Methods..............................................................................................................71
5.5.2. Efficacy Endpoints Related to Skin Disease.........................................................................76
5.5.2.1. Definitions..........................................................................................................................77
5.5.2.1.1. PASI Related Endpoints..................................................................................................77
5.5.2.1.2. Endpoints Related to DLQI ............................................................................................78
5.5.2.2. Analysis Methods...............................................................................................................78
5.5.3. Other Radiographic Endpoints..............................................................................................80
5.5.3.1. Definition..........................................................................................................................81
5.5.3.2. Analysis Methods..............................................................................................................82
5.5.3.2.1.1. Radiographic Reader’s Agreement..................................................................................85
5.5.4. Other Efficacy Endpoints Related to Health-Related Quality of Life and Health Economics..................................................................................................................................................86
5.5.4.1. Definition..........................................................................................................................87
5.5.4.1.1. SF-36 Questionnaire .....................................................................................................87
5.5.4.1.2. FACIT-Fatigue Questionnaire .......................................................................................87
5.5.4.1.3. EQ-5D Questionnaire ...................................................................................................87
5.5.4.1.4. WPAI Questionnaire ....................................................................................................88
5.5.4.2. Analysis Methods..............................................................................................................89
5.5.5. Other Tipping Point Analyses...............................................................................................92
6. SAFETY ........................................................................................................................................93
6.1. Safety Tables Presentation........................................................................................................93
6.1.1. Summaries Through Week 24...............................................................................................93
6.1.2. Summaries Through Week 52...............................................................................................94
6.1.3. Summaries Through End of Study.........................................................................................94
6.2. Adverse Events........................................................................................................................95
6.3. Clinical Laboratory Tests..........................................................................................................96
6.4. Vital Signs and Physical Examination Findings.........................................................................96
6.5. Electrocardiogram ...................................................................................................................97
6.6. Other Safety Parameters...........................................................................................................97
6.6.1. Suicidal Ideation and Behavior .............................................................................................97
7. PHARMACOKINETICS/PHARMACODYNAMICS .......................................................... 98
   7.1. Pharmacokinetics ............................................................................................. 98
   7.2. Immunogenicity (Antibodies to Guselkumab) .................................................... 100
   7.3. Pharmacodynamics ......................................................................................... 101
   7.4. Pharmacokinetic/Pharmacodynamic Relationships ....................................... 102

REFERENCES ............................................................................................................. 103

APPENDICES ............................................................................................................. 105

APPENDIX 1: RULES APPLIED IN DEFINITIONS OF ENDPOINTS ............................ 105

APPENDIX 2: STATISTICAL HYPOTHESIS ............................................................... 109

APPENDIX 3: DESCRIPTION OF STATISTICAL MODELS ........................................... 113
   1. MIXED-EFFECT MODEL REPEATED MEASURES (MMRM) ............................... 113
   2. CONSTRAINED LONGITUDINAL DATA ANALYSIS (CLDA) MODEL .................. 113
   3. MIXED EFFECT LINEAR GROWTH CURVE MODEL ......................................... 113
   4. MEDIATION ANALYSIS ..................................................................................... 114

APPENDIX 4: SUMMARY OF ANALYSES BASED ON MULTIPLE IMPUTATION ............. 115
ABBREVIATIONS

ACR American College of Rheumatology
AE adverse event
ALT Alanine aminotransferase
ANA Antinuclear antibodies
ANCOVA analysis of covariance
ANOVA Analysis of variance
AST Aspartate aminotransferase
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
BMI Body mass index
BSA Body surface area
CASPAR Classification Criteria for Psoriatic Arthritis
CI confidence interval
CMH Cochran-Mantel-Haenszel
CRF case report form
CRP C-reactive protein
CSR Clinical Study Report
DAS28 Disease Activity Index Score 28
DBL database lock
DICOM Digital Imaging and Communications in Medicine
DIP Distal interphalangeal
DLQI Dermatology Life Quality Index
DMARDS Disease-Modifying Antirheumatic Drugs
DMC Data Monitoring Committee
dsDNA Double-stranded DNA
ECG Electrocardiogram
eCRF electronic case report form
EE Early escape
EQ-5D EuroQol 5 Dimensions Health-Related Quality of Life
FACIT-Fatigue Functional Assessment of Chronic Illness Therapy - Fatigue
FAS Full analyses set
FDA Food and Drug Administration
GDEV Physician’s Global Assessment of Disease Activity
GDPT Patient’s Global Assessment of Disease Activity
GMS Global Medical Safety
GO Gross Osteolysis
HAQ-DI Health Assessment Questionnaire Disability Index
ICH International Conference on Harmonization
IRC Imaging research center
ITT Intent-to-Treat
IWRS interactive web response system
JSN Joint space narrowing
LEF Leflunomide
LEI Leeds Enthesitis Index
LLOQ Lower limit of quantification
LOCF last observation carried forward
LSmeans Least square means
MCP Metacarpophalangeal Joint
MCS Mental Component Score
MDA Minimal Disease Activity
MedDRA Medical Dictionary for Regulatory Activities
mITT Modified Intent to Treat
MMRM Mixed effect repeated measures
MTX Methotrexate
NAPSI Nail Psoriasis Severity Index

Approved, Date: 21 March 2019
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCI-CTCAE</td>
<td>National Cancer Institute - Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>NRJ</td>
<td>Non-responder imputation</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>PAIN</td>
<td>Patient’s assessment of pain</td>
</tr>
<tr>
<td>PASDAS</td>
<td>Psoriatic Arthritis Disease Activity Score</td>
</tr>
<tr>
<td>PASI</td>
<td>Psoriasis Area and Severity Index</td>
</tr>
<tr>
<td>PD</td>
<td>Pharmacodynamic</td>
</tr>
<tr>
<td>PI</td>
<td>principal investigator</td>
</tr>
<tr>
<td>PIC</td>
<td>Pencil in cup</td>
</tr>
<tr>
<td>PIP</td>
<td>proximal interphalangeal</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic(s)</td>
</tr>
<tr>
<td>PRO</td>
<td>patient reported outcome</td>
</tr>
<tr>
<td>PsA</td>
<td>Psoriatic Arthritis</td>
</tr>
<tr>
<td>PsARC</td>
<td>Psoriatic Arthritis Response Criteria</td>
</tr>
<tr>
<td>RA</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cell</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SDC</td>
<td>Smallest detectable difference</td>
</tr>
<tr>
<td>SF-36</td>
<td>36-Item Short Form Survey Instrument</td>
</tr>
<tr>
<td>SJC</td>
<td>Swollen joint count</td>
</tr>
<tr>
<td>SMQ</td>
<td>Standardized MedDRA Query</td>
</tr>
<tr>
<td>SSG</td>
<td>Statistical support group</td>
</tr>
<tr>
<td>SSZ</td>
<td>Sulfasalazine</td>
</tr>
<tr>
<td>SUA</td>
<td>Serious unexpected adverse event</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TF</td>
<td>Treatment failure</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor</td>
</tr>
<tr>
<td>TJC</td>
<td>Tender joint count</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual analog scale</td>
</tr>
<tr>
<td>vH-S</td>
<td>Van der Heijde Sharp</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cell</td>
</tr>
<tr>
<td>WLQ</td>
<td>Work limitations questionnaire</td>
</tr>
<tr>
<td>WPAI</td>
<td>Work productivity and activity impairment</td>
</tr>
</tbody>
</table>
SUMMARY OF CHANGES IN AMENDMENT 1 TO THE SAP (APPROVAL DATE: MAY 24, 2018)

This statistical analysis plan (SAP) was amended to implement the following modifications to the original SAP:

1. Modified Treatment failure rules

2. Modified multiplicity control method to separate US and rest of the world
   - Rest of the world: modified overall control for all endpoints and both dose levels to control 2 doses for the primary endpoints, and control within dose level for primary and all major secondary endpoints
   - US: modified overall control for all endpoints and both dose levels to control selective endpoints and both dose levels by removing highly correlated major secondary endpoints from controlled list

3. Modified the Multiple Imputation (MI) methods
   - Impute the continuous components for binary endpoints instead of the composite binary endpoint itself
   - Use the Full Conditional Specifications (FCS) to replace the imputation first imputed non-monotone missing values and then imputed monotone missing values.
   - Added a 2 step MI for X-ray
   - Added an appendix table to specify details and summarize the MI imputation methods for endpoints with possibility to use MI method

2. Modified/added definition of estimands and list of endpoints using each of the estimand
   - Modified composite estimand for binary endpoints with 4 components for clarity and expanded endpoints using composite estimand from primary and major secondary to all binary endpoints.
   - Modified the treatment policy estimand with 4 components for clarity and expanded endpoints using composite estimand from primary and x-ray endpoints to include change from baseline in HAQ, DAS28(CRP), SF36-PCS and SF36-MCS at Week 24.
   - Replace the treatment efficacy estimand with composite estimand for continuous endpoints and use this estimand for all non-x-ray continuous endpoints.
   - Added an expanded composite estimand to incorporate expanded treatment failure rules and use this estimand as supplementary analysis for the primary endpoint.
3. Added/modified analysis methods

- Modified MMRM by adding the interactions of the fix effects to use a model with full parameters, and added cLDA method if more than 2% subjects have missing baseline measurements.

- For non-x-ray continuous major secondary endpoints, added analysis methods when the data have extreme departure from normality.

- Switched ANCOVA on the original scale from sensitivity analysis to main analysis for change from baseline in vdHS score.

- Changed analysis method of other binary endpoints from GLMM model or logistic regression to CMH test.

- Modified or added sensitivity/supplementary analysis for ACR20 at Week 24.
  a) For composite estimand when the main analysis is based on non-responder imputation, replace the sensitivity analysis based on MAR tipping point analysis to Exhaustive Scenario Imputation tipping analysis to cover all possible scenarios.
  b) Added analyses based on expanded composite estimand.
  c) Added analyses based on per-protocol estimand.

- Added/modified sensitivity analysis for Change from baseline in vDHS score at 24.
  a) Switched ANOVA analysis based on van der Waerden normal score from main analysis to sensitivity analysis.
  b) Added analyses based on 2 step MI.
  c) Modified the name of mixed effect regression model to mixed effect linear curve model and incorporated missing data imputation in this analysis.
  d) Modified completers analysis by using the ANCOVA on original scale from ANOVA on van der Waerden normal score.
  e) To evaluate the MCAR assumption added a 2-dimensional tipping point analysis.

- Modified summary tables of analysis methods to the end of the sections for each type of endpoints.

- Added a section for suicidal ideation and behavior.
Additionally, non-content related wording or formatting changes were made to enhance clarity and to generate 2 consistent SAPs.
SUMMARY OF CHANGES IN AMENDMENT 2 TO THE SAP

This statistical analysis plan (SAP) was amended to implement the following modifications to the original SAP:

1. Section 2.4.
   a. Revised the categories for the race subgroup - #1b
   b. Instead of subgrouping by geographical region defining a subgroup called participating countries - #1g.
   c. Added subgroups #2l, #3d, #3e, and #3f.

2. Added clarification to treatment failure (section 2.5) criterion #1 to include adverse events caused by worsening of PsA.

3. Modified multiplicity control method (section 5.2.2)

4. Added a supplementary analysis for IGA response based on the treatment policy estimand to section 5.4.3 and Table 6.

5. Modified assessment of normality of residuals from MMRM/cLDA models by using Q-Q plots in addition to the Shapiro-Wilks test (sections 5.1 and 5.4.1.2, and Table 6).

6. Added clarification to section 5.2.3.1 regarding the imputation of each variable within its possible range of values.

7. Modified/added clarification to the first step of the 2-step MI procedure in section 5.2.3.3.4.

8. Section 5.4.4.2.1 (in-text as well as Table 5):
   a. Modified sensitivity analyses #4. No longer applying using bootstrapping to estimate the SD.
   b. Modified sensitivity analyses #5, and #6 such that they do not use the Multiple Imputation technique to impute missing vdH-S scores.

9. Subgroup analysis for the change from baseline in vdH-S score (section 5.4.4.2.2 and Table 5) are based on observed data and not MI imputed datasets.

10. Modified the enthesitis scoring for subjects with an incomplete set of 6 evaluated sites at a particular visit (section 5.4.5.1). Removed the use of non-missing site score based imputation to adjust for sites with missing scores.

11. Modified analysis methods for enthesitis and dactylitis related endpoints (sections 5.4.5.2 and 5.4.6.2) in accordance with the multiplicity control method (section 5.2.2).
12. Added clarification to analysis methods for enthesitis and dactylitis related endpoints (sections 5.4.5.2 and 5.4.6.2) that the MI method will be applied to each study separately to obtain the MI datasets for each study.

13. Added the definition for low or very lose disease activity based on the PASDAS score (section 5.5.1.1.7) and a corresponding analysis to Table 8.

14. Added the definition of low disease activity based on the GRACE index score (section 5.5.1.1.8) and a corresponding analysis to Table 8.

15. Added the definition of low disease activity based on the mCPDAI score (section 5.5.1.1.9) and a corresponding analysis to Table 8.

16. Added the definition of remission or low disease activity based on the DAPSA score (section 5.5.1.1.10) and a corresponding analysis to Table 8.

17. Added the definition of very low disease activity (section 5.5.1.1.11) and a corresponding analysis to Table 8.

18. Added the requirement of BASDAI>0 at baseline for the analysis of the change from baseline in BASDAI score (section 5.5.1.1.12 and Table 8).

19. Changed threshold for DLQI to 5 instead of 1 (sections 5.5.2 and 5.5.2.1.2, and Table 9)

20. Added clarification to section 6.4, regarding reporting of abnormalities or changes during physical examination as adverse events.

21. Added section on suicidal ideation (section 6.6)

22. Separated joint evaluability rules for surgical joint procedures and injections administered due to PsA or non-PsA reasons in Appendix 1 (Joint Evaluability Rules for Sign and Symptom Data).

23. Added clarification to Table 12 in Appendix 5
   
a. Imputation variables to be used for MIdataset2.

b. Use of enthesitis-4, which is the tender entheses count based on 4 sites (left and right achilles tendon insertion, and left and right humeral epicondyle lateral) instead of 6 sites at baseline and Week 2, in the imputation of enthesitis scores.

c. Change from baseline at Week 24 in enthesitis score will be calculated among subjects with at least one tender enthesis at baseline.

d. Added footnotes “d”, “e”, and “f”.

Approved, Date: 21 March 2019

EDMS-ERI-196141432

Version: 2.0
SUMMARY OF CHANGES IN AMENDMENT 3 TO THE SAP

1. Revised definition of FAS1-SD. It includes all randomized subjects who received at least 1 (partial or complete) dose of study agent, regardless of whether they had a modified vdh-S score at baseline.

2. Similar revision to the definitions of FAS2-SD and FAS3-SD.

3. Revised the definition of subgroups (section 3.4):
   a. Age at baseline (year): < 45, ≥ 45 and < 65, ≥ 65 (revised definition)
   b. Participating countries: Removed Canada and Germany as they are not participating in this study.
   c. CRP at baseline (mg/dL): < 1, 1-2, ≥ 2 (lab data)
   d. Clarified that the following disease characteristics are assessed at baseline: PsA duration, number of swollen joints, number of tender joints, HAQ-DI, dactylitis, enthesitis, PASI, BSA, and IGA.
   e. Clarified that the subgroup of use of non-biologic DMARDs at baseline is based on the eCRF data and not on IWRS randomization factor.
   f. Removed the category of “any DMARDs” from the subgroup of non-biologic DMARDs at baseline. The revised definition includes only three categories: None, MTX, non-MTX DMARDs.
   g. Edited the descriptors for the reason of discontinuation of prior DMARDs.

4. Added the following paragraph to Section 4

   Subject information will be summarized by randomized treatment group based on the FAS1. Treatment exposure (e.g., number of treatment administrations, and cumulative dose received) and duration of study follow-up time will be summarized by treatment actually received based on the safety analysis set (Section 4.4).

5. Added the following information to Section 5.1 for binary response efficacy endpoints:

   The Mantel Fleiss criterion will be used to determine the appropriateness of using the CMH test at each visit for each treatment pair under comparison. If the Mantel Fleiss criterion is not satisfied the Fisher’s exact test will be used instead of the CMH test to compare the two treatment groups.

   For analyses based on Multiple Imputation, the inferences from the analysis of each imputed data are pooled. The within imputation variance and between imputation variance are combined to estimate the total variance of the stratum adjusted difference of proportions. This estimate of the variance and critical values from the t-distribution are used to calculate the confidence interval for the stratum adjusted difference of proportions. The SAS procedure PROC MIANALYZE is used where the critical value is based on the t-distribution which is different from the analysis not based on...
MI where normal distribution is used. The large number of observations in our data imply that the critical values from the t-distribution are almost identical to the critical values from the standard normal distribution.

The Wilson-Hilferty\textsuperscript{34} transformation is used to pool the p-values from each imputed data set.

For endpoints (resolution of enthesitis and resolution of dactylitis) that are based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002 the analysis will be stratified by the combination of study and randomization stratification factors.

6. For major secondary efficacy endpoints other than radiographic endpoints the analysis will be performed using an ANCOVA model based on MI data and will no longer use a Mixed Effect Repeated Measures or Constrained Longitudinal Data Analysis Model. The previously planned sensitivity analyses using an ANOVA model based on the van der Waerden normal score will not be performed. These changes to the plan are reflected in the edits in Section 5.1 for major secondary continuous efficacy endpoints. Added details regarding the calculation of the confidence intervals and p-values.

7. Revisions to section 5.2.2.1 (US-Specific Multiplicity Adjustment for Testing Procedures); switched order in which the endpoints for enthesitis and dactylitis are tested in the graphical testing procedure.

8. Added section 5.2.2.2 (Global Multiplicity Adjustment for Testing Procedure)

9. Added the following to Section 5.2.3.3.1:

   For categorical endpoints (IGA response, enthesitis resolution, dactylitis resolution), the above imputation will be performed for the respective scores on a continuous scale, then rounded to the nearest integer prior to deriving the response or resolution.

10. Revised the definition of the Treatment Failure Criteria (Section 2.5). The TF criteria are expanded by considering discontinuation of study agent due to other reasons (in addition to lack of efficacy) as a criterion for TF. This is reflected in criterion 1 which now states - Discontinued study agent injections due to any reason.

11. Added a definition for the alternative composite estimand (Section 5.2.4.2).

12. Added the following to Section 5.2.4.3:

   The Treatment Policy Estimand will be analyzed for all major secondary endpoints, and selected endpoints (Table 11a) analyzed at Week 16.
13. In section 5.3.2.1, for the primary endpoint, deleted the supplementary analyses based on the previously defined expanded composite estimand, and added a supplementary analysis based on the alternative composite estimand. This is also reflected in Table 4.

14. Added clarification to Section 5.4 about the analysis sets to be used for psoriasis response of IGA, change from baseline in enthesitis score, resolution of enthesitis, change from baseline in dactylitis score, and resolution of dactylitis.

15. Section 5.4.1.2 reflects changes to the analysis methods for HAQ-DI score as those described in item 6 (above) and in Section 5.1.

16. Sections 5.4.5.2, 5.4.6.2, 5.4.7.2, and 5.4.8.2 reflect changes as those described in item 6 above. These changes are also reflected in Table 6, which summarizes analyses related to major secondary endpoints other than the change from baseline in modified vdB-H-S score.

17. Added section 5.4.10 (Additional Tipping Point Analyses) that describes the tipping point analyses to be performed on the major secondary endpoints based on the Treatment Policy Estimand.

18. In section 5.5.1.2, added that change from baseline in HAQ-DI, DAS28 (CRP), dactylitis, and enthesitis scores will be analysed using an ANCOVA model on MI data.

19. Added endpoint - Proportion of subjects with an IGA score of 0 (cleared) at Week 16 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline – to Section 5.5.2.

20. In section 5.5.2 - changed the requirement for baseline DLQI score to be >1 instead of ≥5 for the endpoint:

   “Proportion of subjects who achieve a DLQI score of 0 or 1 by visit through Week 100 among the subjects with baseline DLQI score > 1 and with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline”

21. In Section 5.5.3 the following 3 endpoints were changed from:

   Proportion of subjects with radiographic progression (based on the smallest detectable change [SDC]) from baseline by visit through Week 100.

   Proportion of subjects with radiographic joint erosion progression (based on SDC) from baseline by visit through Week 100.

   Proportion of subjects with radiographic JSN progression (based on the SDC) from baseline by visit through Week 100.

   To,

   Proportion of subjects without radiographic progression (based on the smallest detectable change [SDC]) from baseline by visit through Week 100.
Proportion of subjects without radiographic joint erosion progression (based on SDC) from baseline by visit through Week 100.

Proportion of subjects without radiographic JSN progression (based on the SDC) from baseline by visit through Week 100.

22. Added 2 endpoints - Change from baseline in FACIT-fatigue score at Week 24 by ACR 20 response at Week 24, and Proportion of subjects who achieve ≥ 4-point improvement from baseline in FACIT-fatigue score at Week 24 by ACR 20 response at Week 24 – to Section 5.5.4.

23. In Section 5.5.4.2:

- added that the change from baseline in SF-36 PCS score and SF-36 MCS score will be also be analyzed using an ANCOVA model on MI data.

- Added a description of additional analyses for FACIT-Fatigue.

24. Added section 5.5.5, that explains tipping point analyses to be performed for endpoints other than the primary and major secondary endpoints.

25. Added the following 3 references:


26. Added description of Mediation Analysis to Appendix 3.

27. Revisions to Table 12:

a. Changed “at” to “through” for endpoints HAQ-DI score, DAS28 (CRP) score, Enthesitis score, Dactylitis score, PCS score, and MCS score.

b. Added MI for IGA change from baseline through Week 24.

c. Edit to footnote “a”:

i. MIdataset2 is different from MIdataset1 as the joint scores used in DAS 28 (CRP) are different from those used in ACR. (current footnote)

ii. MIdataset2 is different from MIdataset1 as it is based on a different Estimand. The same, MIdataset2, data set can be used for both HAQ-DI and DAS28(CRP) analyses. (previous footnote).
d. Edit to footnote “c”:

i. Levels for Treatment and Discontinuation of treatment DT combination (HDT: High dose of Guselkumab + disc. of treatment; LDT: Low dose of Guselkumab + disc. of treatment): placebo, HDT, LDT (current footnote)

ii. Levels for Treatment and Discontinuation of treatment DT combination (HDT: High dose of Guselkumab + disc. of treatment; LDT: Low dose of Guselkumab + disc. of treatment): placebo, HDT0-16, HDT16-24, H, LDT0-16, LDT16-24, L. HDT0-16 and HDT16-24 maybe collapsed into HDT, and LDT0-16 and LDT16-24 maybe collapsed into HDT if there are too many missing values within the subgroup of incomplete cases (previous footnote).

e. Edits to footnote “d”:

i. Enthesitis-4 is the tender entheses count based on 4 sites (left and right achilles tendon insertion, and left and right humeral epicondyle lateral) instead of 6 sites. Only baseline, Week 2, Week 4 are included as ancillary variables. (current footnote)

ii. Enthesitis-4 is the tender entheses count based on 4 sites (left and right achilles tendon insertion, and left and right humeral epicondyle lateral) instead of 6 sites at baseline and Week 2. (previous footnote)

28. Revised Appendix 2. Deleted the appendix that was numbered Appendix 3 in SAP Amendment 2. Renumbered Appendices 4 and 5 to 3 and 4, respectively.

Note that changes to the analytic approaches in these amended SAPs also apply to the analysis plan for the Integrated Summary of Efficacy.
1. INTRODUCTION

This statistical analysis plan contains definitions of analysis sets, derived variables, and statistical methods for the analysis of efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD), and Immunogenicity in the CNTO1959PSA3002 study.

1.1. Trial Objectives

Primary Objective

The primary objective of this study is to evaluate the efficacy of SC administration of guselkumab 100 mg in subjects with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Secondary Objectives

The secondary objectives are to assess the following for guselkumab treatment in subjects with active PsA:

- Efficacy in improving psoriatic skin lesions
- Improvement in physical function
- Inhibition of progression of structural damage
- Efficacy in improving general and disease specific health-related quality of life and patient-reported health outcomes
- Safety
- PK, PD, and immunogenicity

1.2. Trial Design

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study of guselkumab in subjects with active PsA who are biologic naïve and have had inadequate response to standard therapies (e.g., non-biologic DMARDs, apremilast, NSAIDs). The study consists of a screening phase of up to 6 weeks, a blinded treatment phase of approximately 2 years (i.e., 100 weeks) including a placebo controlled period from Week 0 to Week 24 and an active treatment period from Week 24 to Week 100, and a safety follow-up phase of 12 weeks after the last administration of study treatment. An overview of the study design is provided in Figure 1.
At Week 0, approximately 684 subjects who have met the study inclusion and exclusion criteria are to be randomized in a blinded fashion in a 1:1:1 ratio to 1 of the following 3 treatment groups using permuted block randomization stratified by baseline non-biologic DMARD (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ], leflunomide [LEF]) use (yes, no) and the most recent available CRP value prior to randomization (<2.0, ≥2.0 mg/dL):

- **Group I** (n=228): Guselkumab 100 mg SC every 4 weeks (q4w) from Week 0 through Week 100.
- **Group II** (n=228): Guselkumab 100 mg SC at Weeks 0, 4, then every 8 weeks (q8w) (at Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo SC at other visits to maintain the blind.
- **Group III** (n=228): Placebo SC q4w from Week 0 to Week 20 and then cross over at Week 24 to receive guselkumab 100 mg SC q4w from Week 24 through Week 100.
Through the study, stable doses of concomitant NSAIDs, oral corticosteroids, and selected non-biologic DMARDs (limited to MTX, SSZ, HCQ, LEF, see Table 1) will be allowed but are not required. At Week 16, subjects in all treatment groups who have <5% improvement from baseline in both swollen and tender joint counts will be considered as meeting early escape (EE) criteria and will be allowed to initiate or increase the dose of one of the permitted concomitant medications up to the maximum dose allowed as specified in Table 1, as selected by the investigator. Titration to a stable dose of the medication should be completed for subjects qualifying for EE by the Week 24 visit. Note that subjects who did not meet EE criteria should not initiate any new treatment for PsA through Week 52.

<table>
<thead>
<tr>
<th>Permitted Concomitant Medications for PsA</th>
<th>Maximum Dose Allowed</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs and other analgesics</td>
<td>Marketed dose approved in the country where the study is being conducted</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
<td>Equivalent to 10 mg/day of prednisone</td>
</tr>
<tr>
<td>Non-biologic DMARDS:</td>
<td></td>
</tr>
<tr>
<td>Methotrexate (MTX)</td>
<td>25 mg/week</td>
</tr>
<tr>
<td>Sulfasalazine (SSZ)</td>
<td>3 g/day</td>
</tr>
<tr>
<td>Hydroxychloroquine (HCQ)</td>
<td>400 mg/day</td>
</tr>
<tr>
<td>Leflunomide (LEF)</td>
<td>20 mg/day</td>
</tr>
</tbody>
</table>

a. Permitted concomitant medications are not supplied by the Sponsor.
b. Subjects may not be receiving more than one non-biologic DMARD from baseline through Week 52. After Week 52 and through the end of the study, subjects may receive another non-biologic DMARD.
c. It is recommended that all subjects taking MTX in this study receive at least 5 mg oral folate or 5 mg folinic acid weekly. Guidelines for dose adjustment in the event of MTX toxicity are included in the Trial Center File.

At Week 24, all subjects who are still on treatment in the placebo group (Group III) will cross over to receive guselkumab 100 mg SC q4w from Week 24 through Week 100. Subjects in the guselkumab groups (Groups I and II) will remain on the same dose regimen at Week 24 and after, that is, there will be no change to the dose regimen.

Starting from Week 52, subjects with ongoing PsA disease activity in all treatment groups will be allowed to initiate any of the permitted concomitant medication (and combinations of them) as specified in Table 1, at the investigator’s discretion, or increase the dose(s) of permitted concomitant medication(s) up to the maximum dose(s) allowed.
Subjects will be followed for adverse events (AE) and serious adverse events (SAE) up to 12 weeks following the last study treatment administration.

The end of the study is defined as the last visit for the last subject. The last visit is the last safety follow-up visit for subjects who complete the Week 100 study treatment and for subjects who terminate study treatment prior to Week 100.

There are 3 planned DBLs in this study. Each of these 3 DBLs will result in a study report. The first DBL will occur when all subjects randomized in this study have either completed the Week 24 assessments or terminated study participation prior to the Week 24 visit (referred to as Week 24 DBL hereafter). The second DBL will occur when all subjects randomized in this study have either completed the Week 52 assessments or terminated study participation prior to the Week 52 visit (referred to as Week 52 DBL hereafter). The third DBL will occur when all subjects randomized in this study have either completed their final safety visit (approximately 12 weeks after the last administration of study agent) or have terminated study participation [referred to as Final (Week 112) DBL hereafter].

The primary endpoint of this study is the proportion of subjects who achieve a 20% improvement from baseline in the American College of Rheumatology criteria (ACR 20) at Week 24 (refer to Section 5.3 for endpoint definition and analyses). This endpoint was chosen because it is well-accepted by regulatory authorities and the clinical PsA community. Additionally, there are 14 major secondary endpoints in the study (Section 5.4 – definitions and analyses methods). The primary and major secondary endpoints will be analyzed at Week 24 DBL.

The study will remain blinded for the duration of the trial, until after the final DBL. Selected Sponsor personnel will be unblinded at Week 24 and Week 52 DBLs for the purposes of performing data analysis and data review. The details regarding the Sponsor personnel that will be unblinded at each DBL will be provided in the Data Release Plans.

An independent, external Data Monitoring Committee (DMC) will monitor the safety of the study in an unblinded fashion on a regular basis and whenever deemed necessary. Additional details related to DMC are provided in Section 3.2.

1.3. Statistical Hypotheses for Trial Objectives

The primary endpoint of this study is proportion of subjects who achieved an ACR 20 response at Week 24 (refer to Section 5.3 for endpoint definition and analyses). This endpoint was chosen because it is well-accepted by regulatory authorities and the clinical PsA community.
The hypotheses related to the primary endpoint are that:

1. treatment with guselkumab 100 mg SC q4w is superior to treatment with placebo SC with respect to reduction of PsA signs and symptoms as measured by proportion of subjects who achieved an ACR 20 response at Week 24 (**primary hypothesis**); and

2. treatment with guselkumab 100 mg SC at Week 0, Week 4 and then q8w is superior to treatment with placebo SC with respect to reduction of PsA signs and symptoms as measured by proportion of subjects who achieved an ACR 20 response at Week 24 (**major secondary hypotheses**).

The first hypothesis is the **primary hypothesis** for this study. If the first hypothesis achieves the statistical significance at a 2-sided α-level of 0.05, the study will be considered positive.

In addition to the primary endpoint, there are 14 major secondary endpoints in this study (refer to Section 5.4 for endpoint definitions and analyses). The hypotheses related to the major secondary endpoints (**all are major secondary hypotheses**) are provided in Appendix 2.

For hypothesis testing order and multiplicity adjustment, refer to Section 5.2.2.

1.4. Sample Size Justification

The sample size selection was determined based on the primary endpoint of proportion of subjects who achieve ACR 20 response at Week 24 and the major secondary endpoint of change from baseline in modified vdH-S score at Week 24.

1.4.1. Primary Endpoint – ACR 20 Response at Week 24

In the Phase 3 CNTO1275PSA3001 PsA study with ustekinumab, the ACR 20 response rates at Week 24 were 22.8%, 42.4% and 49.5%, respectively, for the placebo, ustekinumab 45 mg, and ustekinumab 90 mg treatment groups. In the Phase 2 CNTO1959PSA2001 PsA study with guselkumab, the ACR 20 response rates at Week 24 were 18.4% and 58.0%, respectively, for the placebo and guselkumab 100 mg treatment groups.

For this study, assuming a 45% ACR 20 response rate in the guselkumab group and a 25% ACR 20 response rate in the placebo group, a sample size of 228 subjects per treatment group (684 in total) will provide a power of approximately 99% to detect a significant treatment difference at a 2-sided significance level of α=0.05. The sample size was also evaluated based on the following assumptions:

- 20% to 25% ACR 20 response rates at Week 24 in subjects treated with placebo
- 40% to 50% ACR 20 response rates at Week 24 in subjects treated with guselkumab

Table 2 provides the statistical power under various assumptions using a 2-sided chi-square test.
Table 2: Statistical Power for Treatment Difference in ACR 20 Response at Week 24

<table>
<thead>
<tr>
<th>Sample size per arm</th>
<th>ACR 20 Response Rate</th>
<th></th>
<th></th>
<th>Power</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo Group</td>
<td>Guselkumab Group</td>
<td>Difference (Δ)</td>
<td></td>
</tr>
<tr>
<td>228</td>
<td>20%</td>
<td>40%</td>
<td>20%</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>228</td>
<td>20%</td>
<td>45%</td>
<td>25%</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>228</td>
<td>25%</td>
<td>45%</td>
<td>20%</td>
<td>99%</td>
</tr>
<tr>
<td>228</td>
<td>25%</td>
<td>50%</td>
<td>25%</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>228</td>
<td>30%</td>
<td>50%</td>
<td>20%</td>
<td>99%</td>
</tr>
</tbody>
</table>

1.4.2. Major Secondary Endpoint – Change from Baseline in Modified vdH-S Score at Week 24

For change from baseline in modified vdH-S score, subjects in each treatment group can be considered a mixture of 2 subpopulations: 1 subpopulation with a change score of 0 and 1 subpopulation with a change score sampled from a normal distribution. Therefore, the distribution of the vdH-S change scores is determined by 3 parameters: the probability that a subject has a change score of 0, mean of the normal distribution, and standard deviation (SD) of the normal distribution. The overall mean (ie, crude mean) of the change scores for a treatment group is the overall average of the change scores among all subjects (including both subpopulations 1 and 2) in that treatment group.

In the Phase 3 CNTO1275PSA3001 PsA study with ustekinumab, the following statistics were observed on change from baseline in modified vdH-S score at Week 24:

- The overall mean (SD) of change from baseline in modified vdH-S score at Week 24 (after excluding one extreme outlier who had a change score of 58) was 0.92 (2.15), 0.28 (1.94), and 0.17 (1.45) in the placebo, ustekinumab 45 mg and 90 mg treatment groups, respectively.
  - Approximately 49%, 47%, and 46% subjects had a change score of 0 in the placebo, ustekinumab 45 mg and 90 mg treatment groups, respectively.
    - Approximately 40% of 0’s in each group were ‘true’ 0’s (that is, a difference of ≤ 2 and an average of 0 in the reader-level vdH-S scores from the 2 readers selected).
  - Excluding the true 0’s, the mean (SD) change score (after excluding extreme outlier) was 1.59 (2.60), 0.47 (2.50), and 0.32 (1.96) in the placebo, ustekinumab 45 mg and 90 mg treatment groups, respectively (ie, the subjects from the normal distributions). Excluding all 0’s, the mean (SD) change score for the 3 groups was 1.82 (2.75), 0.52 (2.64), and 0.32 (1.96).

For this study, assuming an overall mean change of 0.9 from baseline in modified vdH-S score in the placebo group, and an overall mean change of 0.3 in the guselkumab group, and a standard deviation of 2.5 for each treatment group, a sample size of 228 subjects per treatment group (684 in total) will provide a power of approximately 90% to detect a significant treatment difference
at a 2-sided significance level of $\alpha=0.05$. The sample size was also evaluated based on the following assumptions:

- The overall mean difference in change from baseline in modified vdH-S score at Week 24 between the placebo group and a guselkumab group ranges from 0.6 to 0.8.
  - 40% – 50% subjects in each treatment group have a change score of 0 from baseline in modified vdH-S score at Week 24 (i.e., the subpopulation with a change score of 0).
  - For the other subjects (those from the normal distributions), the SD of the normal distributions is 2.5 for all treatment groups and the mean of the normal distribution is 1.80 for the placebo group.

Table 3 provides the statistical power under various assumptions. The statistical power was estimated based on 10000 simulations with treatment comparison performed at each simulation using an analysis of variance (ANOVA) test on the van der Waerden normal score. Under these assumptions, the study power ranges approximately from 89% to 99%.

<table>
<thead>
<tr>
<th>Placebo Group</th>
<th>Overall Mean</th>
<th>% subjects without change</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rest of subjects</td>
<td>Overall mean</td>
<td>45%</td>
<td>0.71</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>45%</td>
<td>0.35</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50%</td>
<td>0.60</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50%</td>
<td>0.20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50%</td>
<td>0.55</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50%</td>
<td>0.18</td>
</tr>
</tbody>
</table>

**Note** that, if the SD of the normal distributions is 3.0, the power will go down to as low as approximately 80%.

### 1.5. Randomization and Blinding

#### 1.5.1. Randomization

A central randomization is to be implemented in this study using an interactive web response system (IWRS). When a subject is eligible for randomization at a study site, the randomization requestor at that study site will contact the IWRS using the requester’s own user identification and personal identification number and provide the relevant subject details to uniquely identify that subject. Based on a computer-generated randomization schedule prepared before the study under the supervision of the Sponsor, the IWRS will then assign a unique treatment code, which will dictate the treatment assignment and matching study agent kit for that subject.
At Week 0, approximately 684 subjects will be randomized in a blinded fashion in a 1:1:1 ratio to 1 of the following 3 treatment groups:

- **Group I** (n=228): Guselkumab 100 mg q4w
  - Subjects in this group will receive guselkumab 100 mg q4w from Week 0 through Week 100.

- **Group II** (n=228): Guselkumab 100 mg at Weeks 0, 4, then q8w
  - Subjects in this group will receive guselkumab 100 mg at Weeks 0, 4, and then q8w (at Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) with placebo at other visits (at Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96), i.e., an administration q4w with either guselkumab or placebo, to maintain the blind.

- **Group III** (n=228): Placebo q4w
  - Subjects in this group will receive placebo q4w from Week 0 to Week 20 and then cross over at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 100.

To assure relatively even treatment balance within each stratum defined by baseline use of non-biologic DMARD (yes, no) and the most recent available CRP value prior to randomization (<2.0, ≥2.0 mg/dL), randomization at Week 0 is determined using permuted block randomization stratified by baseline use of non-biologic DMARD (yes, no) and the most recent available CRP value prior to randomization (<2.0, ≥2.0 mg/dL). Specific details are provided in the IWRS Project Requirements Specification Biostatistical Addendum for CNTO1959PsA3002.

At Week 24, all subjects who randomized to placebo at Week 0 and who are still on study treatment at Week 24 will be switched to guselkumab 100 mg q4w by the IWRS to receive guselkumab 100 mg q4w starting from Week 24.

### 1.5.2. Maintenance of the Blind

The study blind will be maintained for the duration of the study, until after the final DBL at end of study.

To maintain the study blind, the study agent container will have a multipart label with directions for use and other information, but not the identity of the study agent, on each part. One part of the label is designed to be torn off, separated from the study agent container, and attached to the subject’s source documents. The rest of the label will remain affixed to the study agent container. Thus, the study agent assigned to a subject will be linked between the container and the subject without breaking the study blind. The study agent kit number will be entered in the electronic case report form (eCRF) or other equivalent data capture method when the drug is administered. The investigator will not be provided with treatment codes, but the codes will be maintained within the IWRS, which has the functionality to allow the investigator to break the blind for an individual subject when there is a need based on medical judgment.
Data that may potentially unblind the treatment assignment (i.e., study agent serum concentrations, antibodies to study agent) will be handled with special care to ensure that the integrity of the blind is maintained and the potential for bias is minimized. This may include making special provisions, such as segregating the data in question from view by the investigators, clinical team, or others as appropriate.

An investigator may be unblinded to a given subject’s treatment allocation when specific emergency treatment would be dictated by knowing the treatment status of the subject. In such cases, the investigator may determine the identity of the treatment by contacting the IWRS provider. It is strongly recommended that the investigator contact the Sponsor or its designee if possible to discuss the situation prior to unblinding via IWRS. Telephone contact with the Sponsor or its designee will be available 24 hours per day, 7 days per week. In the event that the investigator is unable to contact the Sponsor, or emergency unblinding is considered medically necessary, the investigator may determine the identity of the treatment via IWRS. However, the Sponsor must be informed as soon as possible. The date, time, and reason for the unblinding must be documented in the appropriate section of the eCRF, and in the source document. The documentation received from the IWRS indicating the code break must be retained with the subject's source documents in a secure manner (e.g., sealed envelope) so as to not unblind the treatment assignment to the subject, the study site, or Sponsor personnel. The investigator is also advised not to reveal the study treatment assignment to the subject, the study site, or Sponsor personnel. Subjects who have had their treatment assignment unblinded are expected to continue to return for scheduled evaluations. Further study agent administrations should be discussed with the study responsible physician.

A given subject’s treatment assignment may be unblinded to the Sponsor, Institutional Review Board/Independent Ethics Committee (IRB/IEC), and site personnel to fulfill regulatory reporting requirements for suspected unexpected serious adverse reactions (SUSARs). A separate code break procedure will be available for use by Janssen Global Medical Safety (GMS) to allow for unblinding of individual subjects to comply with specific requests from regulatory or health authorities.

A group of prospectively identified Sponsor individuals will be unblinded at the Week 24 DBL and Week 52 DBL for the purposes of performing data analysis and review. Identification of sponsor personnel who will have access to the unblinded data at subject-level and who will have access to the unblinded data at group-level will be documented in the Data Release Plan prior to unblinding at the Week 24 DBL and Week 52 DBL. Investigative sites and subjects will remain blinded to treatment assignment for the duration of the study, till after the Final (Week 112) DBL.

An independent, external DMC will monitor the safety of the study in unblinded fashion on a regular basis and whenever deemed necessary. In addition, the Sponsor Medical Monitor will review safety data in a blinded manner as the study is ongoing. The DMC’s roles and responsibilities, the safety data for DMC review, and other related information (such as, the general procedures, communications, etc.) is defined and documented in the DMC charter.
1.6. Radiographic Image Reading and Scoring

In this study, radiographic images will be read in 3 read campaigns:

- Read Campaign 1: Baseline and Week 24 (or End of Treatment if the subjects are not to continue the scheduled visits through Week 24 and no radiograph was obtained within the previous 6 weeks) for the Week 24 DBL.
- Read Campaign 2: Baseline, Week 24, and Week 52 (or End of Treatment if no radiograph was obtained within the previous 6 weeks) for Week 52 DBL.
- Read Campaign 3: Baseline, Week 24, Week 52, and Week 100 (or End of Treatment if no radiograph was obtained within the previous 6 weeks) for Final DBL.

Adjudication will be conducted in all read campaigns. During each read campaign, the designated radiographic images will be evaluated independently by the 2 primary readers and, in the case of adjudication, by the adjudicator.

Refer to Section 5.4.4.1 and Appendix 1 for scoring method and adjudication criteria.

The radiographic images from a subject at all time points during a given read campaign will be presented to the readers in random order. To maintain objectivity in the evaluations, the readers will be blinded to treatment group, subject’s demographics, and the time point identity.

The radiographic images will be presented to the readers electronically using workstations and high-resolution monitors. All study image data received will be processed and saved in Digital Imaging and Communications in Medicine (DICOM) format. During this process, relevant electronic header information (e.g., subject identifiers) will be blinded within the digital data set. When presented with an image, the reader will evaluate and score for erosions and joint space narrowing (JSN) of individual joints in a region. Once the reader completes the assessments for erosion/JSN, the scores will be locked and changes to completed assessments will not be permitted.

In order to assess intra-reader variability, images of 10% of subjects will be randomly selected and re-read by each of the 2 primary readers in all Read Campaigns.

The intra-reader and inter-reader variability will be monitored by the Sponsor. A high variability is defined as the interclass correlation coefficient (ICC) < 0.5, or smallest detectable change (SDC) > 5, or an absolute difference of ≥ 10 between readers’ change scores or in a reader’s change score between the initial read and the corresponding subsequent re-read. In the event of high variability, the source of greatest variance will be investigated and, if possible, corrective action such as retraining of the readers will be taken.

For more details regarding imaging acquisition, standardization, reading, and data transfer, refer to the Imaging Charter.
2. GENERAL ANALYSIS DEFINITIONS

2.1. Visit Windows

2.1.1. Visit Windows for Dosing and PK Analysis

All post-baseline visits from Baseline through Week 24 will have a visit window of ± 4 days, and from Week 28 through Week 100 will have a visit window of ± 1 week (7 days). The final safety follow-up at Week 112 will have a visit window of ± 2 weeks (14 days).

For PK analyses, if a subject has an administration outside the visit window at a visit, the concentration data collected at and after that visit will be excluded from the by-visit data analyses.

2.1.2. Visit Windows for Radiographic Assessments and Analyses

The windows for taking radiographs of hands and feet at respective scheduled visits are specified in the protocol.

An analytical window of ± 8 weeks inclusive will be used in radiographic data analyses at all scheduled visits (Weeks 0, 24, 52, and 100). Radiographs taken at end of study treatment will be slotted based on the analysis window to the appropriate visits to be included in the data analysis.

2.2. Pooling Algorithm for Analysis

Data from all investigational centers/sites will be pooled for analyses.

2.3. Analysis Sets

2.3.1. Efficacy Analysis Set(s)

2.3.1.1. Full Analysis Set 1 (Week 0 – Week 24)

The full analysis set 1 (FAS1) includes all randomized subjects who received at least 1 dose (complete or partial) of study agent. This analysis set will be used for the efficacy analyses of non-radiographic endpoints through Week 24.

2.3.1.2. Full Analysis Set 2 (Week 24 – Week 52)

The full analysis set 2 (FAS2) includes all randomized subjects who were still on study treatment at Week 24. This analysis set will be used for the efficacy analysis of non-radiographic endpoints from Week 24 through Week 52.

2.3.1.3. Full Analysis Set 3 (Week 52 – Week 100)

The full analysis set 3 (FAS3) includes all randomized subjects who were still on study treatment at Week 52. This analysis set will be used for the efficacy analyses of non-radiographic endpoints from Week 52 through Week 100.
2.3.1.4. **Full Analysis Set 1 for Structural Damage (Read Campaign 1)**

The full analysis set 1 for structural damage (FAS1-SD) includes all randomized subjects who received at least 1 (partial or complete) dose of study agent. This analysis set is the same as Full Analysis Set 1 (FAS1) and is labeled as FAS1-SD to indicate that this analysis set will be used for the efficacy analyses of radiographic endpoints through Week 24 based on data generated from Read Campaign 1.

2.3.1.5. **Full Analysis Set 2 for Structural Damage (Read Campaign 2)**

The full analysis set 2 for structural damage (FAS2-SD) includes all randomized subjects who were still on study treatment at Week 24. This analysis set is the same as Full Analysis Set 2 (FAS2) and is labeled as FAS2-SD to indicate that this analysis set will be used for the efficacy analysis of radiographic endpoints from Week 24 through Week 52 based on data generated from Read Campaign 2.

2.3.1.6. **Full Analysis Set 3 for Structural Damage (Read Campaign 3)**

The full analysis set 3 for structural damage (FAS3-SD) includes all randomized subjects who were still on study treatment at Week 52. This analysis set is the same as Full Analysis Set 3 (FAS3) and is labeled as FAS3-SD to indicate that this analysis set will be used for the analyses of radiographic endpoints from Week 52 through Week 100 based on data generated from Read Campaign 3.

In the efficacy analyses, subjects will be analyzed per the randomized treatment groups they were assigned to, regardless of the treatments they actually received.

2.3.1.7. **Per-Protocol Analysis Set (Week 0 – Week 24)**

The per-protocol analysis set (PPAS) includes all subjects in FAS1 who met all inclusion and exclusion criteria and had no major protocol deviations that could have impacted efficacy assessment per clinical judgement. This analysis set will be used for the analyses of selected efficacy endpoints through Week 24. Subjects to be excluded from this analysis will be identified prior to the Week-24 DBL and un-blinding.

In the efficacy analyses, subjects will be analyzed according to the randomized treatment groups they were assigned to, regardless of the treatments they actually received.

2.3.2. **Safety Analysis Set**

The safety analysis set includes all subjects who received at least 1 (partial or complete) dose of study agent, i.e., the treated population.

In the safety analyses, subjects will be analyzed per the treatment they actually received, regardless of the treatments they are randomized to.

2.3.3. **PK Analysis Set**

The PK analysis set includes all subjects who received at least 1 complete dose of guselkumab and had at least 1 valid blood sample drawn for PK analysis.
In the PK analyses, subjects will be analyzed per the treatment they actually received, regardless of the treatments they are randomized to.

2.3.4. **Immunogenicity Analysis Set**

The immunogenicity analysis set includes all subjects who received at least 1 (partial or complete) dose of guselkumab and who have appropriate samples for detection of antibodies to guselkumab (i.e., subjects with at least 1 sample obtained after their first dose of guselkumab).

In the immunogenicity analyses, subjects will be analyzed per the treatment they actually received, regardless of the treatments they are randomized to.

2.3.5. **Pharmacodynamics Analysis Set**

The pharmacodynamics (PD) analysis set includes all subjects who received at least 1 (partial or complete) dose of study agent, i.e., the treated population.

In the PD analyses, subjects will be analyzed per the treatment they actually received, regardless of the treatments they are randomized to.

2.4. **Definition of Subgroups**

To evaluate the consistency in the primary efficacy endpoint (proportion of subjects who achieve ACR 20 at Week 24) and the major secondary endpoint of structural damage (change from baseline in vdH-S score at Week 24) over demographics, baseline characteristics, prior and baseline medication use, subgroup analyses will be performed. The subgroups include, but are not limited to, the following:

1. **Demographic subgroups**
   a. Gender: Male, Female
   b. Race: White, Other
   c. Age at baseline (year): < 45, ≥ 45 and < 65, ≥ 65
   d. Body weight at baseline (kg): ≤ 90, > 90
   e. Body weight at baseline (kg): (quartiles)
   f. Body mass index at baseline: Normal [< 25], Overweight [≥ 25 to < 30], Obese [≥ 30]
   g. Participating countries: Poland, Russia, Ukraine, Western countries (USA and Spain), Other countries (combining countries in Asia and Eastern European countries other than Poland, Russia and Ukraine)

2. **Baseline disease characteristics subgroups**
   a. PsA duration at baseline (year): < 1, ≥ 1 to < 3, ≥ 3
   b. PsA subtype: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, spondylitis with peripheral arthritis
   c. Number of swollen joints at baseline: < 10, 10 to 15, > 15
   d. Number of tender joints at baseline: < 10, 10 to 15, > 15
   e. HAQ-DI at baseline: < 1, 1 to 2, > 2
   f. CRP at baseline (mg/dL): < 1, 1-2, ≥ 2 (lab data)
g. CRP at baseline (mg/dL): (quartiles)
h. Dactylitis at baseline: Yes, No
i. Enthesitis at baseline: Yes, No
j. PASI at baseline: <12, ≥ 12 to < 20, ≥ 20
k. BSA at baseline: < 3%, ≥ 3% to < 10%, ≥ 10% to < 20%, ≥ 20%
l. IGA at baseline: <2, ≥2

3. Prior and baseline medication use subgroups:
   a. Use of non-biologic DMARDs (MTX, SSZ, HCQ, LEF) at baseline: Yes, No (eCRF)
   b. Oral corticosteroids at baseline: Yes, No
   c. NSAIDs at baseline: Yes, No
   d. Number of prior non-biologic treatments including DMARDs, systemic immunosuppressive drugs, and apremilast: 0, 1, 2, ≥3.
   e. Non-biologic DMARDs (MTX, SSZ, HCQ, LEF) at baseline: None, MTX, non-MTX DMARDs
   f. Reason for discontinuation of prior DMARDs: Efficacy - inadequate response (IR), safety - contraindication or intolerance (but not IR), Other

Note that some of the above subgroup cut-off points may be changed if there are no or few subjects within a subgroup category.

2.5. Treatment Failure

A subject will be considered a treatment failure (TF) from the earliest date that the subject meets any of the following TF criteria onward through Week 24:

1. Discontinued study agent injections due to any reason.
2. Terminated study participation due to any reason.
3. Initiated or increased the dose of non-biologic DMARD (MTX, SSZ, HCQ, LEF) or oral corticosteroids over baseline for PsA.
4. Initiated protocol prohibited medications/therapies for PsA.

All subjects who meet criterion 2 will always meet criterion 1.

3. INTERIM ANALYSIS AND DATA MONITORING COMMITTEE REVIEW

3.1. Interim Analysis

No interim analysis is planned for this study.

3.2. Data Monitoring Committee

An independent, external DMC has been established to monitor data on an ongoing basis to ensure the continuing safety of the subjects while participating in this study. All subjects are to be followed by the DMC from the first dose administrated through at least the Week 24 DBL. The DMC consists of 3 members (including 2 medical experts in the relevant therapeutic areas and 1 statistician) who are independent of the Sponsor. None of the members is participating in
the current study. An independent statistical support group (SSG), not affiliated to the sponsor, supports the DMC and serves the liaison between the DMC and the sponsor.

The major function of the DMC is to monitor the safety of the study agent by reviewing the serious adverse events (SAEs) each month and by periodically reviewing the interim study safety data every 4-month. After each review, the DMC is to make recommendations regarding the continuation of the study or, in the event that any unanticipated serious events occur, placing the study on hold or stopping the study.

The DMC will have access to unblinded data and review tabulated safety summaries (if appropriate) and any additional data as deemed necessary during the conduct of the study. No formal statistical hypothesis testing is planned.

The content of the safety summaries, the DMC role and responsibilities and the general procedures (including communications) and their recommendations on the study conduct are defined and documented in the DMC charter, which will be finalized prior to the first DMC review.

In addition, during the study, the Sponsor's study responsible physician (or designee) will regularly review blinded safety data from the sites and notify the DMC and appropriate Sponsor personnel of any issues.

4. **SUBJECT INFORMATION**

Subject information will be summarized by randomized treatment group based on the FAS1. Treatment exposure (e.g., number of treatment administrations, and cumulative dose received) and duration of study follow-up time will be summarized by treatment actually received based on the safety analysis set (Section 4.4).

4.1. **Demographics and Baseline Characteristics**

Demographic and baseline characteristic variables will be descriptively summarized by randomized treatment group. No formal statistical comparison is planned. P-values will not be provided.

Demographic variables to be summarized will include sex, race, age, height, baseline weight, and baseline body mass index (BMI). Baseline characteristic variables to be summarized will include, but not be limited to, baseline disease characteristics of PsA (e.g., duration of disease, PsA subtypes, baseline efficacy assessments), medical history, prior exposure to non-biologic medications, prior joint procedures/injections, and baseline medication usage for PsA.

In addition, balance between randomized treatment groups will also be explored for the subpopulations used for analyses below:

- subjects with baseline ≥ 3% body surface area (BSA) psoriatic involvement and an IGA score of ≥ 2 (mild) at baseline (for skin disease related endpoint analyses).
- subjects with enthesitis at baseline
- subjects with dactylitis at baseline

### 4.2. Disposition Information

The number of subjects screened, randomized and treated will be summarized by geographic region, country, and investigational site.

Disposition will also include tabulations, by randomized treatment group, of the number of subjects who discontinued study agent administration early and the primary reasons for discontinuation of study agent administration early, and the number of subjects who discontinued study participation early and the primary reason for discontinuation of study participation early. Tabulations by randomized treatment group will also be provided for subjects who met EE criteria at Week 16 and for subjects who met 1 or more TF criteria as defined in Section 2.5.

In addition, subjects who were randomized but never treated and subjects who met any TF criteria will be presented in data listings.

### 4.3. Treatment Compliance

Treatment compliance will be assessed by the number of study agent administrations completed versus the number of study agent administrations planned.

Tabulations of the number of subjects by the study agent lot(s) and by treatment assigned versus treatment received will also be provided.

### 4.4. Treatment Exposure and Study follow-up

The overall treatment exposure (e.g., duration of treatment exposure, number of treatment administrations, and cumulative dose received) and duration of study follow-up time will be descriptively summarized by treatment actually received based on the safety analysis set, ie, all treated subjects.

### 4.5. Protocol Deviations

Subjects with major protocol deviations, defined as having the potential to impact subjects’ rights, safety or well-being, or the integrity and/or result of the clinical trial, will be listed or descriptively summarized by randomized treatment group. The major protocol deviations will be grouped into the following 5 categories:

- Developed study withdrawal criteria but not withdrawn
- Entered the study without satisfying study selection criteria
- Received a disallowed concomitant treatment
- Received wrong treatment or incorrect dose
- Other

The study selection criteria will be grouped into the following 5 categories: PsA disease criteria, medication criteria, laboratory criteria, medical history criteria, and other.
Protocol deviation in study agent administrations includes missing doses, incorrect doses, and treatments administered out of the dosing windows defined in Section 2.1.1.

4.6. Prior and Concomitant Medications

Prior medications taken for PsA and/or psoriasis (e.g., non-biologic DMARDs, apremilast, and NSAIDS) will be summarized by randomized treatment group.

Subjects taking concomitant medications for PsA and/or psoriasis at baseline and post-baseline will be tabulated by drug and randomized treatment group. Additionally, selected concomitant medications may be tabulated by randomized treatment group.

5. EFFICACY

5.1. General Method of Analysis

In general, descriptive statistics, such as mean, standard deviation (SD), median, inter quartile (IQ) range, minimum, and maximum for continuous variables, and counts and percentages for discrete variables will be used to summarize most data.

Statistical comparison between a guselkumab group (100 mg q4w or 100 mg at Weeks 0, 4 and then q8w) and the placebo group will be performed by visit through Week 24. No treatment comparison will be performed after Week 24.

Binary Response Efficacy Endpoints

For binary response efficacy endpoints, treatment comparisons will generally be performed using a Cochran-Mantel-Haenszel (CMH) test stratified by baseline use of non-biologic DMARD (yes, no) and most recent CRP value prior to randomization (<2.0 mg/dL, ≥ 2.0 mg/dL). The magnitude of the treatment difference will be estimated by the difference in response rates between the guselkumab and placebo groups with a 95% confidence interval (CI) calculated based on Wald statistics. In these analyses, subjects with missing data will be imputed as not achieving the response as described in Section 5.2.3.1.

The Mantel Fleiss criterion will be used to determine the appropriateness of using the CMH test at each visit for each treatment pair under comparison. If the Mantel Fleiss criterion is not satisfied the Fisher’s exact test will be used instead of the CMH test to compare the two treatment groups.

For analyses based on Multiple Imputation, the inferences from the analysis of each imputed data are pooled. The within imputation variance and between imputation variance are combined to estimate the total variance of the stratum adjusted difference of proportions. This estimate of the variance and critical values from the t-distribution are used to calculate the confidence interval for the stratum adjusted difference of proportions. The SAS procedure PROC MIANALYZE is used where the critical value is based on the t-distribution which is different from the analysis not based on MI where normal distribution is used. The large number of observations in our data
imply that the critical values from the t-distribution are almost identical to the critical values from the standard normal distribution.

The Wilson-Hilferty\textsuperscript{34} transformation is used to pool the p-values from each imputed data set.

For endpoints (resolution of enthesitis and resolution of dactylitis) that are based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002 the analysis will be stratified by the combination of study and randomization stratification factors.

**Major Secondary Continuous Efficacy Endpoints**

For the major secondary continuous endpoints (Section 5.4) and related continuous efficacy endpoints in Section 5.5.5, treatment comparisons will be performed using an ANCOVA model based on MI data. The MI method will be applied to impute the missing value under the assumption of missing at random (MAR). The estimate of the mean change from baseline is the average of the mean change taken over all the MI data sets. The estimate of the variance of the mean change from baseline is the weighted sum of the average within-imputation variance and the between-imputation variance. The confidence interval for the mean change from baseline uses critical values from the t-distribution. The treatment difference between each guselkumab group versus the placebo group will be tested for each imputation dataset and then the analysis results across all imputation datasets will be combined. The treatment difference in the change from baseline is estimated by the average of the treatment differences over the MI data sets. The estimate of the variance of the treatment difference in the change from baseline is the weighted sum of the average within-imputation variance and the between-imputation variance, under the assumption of homogeneity of variance between treatment groups for performing ANCOVA within each imputation dataset. The confidence interval is based on the critical values from the t-distribution.

The ANCOVA model will be based on the original scale and will include treatment group, baseline score, baseline use of non-biologic DMARD (yes, no and most recent CRP value prior to randomization (<2.0 mg/dL, ≥2.0 mg/dL) as the explanatory factors. The model will include data from all the 3 treatment groups.

For endpoints (change from baseline in enthesitis and change from baseline in dactylitis) that are based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002, the ANCOVA model will include treatment group, baseline score, and the combination of study and randomization stratification factors as the explanatory factors. The model will include data from all 3 treatment groups.

**Other Continuous Efficacy Endpoints**

For all other continuous efficacy endpoints, treatment comparisons will be performed using a MMRM model or a cLDA Model (Appendix 3). The model will include all available data from the 3 treatment groups through Week 24. The treatment difference between a guselkumab group
and the placebo group will be estimated by the difference in the LSmeans. The 95% CIs for the differences in LSmeans and p-values will be calculated.

In addition, graphical data displays (eg, line plots) and subject listings may also be used to summarize/present the data.

5.2. Analysis Specifications

5.2.1. Level of Significance

The overall type I error will be controlled among the primary and major secondary endpoints at 5% as specified in Section 5.2.2.

5.2.2. Multiplicity Adjustment for Testing Procedures

This study has 1 primary endpoint (proportion of subjects who achieved an ACR 20 response at Week 24) and 14 major secondary endpoints. With 15 endpoints and 2 treatment comparisons for each of these endpoints, there are a total of 30 hypotheses to be tested.

The primary hypothesis in this study is that treatment with guselkumab 100 mg SC q4w is superior to treatment with placebo SC with respect to reduction of PsA signs and symptoms as measured by proportion of subjects who achieved an ACR 20 response at Week 24. Due to regional differences in regulatory requirements on multiplicity control from health authorities, two multiplicity control procedures are pre-specified. Details for the US-specific multiplicity adjustment are provided in Section 5.2.2.1, and for the Global(ex-US) multiplicity adjustment procedure are provided in Section 5.2.2.2.

With respect to enthesitis and dactylitis, important soft tissue manifestations of PsA, the resolution of enthesitis and resolution of dactylitis endpoints will be tested by combining data from studies CNTO1959PSA3001 and CNTO1959PSA3002 to provide a more robust comparison with greater power than using data only from study CNTO1959PSA3002. The rationale for combining the two studies for testing the 2 hypotheses associated with each of these 2 endpoints is based on the consideration of a relatively small sample of subjects with enthesitis or dactylitis at baseline. As treatment comparisons for these endpoints are only meaningful in subjects with enthesitis or dactylitis at baseline, the treatment comparisons are extremely underpowered for CNTO1959PSA3001 and slightly under powered for CNTO1959PSA3002, to detect a clinically meaningful difference between each Guselkumab treatment group vs placebo. The study design and populations of these two studies are in general quite similar and therefore are not a hindrance to the pooling of data from these studies. The data in each treatment group from the two studies will be pooled; however, the data from the two Guselkumab dose groups will not be combined. For each treatment comparison between each Guselkumab dose and placebo based on the combined study data, treatment effects for that Guselkumab dose in each study separately are required to be numerically positive to further justify pooling.

There will be total of 38 hypotheses. This includes the hypotheses pertaining to tests based on pooled data from the two studies. Refer to Appendix 2 for the list of all hypotheses to be tested.
5.2.2.1. **US-Specific Multiplicity Adjustment for Testing Procedures**

The multiple comparison procedure pre-specified to address the requirement of the Food and Drug Administration (FDA) of the United States (US) for family-wise control of the primary and major secondary endpoints is described in this section. Per FDA review comment dated 03OCT2017 [IND 124177 – Guselkumab (CNTO 1959) – Guidance regarding statistical analysis plans for CNTO1959PSA3001 and CNTO1959PSA3002 submitted on August 10, 2017], only the primary and major secondary endpoints that are important and assess different attributes of disease will be controlled.

In addition to the primary endpoint, ACR20 at Week 24, 7 major secondary endpoints are identified as important and assess different attributes of the disease:

- Proportion of subjects who achieved a psoriasis IGA response at Week 24 among the subjects with ≥ 3% BSA psoriatic involvement and an IGA score of ≥ 2 at baseline
- Change from baseline in HAQ-DI score at Week 24
- Change from baseline in modified van der Heijde-Sharp (vdH-S) score at Week 24
- Change from baseline in SF-36 PCS at Week 24
- Proportion of subjects with resolution of dactylitis at Week 24 among the subjects with dactylitis at baseline with combined data from studies CNTO1959PSA3002 and CNTO1959PSA3002
- Proportion of subjects with resolution of enthesitis (based on the Leeds Enthesitis Index [LEI]) at Week 24 among the subjects with enthesitis at baseline with combined data from studies CNTO1959PSA3002 and CNTO1959PSA3002
- Change from baseline in SF-36 MCS at Week 24.

The overall Type I error of the treatment comparisons of both doses versus placebo for the primary and the 7 selected major secondary endpoints will be controlled at a significance level of ≤ 0.05. Refer to Appendix 2 for the 16 hypotheses to be tested and controlled with the graphical procedure as specified in Figure 2. For all endpoints specified in the graphical procedure, both adjusted and nominal p-values will be provided. In the instance that an adjusted p-value is not significant, the nominal p-value must only be interpreted as supportive.

The method of controlling the type I error across the testing of the hypotheses is described below and in Figure 2.

The 2 hypotheses associated with the endpoint of the change from baseline at Week 24 in MCS will be tested only for study CNTO1959PSA3002.
Figure 2: US-Specific Multiple Comparison Procedure

Some major secondary endpoints that are important but assess similar attributes of the disease as those that are included in Figure 2 are listed below:

- ACR 20 at Week 16, ACR 50 at Week 16, ACR 70 at Week 24, and DAS28 (CRP) change from baseline at Week 24 are closely related to the primary endpoint (ACR 20 at Week 24) in assessing PsA signs and symptoms.

- The change from baseline in dactylitis score at Week 24 with combined data from CNTO1959PSA3001 and CNTO159PSA3002 is closely related to the proportion of subjects with resolution of dactylitis at Week 24 with combined data from CNTO1959PSA3001 and CNTO159PSA3002.

- The change from baseline in enthesitis score at Week 24 with combined data from CNTO1959PSA3001 and CNTO159PSA3002 is closely related to the proportion of subjects with enthesitis at Week 24 with combined data from CNTO1959PSA3001 and CNTO159PSA3002.

When an endpoint included in Figure 2 (ACR 20 at Week 24, or proportion of subjects with resolution of dactylitis at Week 24, or proportion of subjects resolution of enthesitis at week 24) is significant for a guselkumab dose group versus the placebo group, correlated major secondary endpoints which are not included in Figure 2 as specified above will be tested for that guselkumab dose group versus the placebo group at a 2-sided α-level of 0.05 without strict control of the overall type I error. A total of 14 tests fall in this category of weakly controlled hypothesis tests. Refer to Appendix 2 for the list of these 14 hypotheses:

Nominal p-values for the proportion of subjects with resolution of dactylitis at Week 24, the proportion of subjects with resolution of enthesitis at Week 24, the change from baseline in the dactylitis, and the change from baseline in the enthesitis using data from CNTO1959PSA3002 only. Refer to Appendix 2 for the list of these 8 hypotheses. The treatment comparisons are underpowered for these hypotheses.
5.2.2.2. **Global(Ex-US) Multiplicity Adjustment for Testing Procedures**

There are 2 hypotheses for the primary endpoint with 2 treatment comparisons:

- The Guselkumab 100 mg q4w group is superior to placebo group as measured by ACR20 response at Week 24 (**primary hypothesis**).

- The Guselkumab 100 mg at Weeks 0, 4, and then q8w group is superior to placebo group as measured by ACR20 response at Week 24.

These 2 hypotheses will be tested in a fixed sequence in the order specified above. The overall type I error of treatment comparison for the primary endpoint be controlled at a significance level of \( \leq 0.05 \). If the primary hypothesis achieves statistical significance at a 2-sided \( \alpha \)-level of 0.05, the study will be considered positive. If the primary hypothesis does not achieve statistical significance (ie, the Guselkumab 100mg q4w dose group comparison against placebo is not significant), the treatment group comparison for the second hypothesis will not be formally tested and the p-value for the treatment group comparison of the Guselkumab 100mg at Weeks 0, 4, and then q8w group against placebo will be considered nominal.

For each Guselkumab dose group, the overall Type I error of treatment comparison for primary and the selected major secondary endpoints will be controlled at a significance level of \( \leq 0.05 \) as specified below:

- The hypotheses for the selected major secondary endpoints for a Guselkumab dose group will be formally tested only if the primary endpoint is significant for that Guselkumab dose group. For each Guselkumab dose group, the overall Type I error of treatment comparison for the selected major secondary endpoints will be controlled at a significance level of \( \leq 0.05 \) according to the graphical procedure shown in Figure 3. Refer to Appendix 2 for the 24 hypotheses for the major secondary endpoints to be tested and controlled as specified in Figure 3. For all endpoints specified in the graphical procedure, both adjusted and nominal p-values will be provided. In the instance that an adjusted p-value is not significant, the nominal p-value must only be interpreted as supportive.

- If the primary endpoint is not significant for that Guselkumab dose group, all treatment group comparisons for the major secondary endpoints for that Guselkumab dose group will not be formally tested and the p-values for the treatment group comparisons will be considered nominal.

Nominal p-values will be reported for the major secondary endpoints of the change from baseline in the dactylitis and enthesitis scores with data combined from CNTO1959PSA3001 and CNTO1959PSA3002. Nominal p-values will also be reported for proportion of subjects with resolution of dactylitis at Week 24 with data combined from CNTO1959PSA3001 and
CNTO1959PSA3002, the proportion of subjects with resolution of enthesitis at Week 24 with data combined from CNTO1959PSA3001 and CNTO1959PSA3002, the change from baseline in the dactylitis score at Week 24 using data from CNTO1959PSA3002 only, and the change from baseline in the enthesitis score using data from CNTO1959PSA3002 only. Refer to Appendix 2 for the list of these 12 hypotheses. The treatment comparisons are underpowered for these hypotheses.

Figure 3: Global Multiple Comparison Procedure
5.2.3. Data Handling Rules

5.2.3.1. Missing Data Non-Responder Imputation (NRI)

For response efficacy endpoints, subjects with missing response status will be considered non-responders.

5.2.3.2. Missing Data Exhaustive Scenario Imputation

For selected response efficacy endpoints, the exhaustive scenario tipping point analyses will be performed to evaluate the deviation of the imputation of all missing data as non-responder, by varying the amount of non-responder and responder imputation for missing data.

Let $T_A$ be the total number of imputed values to-be-varied in the Active arm, where $i$ of them will be set to ‘Yes’ response and $(T_A-i)$ of them set to ‘No’ response. In the same vein, let $T_P$ be the total number of imputed values to-be-varied in the Placebo arm, where $j$ of them will be set to ‘Yes’ response and $(T_P-j)$ of them set to ‘No’ response. The range of $i$ is from 0 to $T_A$, and a range of $j$ is from 0 to $T_P$, which is an ‘exhaustive approach’.

5.2.3.3. Multiple Imputation (MI)

5.2.3.3.1. MI Using FCS Regression

Under the assumption of missing at random (MAR), multiple imputation (MI) will be used to impute the missing data for the continuous/ordinal measurements. The missing data will be imputed using the predicted value from an imputation model using the Full Conditional Specification (FCS) regression method for any missing pattern. Each variable will be restricted to only impute within its possible range of values (e.g., HAQ Score may only be imputed to within 0-3. The explanatory variables in the imputation model include imputation variables and ancillary variables which are specified in Table 12. For these variables all measurements from baseline through Week 24 are included.

The number of imputations (N) and the starting seeds are specified in Table 12 (Appendix 4).

For the composite continuous endpoints (such as DAS28), the above imputation will be performed on components with missing data and then the composite score will be derived based on the imputed components.

For categorical endpoints (IGA response, enthesitis resolution, dactylitis resolution), the above imputation will be performed for the respective scores on a continuous scale, then rounded to the nearest integer prior to deriving the response or resolution.

For the composite binary endpoints (such as ACR 20), the above imputation will be performed on each component with missing data and then response status will be determined based on such imputed components.
The treatment comparisons between a guselkumab group versus the placebo group will be performed using the analysis method specified for each of the N imputation datasets. The analysis results from all the N imputation datasets will be combined according to Rubin\textsuperscript{25}, and the p-value for testing the treatment difference will be obtained.

5.2.3.3.2. MI for Binary Endpoints for Tipping Point Sensitivity Analysis of MAR Assumption

For selected binary endpoints, the tipping point analyses based on imputed data by MI will be performed to evaluate the impact of missing data when deviating from MAR assumption.

- A pair of deltas (e.g., Dg = -0.1, Dp = 0.2) will be added to the predicted response rates of each missing data from the MI method depending on guselkumab or placebo group.
- With the new response rate, the missing response will be imputed for N (e.g., N=200) times to generate N multiple imputations based on a Bernoulli distribution. Treatment comparisons will then be performed same as treatment comparison with MI.
- The range of delta values include the scenarios where subjects on guselkumab have worse outcomes than subjects on placebo.

5.2.3.3.3. Missing Data Handling for Tipping Point Sensitivity Analysis for Continuous Endpoints

For the change from baseline in selected endpoints, tipping point analyses based on imputed data by MI will be performed to evaluate the impact of missing data when deviating from the MAR assumption.

- A delta (e.g., Dg = 0.2, Dp = 0.1) will be added to the imputed value for each subject with missing value from the MI depending on whether the subject is in the guselkumab or placebo group.
- With the new datasets, treatment comparisons will be performed similar to treatment comparisons with MI data.
- The analysis will be repeated for a range of Dg and Dp by varying Dg and Dp independently, including the scenarios where subjects on guselkumab have worse outcomes than subjects on placebo.

5.2.3.3.4. 2-Step MI (for X-ray Imaging Data)

Due to the slow progression in structural damage and over a short period of time, it is reasonable to assume that progression in structural damage is linear. To utilize all available post-treatment data that are collected outside of the analytical window for Week 24 and to properly account for uncertainty, missing Week 24 data, from subjects with an x-ray measurement at baseline and at a timepoint prior to week 24, will be imputed multiple times using a mixed effect linear growth curve model (Appendix 3) and multiple imputation.

1. Only subjects with postbaseline data will be included to fit the model. The missing data will be sampled N times from the subject specific distribution of predictive change at week 24 from MLGC model.
2. Missing data from subjects with only a baseline x-ray measurement will be imputed once with the FCS regression method (Section 5.2.3.3) for each imputed dataset from the 1st step.

5.2.3.4. Missing Data Linear Extrapolation (LEXT)

For comparison to historical radiographic data analyses, the missing values of selected continuous radiographic endpoint(s) will be imputed using linear extrapolation (LEXT), i.e., the predicted value at the time of interest using a linear regression model based on all observed values (including baseline) prior to the visit of interest for each applicable subject. When no post-baseline value is available, the missing value will be replaced by the baseline value. For a continuous composite endpoint, LEXT will be applied first to each of its missing components (hand erosion scores, foot erosion scores, hand JSN scores, and foot JSN score) and then the value of the composite endpoint will be derived based on the imputed components.

The LEXT method will be used for missing data imputation in sensitivity analysis 2 of change from baseline in modified vdH-S score at Week 24 (Section 5.4.4.2.1).

5.2.3.5. Missing Data Last Observation Carried Forward (LOCF)

For comparison to historical radiographic data analyses, the missing values of selected continuous radiographic endpoint(s) will be imputed using the last observation (including baseline) carried forward (LOCF). For a continuous composite endpoint, LOCF will be applied to its missing components first and then the value of the composite endpoint will be derived based on the imputed components.

The LOCF method will be used for missing data imputation in sensitivity analysis 3 of change from baseline in modified vdH-S score at Week 24 (Section 5.4.4.2.1).

5.2.3.6. Missing Data as Missing for Continuous Endpoints

For continuous endpoints, when treatment comparisons are performed using a Mixed-Effect Model Repeated Measures (MMRM) or Constrained Longitudinal Data Analysis (cLDA) Model (Appendix 3), all available data from the 3 treatment groups through Week 24 will be included. Missing data will not be imputed. Under the assumption of MAR, the missing data will be accounted for through correlation of repeated measures in the model.

5.2.3.6.1. Missing Data Handling for Tipping Point Analysis Evaluating the Assumption of MCAR for Continuous Endpoints

For the change from baseline in the modified vdH-S score, tipping point analyses based on observed data will be performed to evaluate the impact of missing data when deviating from the MCAR assumption

- An ANCOVA model will be fitted to obtain the LS mean for each treatment group and SE of LS mean based on subjects with observed data.

- The LS mean of subject with missing data will be assumed to be LS mean of subjects with observed data plus a delta (e.g., Dg =0.2, Dp =0.1) for each treatment group.
• The overall LSmean will be obtained as the weighted average of the LSmean of subjects with observed data and with missing data. The treatment comparisons will be based on the F test using overall LSmean difference and SE of LSmean from the Analysis of Covariance model from 1st step

• The analysis will be repeated for a range of Dg and Dp by varying Dg and Dp independently, including the scenarios where subjects on guselkumab have worse outcomes than subjects on placebo.

5.2.4. Estimands
The same population, ie, all subjects with active psoriatic arthritis who are biologic naive will be used for all estimands defined below. The FAS1 (Section 2.3.1.1) or a subset of FAS1 so that the endpoint measurement is meaningful, will be used to analyze data.

5.2.4.1. Composite Strategy
The Composite Strategy assesses the treatment effects not only based on the variable measurements, but also based on intercurrent events defined in TF criteria. When subjects maintain their background PsA medications at their baseline levels, the values based on the variable measurements will be used. If a subject met any of the TF criteria the subject will be a non-responder for response variables and will have a score of no improvement for continuous variables for signs and symptoms. This estimand acknowledges that meeting the TF criteria is an unfavorable outcome.

Variables:

• Binary: The endpoint (e.g. ACR 20) is defined as responders who had not met any TF criteria prior to the specific visit at which the endpoint was assessed.

• Continuous: The endpoint is defined as change from baseline score prior to meeting TF criteria and 0 (no improvement) after meeting TF criteria. This is based on the placebo response observed in prior PsA studies: the over-time mean improvements in the placebo group is generally greater than 0 by a meaningful amount. Therefore, no change is considered an extremely unfavorable outcome.

Intercurrent Events: The intercurrent event is captured through variable definitions.

Population level summary:

• Binary: difference in proportion of responders between guselkumab group and placebo group.
• Continuous: difference in mean changes between guselkumab group and placebo group.

The Composite Estimand will be analyzed for all efficacy endpoints through Week 24.
5.2.4.2. **Alternative Composite Strategy**

The Alternative Composite Strategy is similar to the Composite Strategy described in Section 5.2.4.1, however, discontinuation of study agent due to reasons other than lack of efficacy (including adverse events caused by worsening of PsA) are not considered treatment failure. In other words, the intercurrent events include TF criterion 2, 3, 4, and a subset of criterion 1 from those listed in section 2.5.

This estimand is only used at Week 24, the last visit of the placebo-controlled period.

The Alternative Composite Estimand (Binary) will be analyzed for ACR 20 at Week 24.

5.2.4.3. **Treatment Policy Strategy**

The treatment policy strategy is to use all observed data collected for the endpoint. The occurrence of the intercurrent event is irrelevant: the value for the variable of interest is used regardless of whether or not the intercurrent event occurs. This is the supplementary strategy aiming to achieve a robust treatment effect for regulatory decision making for primary and some major secondary endpoints.

**Variable:**

- Binary: response endpoint (e.g. ACR 20)
- Continuous: change from baseline

**Intercurrent Events:** Regardless of the intercurrent event of meeting TF criteria

**Population level summary:**

- Binary: difference in proportion of responders between guselkumab group and placebo group.
- Continuous: difference in mean changes between guselkumab group and placebo group.

The Treatment Policy Estimand will be analyzed for all major secondary endpoints (Table 6a), and selected endpoints (Table 11a) analyzed at Week 16.

5.2.4.4. **Per-Protocol Strategy**

The per-protocol strategy is to use the last assessment while on randomized treatment up to a specific visit (e.g., Week 24). For subjects who met TF criteria 3 or 4 prior to the said visit, the last assessment while on randomized treatment is the last assessment prior to meeting TF criteria 3 or 4. This is the supplementary strategy aiming to achieve a robust treatment effect for regulatory decision making for the primary endpoint of ACR 20 response at Week 24.

**Variable:** last measurement while on randomized treatment prior to meeting TF criteria 3 and 4 (Section 2.5) or up to a specific visit (e.g., Week 24), whichever is earlier, \textit{where},
while on randomized treatment is defined as the time from first administration of randomized treatment through onset of TF criteria 3 or 4 being met or through 4 weeks after last administration of randomized treatment up to the said specific visit (e.g., Week 24), whichever is earlier.

**Intercurrent Events:** the intercurrent event is captured through variable definitions.

**Population level summary:**

- Binary: difference in proportion of responders between guselkumab group and placebo group.

The Per-Protocol Strategy Estimand will be analyzed for ACR20 at Week 24.

### 5.3. Primary Efficacy Endpoint(s)

The primary endpoint of this study is proportion of subjects who achieved an ACR 20 response at Week 24. This section outlines the definitions and analyses of this primary endpoint.

#### 5.3.1. Definition

ACR response is a composite measurement of change in PsA signs and symptoms and is presented as the numerical measurement of improvement in multiple disease assessment criteria. An ACR20 response is defined as:

1. ≥ 20% improvement from baseline in both tender joint count (68 joints) [TJC68] and swollen joint count (66 joints) [SJC66]

AND

2. ≥ 20% improvement from baseline in at least 3 of the following 5 assessments:
   
   a. Patient’s Assessment of Pain (VAS) [PAIN]
   
   b. Patient’s Global Assessment of Disease Activity (arthritis, VAS) [GDPT]
   
   c. Physician’s Global Assessment of Disease Activity (VAS) [GDEV]
   
   d. Patient’s Assessment of Physical Function as measured by HAQ-DI
   
   e. C-reactive protein (CRP)

Following are the definitions of each of the forgoing disease assessment criteria (components) that are used in the determination of ACR20 response:

3. Tender Joint Count 68 (TJC68): a total number of tender joints among the 68 joints evaluated for tenderness. Each of the 68 joints will be evaluated for tenderness, categorized as tender or not tender. Joint evaluability rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with joint injection(s)/surgical joint procedure(s).
For subjects with any joint not evaluable in the 68 joint set, joint count adjustment rules described in Appendix 1 will be applied in determining the ultimate count of tender joints.

4. Swollen Joint Count 66 (SJC66): a total number of swollen joints among the 66 joints evaluated for swelling. (Note: The 2 hip joints are excluded from swelling assessment.) Each of the 66 joints will be evaluated for swelling, categorized as swollen or not swollen. Joint evaluability rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with joint injection(s)/surgical joint procedure(s). For subjects with any joint not evaluable in the 66 joint set, joint count adjustment rules described in Appendix 1 will be applied in determining the ultimate count of swollen joints.

5. Patient’s Assessment of Pain (PAIN): a measure from 0 (no pain) to 10 (the worst possible pain) on a 10-unit VAS.

6. Patient’s Global Assessment of Disease Activity (arthritis, GDPT): a measure from 0 (very well) to 10 (very poor) on a 10-unit VAS.

7. Physician’s Global Assessment of Disease Activity (GDEV): a measure from 0 (no arthritis activity) to 10 (extremely active arthritis) on a 10-unit VAS.

8. HAQ-DI: a measure of difficulty a subject may have in accomplishing tasks in 8 functional areas. For additional details, please refer to the definition of HAQ-DI in Section 5.4.1.1.

9. C-reactive protein (CRP): a lab parameter measured in mg/dL. LLOQ rule specified in Appendix 1 will be applied to values < LLOQ.

If a subject’s baseline value for a component is zero (ie, no disease activity as measured by that component), the subject should be considered as not achieving 20% improvement from baseline for that component since there is no room for improvement.

5.3.2. Analysis Methods

The primary endpoint will be analyzed at Week 24 DBL based on the Composite Estimand (Section 5.2.4.1). In the primary efficacy analysis, data from all subjects in FAS1 (Section 2.3.1.1) will be analyzed according to randomized treatment group regardless of the treatment actually received.

The primary endpoint to be analyzed is proportion of subjects who achieved an ACR 20 response at Week 24 and who did not meet any TF criteria (Section 2.5) prior to Week 24. Subjects who met any TF criteria prior to Week 24 will be considered non-responders at Week 24 regardless of the observed ACR 20 response status.

The treatment difference between each guselkumab group versus the placebo group will be tested using a CMH test stratified by baseline use of non-biologic DMARD (yes, no) and most recent CRP value prior to randomization (<2.0 mg/dL, ≥2.0 mg/dL). The magnitude of the treatment difference will be estimated by the difference in ACR 20 response rates between the guselkumab and placebo groups with a 95% CI calculated based on Wald statistics.

Data Handling Rules

- Missing Data NRI rules (Section 5.2.3.1) will be applied, i.e., subjects with missing data for ACR 20 response at Week 24 will be considered ACR 20 non-responders at Week 24.
In order to control the overall Type 1 error rate, the primary endpoint will be tested in a fixed sequence.

1. Guselkumab 100 mg q4w versus placebo in ACR 20 response at Week 24

2. Guselkumab 100 mg at Weeks 0, 4, and then q8w versus placebo in ACR 20 response at Week 24

If the first test is significant at a 2-sided α-level of 0.05, the study will be considered positive and the second test can then be performed.

**5.3.2.1. Sensitivity and Supplementary Analyses**

1. To evaluate the robustness of the Composite Estimand regarding the assumption of all missing data as non-responder, sensitivity analyses with the exhaustive scenario tipping point analyses will be performed. The analysis will be conducted for an ‘exhaustive approach’ testing all combinations of missing data imputation as responder and NR (Section 5.2.3.2). The chi-square test will be used to compare each guselkumab group versus the placebo group. This will avoid the complication of having to incorporate baseline stratification in the mix when generating all combinations of responders and non-responders for the missing data for CMH test. As all combinations will be presented, both the points where tipping occurs, as well as the proportion of non-tipping combinations, are of interest.

2. To support regulatory decision making, the Treatment Policy Estimand will also be evaluated (Section 5.2.4.3) as a supplementary analysis. In this analysis, however, the observed ACR 20 response for all subjects will be used regardless of whether or not TF criteria are met prior to Week 24, and the missing ACR 20 response for all subjects will be imputed by MI method (Section 5.2.3.3) under the assumption that data are MAR. Treatment comparisons for each imputation data set will be based on a CMH test stratified by baseline use of non-biologic DMARD (yes, no) and most recent CRP value prior to randomization (<2.0 mg/dL, ≥ 2.0 mg/dL). The analysis results from the N imputation datasets will be combined, according to Rubin²⁵, and the p-value for testing the treatment difference will be obtained.

3. Two-dimensional tipping point analyses based on MI imputed data will be included for the Treatment Policy Estimand (Section 5.2.4.3) to assess the robustness for Treatment Policy Estimand regarding the assumption that data are MAR. A pair of deltas will be added to the predicted response rates from MI method depending on guselkumab or placebo group to new MI datasets (Section 5.2.3.3.2). The same analysis method as in sensitivity and supplementary analysis 2 will be applied for the pairs of deltas. The analysis will be done for pairs of delta values include the scenarios where subjects on guselkumab have worse outcomes than subjects on placebo.

4. In addition, the Alternative Composite Estimand will also be evaluated as a supplemental analysis (section 5.2.4.2). Subjects with missing data will be considered non-responders. The same analysis method as that used for the primary analysis will be applied.
5. A supplemental analysis will be performed similar to the primary analysis (Section 5.3.2), however, based on the Per-Protocol Strategy Estimand (Section 5.2.4.4). In this analysis, ACR response status will be determined based on the last assessment up to Week 24 while subjects on randomized treatment or the last non-missing assessment prior to meeting TF criteria 3 or 4, whichever is earlier. This analysis will use the per protocol analysis set.

### 5.3.2.2. Subgroup Analyses

Subgroup analyses will be performed using a logistic regression model to evaluate treatment consistency in proportion of subjects who achieve an ACR 20 response at Week 24 over baseline demographics, baseline disease characteristics, and prior and baseline medication use. A forest plot will be produced for all subgroups listed in Section 2.4. Odds ratios and the corresponding 95% CIs will also be provided for each of subgroups. In addition, the p-values for interaction of the treatment groups and the subgroups will also be provided when a subgroup has at least 2 categories.

If the number of subjects in a subgroup is too small (eg., < 10), subgroups may be pooled for analyses.

### 5.3.2.3. Summary of Analyses Related to the Primary Endpoint of ACR 20 Response at Week 24

Table 4 below provides an overview on all the analyses related to the primary endpoint of ACR 20 response at Week 24, the estimands, the data handling rules to be used, and the analysis methods and summary statistics. All the analyses, except the subgroup analyses, will be based on the FAS1. For subgroup analyses, the analysis sets are the individual subgroups (Section 2.4) of FAS1. Table 12 provides a summary of the Multiple Imputation method.
#### Table 4: Summary of Analyses Related to the Primary Endpoint of ACR 20 Response at Week 24

<table>
<thead>
<tr>
<th>Analysis (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method/Summary statistics</th>
</tr>
</thead>
</table>
| **Primary Analysis (FAS1)** | Subjects with missing data are considered to be non-responders | • Response rates  
• Treatment difference in response rates and 95% CI  
• P-value from the CMH test (stratified by randomization stratification factors) for treatment comparison |
| **Sensitivity Analysis (FAS1)** | Subjects with missing data are considered to be non-responders | • Exhaustive tipping point analysis  
• The chi-squared test to compare treatment groups.  
• Analysis results to be presented graphically |
| **Subgroup Analyses (Individual subgroup levels defined in Section 2.4)** | Subjects with missing data are considered to be non-responders | • Response rates  
• Odds ratio and 95% CI for treatment comparison  
• P-value from logistic regression for the interaction of treatment group and subgroup variable  
• Analysis results to be presented in forest plots |
| **Supplementary Analysis 1 (FAS1)** | Multiple imputation with FCS regression of component scores (Table 12) | • Response rates  
• Treatment difference in response rates and 95% CI  
• P-value from the CMH test (stratified by randomization stratification factors) for treatment comparisons. |
| **Supplementary Analysis 2 (FAS1)** | Multiple imputation with FCS regression of component scores (Table 12) | • Tipping point analysis.  
• The CMH test (stratified by randomization stratification factors) to compare treatment groups.  
• Analysis results to be presented graphically |
| **Supplementary Analyses 3** | Subjects with missing data considered to be non-responders | • Response rates  
• Treatment difference in response rates and 95% CI  
• P-value from the CMH test (stratified by randomization stratification factors) for treatment comparison |

Analyses based on the **Composite Estimand**, in which, subjects meeting any TF criteria (defined in Section 2.5) prior to Week 24 will be considered as ACR 20 non-responders at Week 24.

Analyses based on the **Treatment Policy Estimand**, in which, all observed data will be used, regardless of whether or not the subjects meet any TF criteria (defined in Section 2.5).

Analyses based on the **Alternative Composite Estimand**, in which, subjects meeting any TF criteria (defined in section .2.5) except discontinuation of study agent due to reasons other lack of efficacy will be considered as ACR 20 non-responders at Week 24.

Analyses based on **Per-Protocol Strategy Estimand**, in which, ACR 20 response is determined based on the last measurement while subjects on randomized treatment up to Week 24 or prior to meeting TF criteria 3 or 4, whichever is earlier.

---

When combining analysis results for the CMH test, the Wilson-Hiferty transformation will be applied to the test statistics to achieve an approximate normal distribution.
5.4. **Major Secondary Endpoints**

The major secondary endpoints in this study are:

1. Change from baseline in HAQ-DI score at Week 24.

2. Proportion of subjects who achieve an ACR 50 response at Week 24.

3. Proportion of subjects with a psoriasis response of an Investigator Global Assessment (IGA) (ie, an IGA psoriasis score of 0 [cleared] or 1 [minimal]) AND ≥2-grade reduction from baseline) at Week 24 among the subjects with ≥3% body surface area (BSA) psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

4. Proportion of subjects who achieve an ACR 20 response at Week 16.

5. Change from baseline in modified van der Heijde-Sharp (vdH-S) score at Week 24.

6. Proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline.

7. Proportion of subjects with resolution of dactylitis at Week 24 among the subjects with dactylitis at baseline.

8. Change from baseline in enthesitis score (based on Leeds Enthesitis Index [LEI]) at Week 24 among the subjects with enthesitis at baseline.

9. Change from baseline in dactylitis scores at Week 24 among the subjects with dactylitis at baseline.

10. Change from baseline in SF-36 Physical Component Score (PCS) at Week 24.

11. Change from baseline in DAS28 (CRP) at Week 24.

12. Change from baseline in SF-36 Mental Component Score (MCS) at Week 24.

13. Proportion of subjects who achieve an ACR 50 response at Week 16.


This section outlines the definition and analyses of these major secondary endpoints. All the secondary endpoints will be analyzed at Week 24 DBL according to the randomized treatment groups. Data from all subjects in FAS1 (Section 2.3.1.1) will be included with the following exceptions:

- the analysis of the psoriasis response of IGA will be based on FAS1 among the subjects with a ≥ 3% BSA psoriatic involvement and an IGA score of ≥ 2 (mild) at baseline
the analysis of change from baseline in enthesitis score change and resolution of enthesitis will be based on FAS1 among the subjects with enthesitis at baseline based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002.

the analysis of change from baseline in dactylitis score and resolution of dactylitis will be based on FAS1 among the subjects with dactylitis at baseline based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002.

5.4.1. Change from Baseline in HAQ-DI Score at Week 24

5.4.1.1. Definition

HAQ\(^{11}\) disability index (HAQ-DI) score is an evaluation of the functional status for a subject. The 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (i.e., lower scores are indicative of better functioning).

The HAQ-DI score is the sum of computed category scores divided by the number of categories answered. The HAQ-DI score will not be computed if the subject does not have scores for at least 6 of the 8 categories.

The scoring algorithm (including adjusting the use of aids or devices) is provided by http://patienteducation.stanford.edu/research/haq20.html and is detailed in a separate document.

Change from baseline in HAQ-DI score is a measure of the change in the functional status, where a negative change reflects an improvement and a positive change reflects a worsening.

5.4.1.2. Analysis Methods

The change from baseline in HAQ–DI score at Week 24 will be analyzed at Week 24 DBL based on the Composite Estimand (Section 5.2.4.1). In this analysis, data from all subjects in FAS1 (Section 2.3.1.1) will be analyzed according to randomized treatment group regardless of the treatment received.

Analysis of the change from baseline in HAQ–DI score at Week 24 will be performed using an ANCOVA model based on MI data. The MI method will be applied to impute, under the assumption of MAR, the missing change score of HAQ-DI from baseline at Week 24 defined in the Composite Estimand (i.e., change from baseline with no change assumed at and after meeting TF criteria). The treatment difference between each guselkumab group versus the placebo group will be tested for each imputation dataset and then the analysis results across all imputation datasets will be combined.
5.4.2. Proportion of Subjects with ACR 50 Response at Week 24, Proportion of Subjects with ACR 20 Response at Week 16, Proportion of Subjects with ACR 70 Response at Week 24

5.4.2.1. Definition

For definition of ACR 20 response, refer to Section 5.2.1.

ACR 50 and ACR 70 responses are defined similarly to ACR 20 response, except that the improvement threshold of 20% from baseline in ACR 20 response is replaced by 50% and 70%, respectively.

5.4.2.2. Analysis Methods

Data from all subjects in FAS1 will be analyzed according to randomized treatment group regardless of the treatment actually received.

The same analysis method as described in Section 5.3.2 will be applied to the treatment comparisons on proportion of subjects with ACR 50 response at Week 24, proportion of subjects with ACR 50 response at Week 16, proportion of subjects with ACR 20 response at Week 16, and proportion of subjects with ACR 70 response at Week 24. The analyses are based on the Composite Estimand (Section 5.2.4.1).

5.4.3. Proportion of Subjects who Achieve a Psoriasis IGA Response at Week 24 Among the Subjects with ≥3% BSA Psoriatic Involvement and an IGA Score of ≥2 (mild) at Baseline

5.4.3.1. Definition

The Investigator’s Global Assessment (IGA) documents the investigator’s assessment of the subject’s psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling using a scale of 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe). The subject’s psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

A psoriasis IGA response is defined as an IGA psoriasis score of 0 (cleared) or 1 (minimal) AND ≥ 2-grade reduction from baseline in the IGA psoriasis score.

5.4.3.2. Analysis Methods

Data from all subjects in FAS1 who had ≥ 3% BSA psoriatic involvement and an IGA score of ≥ 2 (mild) at baseline will be included and analyzed according to the randomized treatment groups.

The same analysis method as described in Section 5.3.2 will be applied to the treatment comparisons on proportion of subjects with a psoriasis IGA response at Week 24. The analyses are based on the Composite Estimand (Section 5.2.4.1).
5.4.4. Change from Baseline in Modified vdH-S Score at Week 24

5.4.4.1. Definition

The vdH-S score is an original vdH-S score, modified for PsA. The modification for PsA includes addition of distal inter-phalangeal (DIP) joints of both hands scored for erosions and joint space narrowing (JSN), and assessments of radiographic features known as “pencil in cup” (PIC) and “gross osteolysis” (GO) that are specific to PsA. The vdH-S score is a measurement of progression in structural damage. It is the sum of joint erosion score and JSN score. The erosion score and JSN score, respectively, is a measurement of 2 types of structural damage.

The joint erosion score is a summary of erosion severity in 40 joints of the hands (20 joints per hand) and 12 joints in the feet (6 in each foot). Each joint is scored according to the surface area involved, from 0 to 5, with 0 indicating no erosion and 5 indicating complete collapse of bone. To identify the presence of pencil in cup (PIC) and gross osteolysis (GO) in the hands, a modification of erosions scores of 6 and 7 are applied by IRC radiologists. For joints with one of these abnormalities, the maximum score of 5 will be applied. To identify the presence of PIC and GO in the feet, a modification of erosions scores of 11 and 12 are applied by IRC radiologists. For joints with one of these abnormalities the maximum score of 10 will be applied. Therefore, the maximum erosion score for a hand joint is 5 and the maximum erosion score for hands is 200. Because each side of a foot joint is graded on the scale of 0 to 5, the maximum erosion score for a foot joint is 10 and the maximum erosion score for feet is 120. Thus, the maximal erosion score (i.e., hand erosion score + foot erosion score) is 320.

The joint space narrowing score summarizes the severity of JSN in 40 joints in the hands and 12 joints of the feet. Assessment of JSN is scored from 0 to 4, with 0 indicating no JSN and with 4 indicating absence of a joint space, presumptive evidence of ankylosis or complete luxation. Therefore, the maximum JSN score for a hand joint is 4 and the maximum JSN score for hands is 160. The maximum JSN score for a foot joint is 4 and the maximum JSN score for feet is 48. Thus, the maximal JSN score (i.e., hand JSN score + foot JSN score) is 208.

The maximal erosion score of 320 combined with the maximal JSN score of 208 gives worst possible modified vdH-S score (ie, erosion score + JSN score) of 528.

Joint Evaluability Rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with surgery/joint replacement or with radiographically insufficient data for reading. For subjects with incomplete set of evaluable joints, Erosion and JSN Score Adjustment Rules described in Appendix 1 will be applied to determine the ultimate sub-scores (i.e., scores of hand erosion, hand JSN, foot erosion, and foot JSN) for each reader. A composite score [including erosion, JSN, hand (i.e., hand erosion + hand JSN), foot (i.e., foot erosion + foot JSN), and vdH-S scores)] will be set to missing if any of its corresponding sub-scores is missing.

Adjudication will occur when the 2 primary readers do not agree with each other with respect to change from baseline in vdH-S score at any post-baseline visit. The criteria for triggering adjudication can be found in Appendix 1. Note that the criteria for triggering adjudication should be determined based on the observed data (i.e., data without application of those data...
handling rules specified in Section 5.2.3). Appendix 1 outlines the rules to select which 2 readers’ scores to be used in the analysis for subjects with adjudication.

The final scores or sub-scores at each visit are the average of corresponding scores from the 2 primary readers for a subject without adjudication or from one of the 2 primary readers and adjudicator for a subject with adjudication.

**Change from baseline in vdH-S score** measures the change in progression of structural damage, where a negative change indicates an improvement and a positive change indicates a worsening.

### 5.4.4.2. Analysis Methods

Change from baseline in modified vdH-S score at Week 24 will be analyzed at the Week 24 DBL based on data from Read Campaign 1, data from all subjects in FAS1-SD will be included and analyzed according to the randomized treatment groups. The De Facto (Treatment Policy) Estimand (Section 1.1) will be used for all radiographic analysis.

Due to non-normality of the modified vdH-S score, MI as described in Section 5.2.3.3 will be applied to account for missing data at Week 24 under the assumption that data are MAR where data from unscheduled visits will not be used. Treatment comparisons for each imputation data set will be based on an ANCOVA model adjusted for baseline score, baseline use of non-biologic DAMRDS (yes, no), and most recent CRP value prior to randomization (<2.0 mg/dL, ≥2.0 mg/dL). The analysis results from the N imputation datasets will be combined, according to Rubin\textsuperscript{25} and the p-value for testing the treatment difference will be obtained.

### 5.4.4.2.1. Sensitivity Analysis

To test the robustness of the above analysis results, the following sensitivity analyses will be performed:

1. This analysis will use the same MI imputed dataset as that used for the main analysis, however, this analysis will be performed with ANOVA on the van der Waerden normal score for each imputed dataset (Section 5.2.3.3).

2. Two-dimensional tipping point analyses based on MI imputed data will be performed to evaluate the deviation from the assumption of MAR for missing data (Section 5.2.3.3) using the same MI imputed dataset as that used for the main analysis. The same analyses method as that described in Section 5.4.4.2 for the main analysis, will be fitted. The analysis results from the N imputation datasets will be combined, according to Rubin\textsuperscript{25} and the p-value for testing the treatment difference will be obtained.

3. Using the same ANCOVA model as the main analysis to compare the treatment differences based on multiple imputed dataset, however, a 2-step MI will be used: 1) Missing week 24 data from subjects with an x-ray measurement at baseline and a measurement post baseline during the placebo controlled period will be imputed through a mixed effect linear growth curve model (see Appendix 3) (2) Missing data from subjects with only baseline x-ray measurements will be imputed with FCS regression method based on the imputed dataset.
from the 1st step. The 2-step imputation will be applied only to the total vdh-S score and not to the erosion/JSN scores for hand and feet.

4. Using the MI imputed dataset as that used for the main analysis for subjects with just a baseline value, a mixed effect linear growth curve model (see Appendix 3) will be used to assess the statistical significance of the treatment difference of the progression rate in 24 weeks. The analysis results from the N imputation datasets will be combined, according to Rubin²⁵ and the p-value for testing the treatment difference will be obtained.

5. The same analysis model as sensitivity analysis 1 will be applied to analyze the observed data as an additional supportive analysis. In this analysis, treatment comparisons will be performed using an ANOVA test on the van der Waerden normal score of change from baseline in modified vdh-S score at Week 24 based on imputed data, where the missing vdh-S score at Week 24 will be imputed by Missing Data LOCF rules (Section 5.2.3.5).

6. An analysis similar to sensitivity analysis 5, however, Missing Data LEXT Rules (Section 5.2.3.4) will be applied for subjects with missing vdh-S score at Week 24.

7. An analysis similar to main analysis, however, based on the observed data. Subjects with missing vdh-S score at Week 24 will be excluded from the analysis. This analysis assumes that missing data is MCAR.

8. Two-dimensional tipping point analyses based on observed data will be performed to evaluate the impact of missing data when the pattern of missing data deviates from the assumption of MCAR (section5.2.3.6.1). The same ANCOVA model as that described in Section 5.4.4.2 for the main analysis, will be fitted.

The following table summarizes the primary and sensitivity analyses of the modified vdh-S score change at Week 24.

<table>
<thead>
<tr>
<th>Analysis (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method/Summary statistics</th>
</tr>
</thead>
</table>
| Main Analysis (FAS1-SD) | MI with FCS regression (Section 5.2.3.3, Table 12) | • Summarized descriptively  
• For each imputed dataset, treatment comparison using ANCOVA model  
• P-value by combining treatment differences from all MI imputed datasets |
| 1 Sensitivity Analysis (FAS1-SD) | MI with FCS regression (Section 5.2.3.3, Table 12) | • Summarized descriptively  
• For each imputed dataset, treatment comparison using ANOVA model on van der Waerden normal score  
• P-value by combining treatment differences from all MI imputed datasets |
| 2 Sensitivity Analysis (FAS1-SD) | MI with FCS regression (Section 5.2.3.3, Table 12) | • Two-dimensional tipping point analysis  
• Treatment comparison using ANCOVA model  
• Analysis results to be presented |
### Table 5: Summary of Analyses Related to the Major Secondary Endpoint of change from baseline in vdH-S score at Week 24

<table>
<thead>
<tr>
<th>Analysis (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method/Summary statistics</th>
</tr>
</thead>
</table>
| 3 Sensitivity Analysis (FAS1-SD) | 2 step MI | • Summarized descriptively  
• For each imputed dataset, treatment comparison using ANCOVA model  
• P-value by combining treatment differences from all MI imputed datasets |
| 4 Sensitivity Analysis (FAS1-SD) | MI with FCS regression (Section 5.2.3.3, Table 12) | • Summarized descriptively  
• For each imputed dataset, treatment comparison using a mixed effect linear growth curve model  
• P-value by combining treatment differences from all MI imputed datasets |
| 5 Sensitivity Analysis (FAS1-SD) | LOCF (Section 5.2.3.5) | • Summarized descriptively  
• ANOVA model on van der Waerden normal score |
| 6 Sensitivity Analysis (FAS1-SD) | LEXT (Section 5.2.3.4) | • Summarized descriptively  
• Treatment comparison using ANOVA model on van der Waerden normal score |
| 7 Sensitivity Analysis (FAS1-SD) | No imputation of missing data. Exclude subjects with missing Week 24 vdH-S score | • Summarized descriptively  
• Treatment comparison using ANCOVA model |
| 8 Sensitivity Analysis (FAS1-SD) | The LSmean of subjects with missing data will be assumed to be the LSmean of subjects with observed data plus a delta. | • Two-dimensional tipping point analysis  
• Treatment comparison using ANCOVA model  
• Analysis results to be presented graphically |
| Subgroup Analyses (Individual subgroup levels defined in Section 2.4) | MI with FCS regression (Section 5.2.3.3, Table 12) | • LSMeans (95% CI) for treatment groups  
• P-value for the interaction of treatment group and subgroup variable using observed data and not MI imputed datasets.  
• Comparison using ANCOVA model |

### 5.4.4.2.2. Subgroup Analysis

Subgroup analyses will be performed to evaluate treatment consistency in modified vdH-S score change from baseline at Week 24 over baseline demographics, baseline disease characteristics, and prior and baseline medication use. The LS Means of the difference between treatment groups in modified vdH-S score change from baseline at Week 24 and the associated 95% CI
estimated by the ANCOVA model will be plotted for each of the subgroup factors defined in Section 2.4.

5.4.5. **Change from Baseline in Enthesitis Score at Week 24 and Proportion of subjects with Resolution of Enthesitis at Week 24 in Subjects with Enthesitis at Baseline**

5.4.5.1. **Definition**

Enthesitis is an important feature of psoriatic arthritis and other spondyloarthropathies. In this study, enthesitis will be assessed by an independent joint assessor using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in subjects with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses:

- Lateral epicondyle humerus, left and right
- Medial femoral condyle, left and right
- Achilles tendon insertion, left and right

The enthesitis index score is a total score of the 6 evaluated sites as listed above, with range from 0 to 6. For subjects who have an incomplete set of 6 evaluated sites, the enthesitis index score based on the observed data cannot be calculated.

**Change from baseline in enthesitis score** measures the change in enthesitis, where a negative change indicates an improvement and a positive change indicates a worsening.

**Subject with enthesitis at baseline** are those subjects with at least one tender enthesis among the 6 sites include in the LEI.

**Subjects with resolution of enthesitis** are those subjects who had at least one tender enthesis at baseline and none at the analysis visit among the 6 sites included in the LEI.

5.4.5.2. **Analysis Methods**

Data from all subjects in FAS1 who had at least one tender enthesis among the 6 sites included in the LEI, at baseline, will be included and analyzed according to the randomized treatment groups. The data from studies CNTO1959PSA3001 and CNTO1959PSA3002 will be combined together for the analysis of the major secondary endpoints and the analysis will be stratified by the combination of study and randomization stratification factors. However, nominal p-values for the CNTO1959PSA3002 study will also be reported. Refer to section 5.2.2.1 for details on the multiplicity adjusted testing procedure for the resolution of enthesitis and the change from baseline in enthesitis score endpoints.

Similar analysis methods as described in Section 5.4.1.2 (ANCOVA on MI data) will be applied to treatment comparisons on the change from baseline in enthesitis score at Week 24. The MI method will be applied to each study separately to obtain the MI data sets for each study. The analyses are based on the Composite Estimand (Section 5.2.4.1).
The same analysis method as described in Section 5.3.2 will be applied to the treatment comparisons on proportion of subjects with resolution of enthesitis at Week 24. The analyses are based on the Composite Estimand (Section 5.2.4.1).

### 5.4.6. Change from Baseline in Dactylitis Scores at Week 24 and Proportion of subjects with Resolution of Dactylitis at Week 24 in Subjects with Dactylitis at Baseline

#### 5.4.6.1. Definition

Presence and severity of dactylitis will be assessed in both hands and feet using a scoring system from 0 to 3 (0 – no dactylitis, 1 – mild dactylitis, 2 – moderate dactylitis, and 3 – severe dactylitis).\(^ {12,13}\)

The results for each digit are summed to produce a final dactylitis score with a range from 0 to 60.

**Change from baseline in dactylitis score** measures the change in dactylitis, where a negative change indicates an improvement and a positive change indicates a worsening.

**Subject with dactylitis at baseline** are those subjects with a dactylitis score > 0 at baseline.

**Subjects with resolution of dactylitis** are those subjects who had a dactylitis score > 0 at baseline and a score of 0 at the analysis visit.

#### 5.4.6.2. Analysis Methods

Data from all subjects in FAS1 who had dactylitis at baseline will be included and analyzed according to the randomized treatment groups. The data from studies CNTO1959PSA3001 and CNTO1959PSA3002 will be combined together for the analysis of the major secondary endpoints and the analysis will be stratified by the combination of study and randomization stratification factors. However, nominal p-values for the CNTO1959PSA3002 study will also be reported. Refer to section 5.2.2.1 for details on the multiplicity adjusted testing procedure for the resolution of dactylitis and the change from baseline in dactylitis score endpoints.

The same analysis methods as described in Section 5.4.1.2 (ANCOVA on MI data) will be applied to treatment comparisons on the change from baseline in dactylitis score at Week 24. The MI method will be applied to each study separately to obtain the MI data sets for each study. The analyses are based on the Composite Estimand (Section 5.2.4.1).

The same analysis method as described in Section 5.3.2 will be applied to the treatment comparisons on proportion of subjects with resolution of dactylitis at Week 24. The analyses are based on the Composite Estimand (Section 5.2.4.1).
5.4.7. Change from Baseline in SF-36 PCS Score at Week 24 and Change from Baseline in SF-36 MCS score at Week 24

5.4.7.1. Definition

The questionnaire of the 36-item short form health survey (SF-36) is a health-related quality of life instrument with 36 questions, developed as part of the Rand Health Insurance Experiment. Version 2 will be used. This instrument consists of 8 multi-item scales (domains).\(^{30}\)

- Limitations in physical functioning due to health problems
- Limitations in usual role activities due to physical health problems
- Bodily pain
- General mental health (psychological distress and well-being)
- Limitations in usual role activities due to personal or emotional problems
- Limitations in social functioning due to physical or mental health problems
- Vitality (energy and fatigue)
- General health perception

Each of these 8 scales (domains) is scored from 0 to 100 with higher scores indicating better health. Based on the scale scores, the 2 summary scores, physical component summary (PCS) score and mental component summary (MCS) score, will be derived. These summary scores are also scaled with higher scores indicating better health.

*Note* that, the SF-36 scale scores will be derived based on the algorithm and software provided by the developer.\(^{26}\) The norm-based score will be used for data analysis and derived by using the 2009 general US population with missing value estimated based on Advanced Data Recovery with Missing Score Estimator (MSE) provided in the user manual.\(^{26}\)

**Change from baseline in PCS score** measures the change in health-related quality of life, where a positive change indicates an improvement and a negative change indicates a worsening.

Similarly, **change from baseline in MCS score** measures the change in health-related quality of life, where a positive change indicates an improvement and a negative change indicates a worsening.

5.4.7.2. Analysis Methods

Data from all subjects in FAS1 will be included and analyzed according to the randomized treatment groups.

The same analysis methods as described in Section 5.4.1.2 (ANCOVA on MI data) will be applied to treatment comparisons on change from baseline in PCS at Week 24 and change from baseline in MCS at Week 24. The analyses are based on the Composite Estimand (Section 5.2.4.1).
5.4.8. Change from Baseline in DAS28 (CRP) at Week 24

5.4.8.1. Definition

The Disease Activity Index Score 28 using CRP [DAS28 (CRP)] is a derived score combining tender joints (28 joints), swollen joints (28 joints), CRP, and Patient’s Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness are shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities.

The DAS28 (CRP) is a continuous parameter and is defined as follows:

$$DAS28\ (CRP) = 0.56 \times \text{SQRT(TJC28)} + 0.28 \times \text{SQRT(SJC28)} + 0.36 \times \ln(CRP\ mg/L + 1) + 0.014 \times GDPT\ mm + 0.96,$$

where

1. $\text{TJC28}$: a total number of tender joints among the 28 joints evaluated for tenderness. Each of the 28 joints will be evaluated for tenderness, categorized as tender or not tender. Joint evaluability rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with joint injection(s)/surgical joint procedure(s). For subjects with any joint not evaluable in the 28 joint set, joint count adjustment rules described in Appendix 1 will be applied in determining the ultimate count of tender joints.

2. $\text{SJC28}$: a total number of swollen joints among the 28 joints evaluated for swelling. Each of the 28 joints will be evaluated for swelling, categorized as swollen or not swollen. Joint evaluability rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with joint injection(s)/surgical joint procedure(s). For subjects with any joint not evaluable in the 28 joint set, joint count adjustment rules described in Appendix 1 will be applied in determining the ultimate count of swollen joints.

3. $\text{CRP}_{mg/L}$: CRP in mg/L. In the calculation of DAS28 (CRP) value, the natural logarithm of $(\text{CRP}_{mg/L} + 1)$ is used. LLOQ rule specified in Appendix 1 will be applied to values < LLOQ.

4. $\text{GDPT}_{mm}$: Patient’s Global Assessment of Disease Activity (arthritis) scaled from 0 (very well) to 100 (very poor) on a 100-unit VAS for the calculation of DAS28 (CRP) value.

If any of the components required for computing the DAS28 (CRP) value is missing, the DAS 28 (CRP) score will be set to missing.

Change from baseline in DAS28 (CRP) measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

5.4.8.2. Analysis Methods

Data from all subjects in FAS1 will be included and analyzed according to the randomized treatment groups.
The same analysis methods as described in Section 5.4.1.2 (ANCOVA on MI data) will be applied to treatment comparisons on change from baseline in DAS28 (CRP) at Week 24. The analyses are based on the Composite Estimand (Section 5.2.4.1).

5.4.9. **Summary of Analyses Related to Major Secondary Endpoints**

Table 6 below provides an overview of all the analyses related to the major secondary endpoints other than the analyses for the change from baseline in modified vdH-S score, the estimands, the data handling rules to be used, and the analysis methods and summary statistics. All the analyses will be based on the FAS1. Table 12 provides a summary of the Multiple Imputation method. For the summary of analyses related to the change from baseline in modified vdH-S score refer to Table 5.

<table>
<thead>
<tr>
<th>Endpoints (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method/Summary statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analyses of <strong>Response Endpoints based on Composite Estimand</strong>, in which, subjects meeting any TF criteria (defined in Section 2.5) prior to a visit (e.g., Week 16) will be considered as non-responders at the said visit (e.g., Week 16).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ACR 50 Response at Week 24 (FAS1)</td>
<td>Subjects with missing data are considered to be non-responders</td>
<td>• Response rates</td>
</tr>
<tr>
<td>• ACR 70 Response at Week 24 (FAS1)</td>
<td></td>
<td>• Treatment difference in response rates and 95% CI</td>
</tr>
<tr>
<td>• ACR 20 Response at Week 16 (FAS1)</td>
<td></td>
<td>• P-value from the CMH test (stratified by randomization stratification factors) for treatment comparison</td>
</tr>
<tr>
<td>• ACR 50 at Week 16 (FAS1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• IGA Response at Week 24 (FAS1 with ≥3% BSA psoriatic involvement and an IGA score of ≥2 at baseline)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Resolution of enthesitis (LEI) at Week 24 among subjects with enthesitis (LEI) at baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Resolution of dactylitis at Week 24 among subjects with dactylitis at baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analyses of <strong>Continuous Endpoints based on Composite Estimand</strong>, in which, subjects meeting any TF criteria (defined in Section 2.5) prior to a visit (e.g., Week 24) will be considered as no change (no improvement) from baseline at the said visit (e.g., Week 24).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 6: Summary of Analyses Related to Major Secondary Endpoints Other Than Change from baseline in Modified vdH-S Score.

<table>
<thead>
<tr>
<th>Endpoints (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method/Summary statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change from baseline at Week 24 in:</td>
<td>MI (Section 5.2.3.3)</td>
<td>Main Analysis:</td>
</tr>
<tr>
<td>• HAQ-DI score (FAS1)</td>
<td></td>
<td>• Descriptive summary statistics</td>
</tr>
<tr>
<td>• DAS28(CRP) (FAS1)</td>
<td></td>
<td>• ANCOVA for each MI dataset and then analysis results across all MI datasets combined</td>
</tr>
<tr>
<td>• Enthesitis (LEI) score (FAS1 in subjects with enthesitis (LEI at baseline)</td>
<td></td>
<td>• LS mean (95% CI) for each treatment group and for differences between groups.</td>
</tr>
<tr>
<td>• Dactylitis score (FAS1 in subjects with dactylitis at baseline)</td>
<td></td>
<td>• P-values for treatment comparisons</td>
</tr>
<tr>
<td>• SF-36 PCS score (FAS1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• SF-36 MCS score (FAS1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.4.10. Additional Tipping Point Analyses

To support regulatory decision making per the FDA review comment dated 14MAR2019 [IND 124177 - Guselkumab (CNTO 1959) - Comments for IND 124177], additional tipping point analyses will be performed for each major secondary endpoint to evaluate the impact when the missing data deviate from the MAR assumption. Analyses will be performed for the Treatment Policy Estimand (Section 5.2.4.3), where observed data is included regardless of whether or not TF criteria are met prior to the time at which the endpoint is assessed.

Missing data in **binary endpoints** will first be imputed using multiple imputation, then a pair of deltas will be added to the predicted response or resolution rates of each missing subject from the MI method depending on guselkumab or placebo group to new MI datasets (Section 5.2.3.3.2). The same CMH test as that used for the main analysis of the endpoint will be used for each imputation set, and the analysis results from the N imputation datasets will be combined for each pair of deltas, according to Rubin\(^{25}\), and the p-values for testing the treatment difference will be obtained. When combining analysis results for the CMH test, the Wilson-Hilferty-transformation\(^{24}\) will be applied to the test statistics to achieve an approximate normal distribution.

Missing data for **continuous endpoints** will first be imputed using multiple imputation, then a pair of deltas will be added to the imputed values from the MI method depending on guselkumab or placebo group (Section 5.2.3.3.3). The same ANCOVA model as that used for the main analysis of the endpoint will be used for each imputation set, and the analysis results from the N imputation datasets will be combined for each pair of deltas, according to Rubin\(^{25}\), and the p-values for testing the treatment difference will be obtained.

Table 6a below summarizes the tipping point analyses for major secondary endpoints other than the modified vdH-S Score. For the summary of additional tipping point analyses other than for primary and major secondary endpoints see Section 5.5.5.
### Table 6a: Summary of Tipping Point Analyses for Major Secondary Endpoints Other Than Change from baseline in Modified vdH-S Score

<table>
<thead>
<tr>
<th>Endpoints (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Supplementary Analyses of Continuous Endpoints based on Treatment Policy Estimand</strong> in which all observed data will be used, regardless of whether or not the subjects meet any TF criteria.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at Week 24 in:</td>
<td>MI with FCS regression (Section 5.2.3.3.3, Table 12)</td>
<td>Two-dimensional tipping point analysis</td>
</tr>
<tr>
<td>• HAQ-DI score (FAS1)</td>
<td></td>
<td>Treatment comparison using ANCOVA model</td>
</tr>
<tr>
<td>• SF-36 PCS score (FAS1)</td>
<td></td>
<td>Analysis results to be presented graphically</td>
</tr>
<tr>
<td>• SF-36 MCS score (FAS1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• DAS28(CRP) (FAS1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Enthesitis (LEI) among subjects with enthesitis (LEI) at baseline (FAS1) based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Dactylitis among subjects with dactylitis at baseline (FAS1) based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Supplementary Analyses of Binary Endpoints based on Treatment Policy Estimand</strong> in which, all observed data will be used, regardless of whether or not the subjects meet any TF criteria.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ACR 50 Response at Week 24 (FAS1)</td>
<td>MI with FCS regression (Section 5.2.3.3.2, Table 12)</td>
<td>Two-dimensional tipping point analysis</td>
</tr>
<tr>
<td>• ACR 70 Response at Week 24 (FAS1)</td>
<td></td>
<td>The CMH test (stratified by randomization stratification factors) to compare treatment groups.</td>
</tr>
<tr>
<td>• ACR 20 Response at Week 16 (FAS1)</td>
<td></td>
<td>Analysis results to be presented graphically</td>
</tr>
<tr>
<td>• ACR 50 at Week 16 (FAS1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• IGA Response at Week 24 (FAS1 with (\geq 3%) BSA psoriatic involvement and an IGA score of (\geq 2) at baseline)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Resolution of enthesitis (LEI) at Week 24 among subjects with enthesitis (LEI) at baseline based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Resolution of dactylitis at Week 24 among subjects with dactylitis at baseline based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* When combining analysis results for the CMH test, the Wilson-Hilferty transformation will be applied to the test statistics to achieve an approximate normal distribution.

### 5.5. Other Efficacy Variable(s)

In addition to the primary and major secondary endpoints, other efficacy analyses related to reduction of signs and symptoms and physical function, skin disease, joint structural damage, and health related quality of life will be analyzed.
This section outlines the definition and analyses of the other efficacy endpoints.

Efficacy endpoints through Week 24 will be analyzed at Week 24 DBL based on the Composite Estimand (Section 5.2.4.1); efficacy endpoints from Week 24 through Week 52 will be analyzed at Week 52 DBL; and efficacy endpoints from Week 52 through Week 100 will be analyzed at Final (Week 112) DBL.

5.5.1. Efficacy Endpoints Related to Reduction of Signs and Symptoms and Physical Function

5.5.1.1. Definition

5.5.1.1.1. ACR Related Endpoints

Other efficacy endpoints related to ACR include:

- Proportion of subjects who achieve an ACR 20 response by visit through Week 100
- Proportion of subjects who achieve an ACR 50 response by visit through Week 100
- Proportion of subjects who achieve an ACR 70 response by visit through Week 100
- ACR components by visit through Week 100
- Percent change (improvement) from baseline in ACR components by visit through Week 100
- Proportion of subjects who maintain an ACR 20 response at Week 52 and Week 100 among the subjects who achieved an ACR 20 response at Week 24.
- Proportion of subjects who maintain an ACR 50 response at Week 52 and Week 100 among the subjects who achieved an ACR 50 response at Week 24.
- Proportion of subjects who maintain an ACR 70 response at Week 52 and Week 100 among the subjects who achieved an ACR 70 response at Week 24.

For definition of ACR 20 response, refer to Section 5.3.1. For definition of ACR 50 response and ACR 70 response, refer to Section 5.4.2.1.

5.5.1.1.2. HAQ-DI Related Endpoints

The other efficacy endpoints related to HAQ-DI include:

- Change from baseline in HAQ-DI score by visit overtime through Week 100.
- Proportion of subjects who achieve a HAQ-DI response (i.e., a ≥ 0.35 improvement from baseline in HAQ-DI score) by visit overtime through Week 100 among those subjects with HAQ-DI score ≥ 0.35 at baseline.
- Proportion of subjects who maintain a HAQ-DI response at Week 52 and Week 100 among the subjects who achieved a HAQ-DI response at Week 24.

For definitions of HAQ-DI and change from baseline in HAQ-DI score, refer to Section 5.4.1.1.
HAQ-DI responders are subjects who achieved ≥ 0.35 improvement in HAQ-DI score. Note that a ≥ 0.35 improvement in HAQ-DI score is considered a clinically meaningful improvement in PsA. The responders are only applicable to subjects whose baseline HAQ-DI score ≥ 0.35.

5.5.1.1.3. DAS28 Related Endpoints

The other efficacy endpoints related to DAS28 (CRP) include:

- Proportion of subjects with DAS28 (CRP) response by visit overtime through Week 100
- Proportion of subjects with DAS28 (CRP) remission by visit overtime through Week 100
- Change from baseline in DAS28 (CRP) by visit overtime through Week 100

For definitions of DAS28 (CRP), refer to Section 5.4.8.1.

### Table 7: DAS28 (CRP) Response Criteria

<table>
<thead>
<tr>
<th>DAS28 (CRP) at the visit</th>
<th>Improvement from Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt; 1.2</td>
</tr>
<tr>
<td>≤ 3.2</td>
<td>Good response</td>
</tr>
<tr>
<td>&gt; 3.2 – 5.1</td>
<td>Moderate response</td>
</tr>
<tr>
<td>&gt; 5.1</td>
<td>Moderate response</td>
</tr>
</tbody>
</table>

DAS28 (CRP) remission is defined as a DAS28 (CRP) value of < 2.6 at a visit.

5.5.1.1.4. Responders Based on Modified Psoriatic Arthritis Responder Criteria (PsARC)

A subject will be considered a responder based on Modified Psoriatic Arthritis Responder Criteria (PsARC) if the subject meets at least 2 of the following criteria at a visit, including at least 1 of the 2 joint criteria and with no deterioration in the other criteria. No deterioration means ≥ 0% improvement.

- ≥ 30% decrease in swollen joint count (SJC66)
- ≥ 30% decrease in tender joint count (TJC68)
- ≥ 20% improvement in Patient’s Global Assessment of Disease Activity (arthritis) on a VAS
- ≥ 20% improvement in Physician’s Global Assessment of Disease Activity on a VAS

5.5.1.1.5. Enthesitis Related Endpoints

Refer to Section 5.4.5.1 for definitions of enthesitis score, change from baseline in enthesitis score, and subjects with resolution of enthesitis.
5.5.1.1.6. Dactylitis Related Endpoints

Refer to Section 5.4.6.1 for definitions of dactylitis score, change from baseline in dactylitis score, and subjects with resolution of dactylitis.

5.5.1.1.7. PASDAS Related Endpoints

The Psoriatic Arthritis Disease Activity Score (PASDAS) is a derived score combining Patient’s Global Assessment of Disease Activity (arthritis and psoriasis, on a 100-unit VAS), Physician’s Global Assessment of Disease Activity (on a 100-unit VAS), swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/L), enthesitis based on LEI (scaled to a 0–6 range), dactylitis count (scoring each digit from 0–3 and recoding to 0–1, where any score > 0 equaled 1), and the PCS score of the SF-36 health survey.\textsuperscript{16,18}

The PASDAS is a continuous parameter and is defined as follows:

\[
PASDAS = 1.5 \times \left\{ 0.18 \times \text{SQRT}(\text{GDEV}_{\text{mm}}) + 0.159 \times \text{SQRT}(\text{GDPTS}_{\text{mm}}) - 0.253 \times \text{SQRT}(\text{SF} - \text{PCS}) + 0.101 \times \ln(\text{SJC66} + 1) + 0.048 \times \ln(\text{TJC68} + 1) + 0.23 \times \ln(\text{ENTHE} + 1) + 0.377 \times \ln(\text{DACTY} + 1) + 0.102 \times \ln(\text{CRP}_{\text{mg/L}} + 1) \right\} + 2 , \]

where

1. \text{GDEV}_{\text{mm}}: Physician’s Global Assessment of Disease Activity on a 100-unit VAS.
2. \text{GDPTS}_{\text{mm}}: Patient’s Global Assessment of Disease Activity (arthritis and psoriasis) on a 100-unit VAS.
3. \text{SF-PCS}: PCS score of the SF-36 health survey.
4. \text{SJC66}: a total number of swollen joints among the 66 joints evaluated for swelling. Each of the 66 joints will be evaluated for swelling, categorized as swollen or not swollen. Joint evaluability rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with joint injection(s)/surgical joint procedure(s). For subjects with any joint not evaluable in the 66 joint set, joint count adjustment rules described in Appendix 1 will be applied in determining the ultimate count of swollen joints.
5. \text{TJC68}: a total number of tender joints among the 68 joints evaluated for tenderness. Each of the 68 joints will be evaluated for tenderness, categorized as tender or not tender. Joint evaluability rules specified in Appendix 1 for overwriting joint evaluation will be applied to those joints with joint injection(s)/surgical joint procedure(s). For subjects with any joint not evaluable in the 68 joint set, joint count adjustment rules described in Appendix 1 will be applied in determining the ultimate count of tender joints.
6. \text{ENTHE}: enthesitis score based on LEI with a range from 0 to 6.
7. \text{DACTY}: dactylitis count (scoring each digit from 0–3 and recoding to 0–1, where any score > 0 equaled 1).
8. \text{CRP}_{\text{mg/L}}: CRP in mg/L. LLOQ rule specified in Appendix 1 will be applied to values < LLOQ.
If any of the components required for computing the PASDAS value is missing, the PASDAS will be set to missing.

**Change from baseline in PASDAS** measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

**Subjects with very low or low disease activity** based on the PASDAS score are those subjects who have a PASDAS score less than or equal to 1.9, or greater than 1.9 and less than or equal to 3.2, respectively.

### 5.5.1.1.8. GRACE Related Endpoints

GRAppa Composite scorE (GRACE) Index score is a composite score of Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), derived as

\[
GRACE\ \text{Index} = (1 - \text{AMDF}) \times 10,
\]

where, AMDF is the Arithmetic Mean of the Desirability Function (AMDF).\(^{18,17}\)

AMDF is calculated by transforming the following variables using predefined algorithms and expressing the total score as a mean with a score range of 0 – 1, where 1 indicates a better state than 0:

- Tender joint count (68 joints)
- Swollen joint count (66 joints)
- HAQ-DI score
- Patient’s Global Assessment of Disease Activity (arthritis and psoriasis) on a 100-unit VAS
- Patient’s Assessment of Skin Disease Activity on a 100-unit VAS
- Patient’s Global Assessment of Disease Activity (arthritis) on a 100-unit VAS
- Psoriasis Area and Severity Index PASI score (Section 5.5.2.1.1)
- Psoriatic Arthritis Quality of Life Index (PsAQOL) score, which is derived as follows:

\[
\text{PsAQOL} = 25.355 + (2.367 \times \text{HAQ-DI}) - (0.234 \times \text{SF-PCS}) - (0.244 \times \text{SF-MCS})
\]

where,

- HAQ-DI: HAQ-DI score (0-3)
- SF-PCS: PCS score of SF-36 Health Survey
- SF-MCS: MCS score of SF-36 Health Survey

If any of the components required for computing the PsAQOL score is missing, the PsAQOL score will be set to missing.

**Change from baseline in GRACE index score** measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

**Subjects with low disease activity** based on the GRACE index score are those subjects who have a GRACE index score less than or equal to 2.3.
5.5.1.1.9. mCPDAI Related Endpoints

The modified Composite Psoriatic Disease Activity Index (mCPDAI) assesses 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores are calculated using the following assessments: swollen or tender joint count (66/68 joints), HAQ-DI, PASI, Dermatology Life Quality Index (DLQI), dactylitis, and enthesitis. Within each domain a score (range 0–3) is assigned according to predefined cutoffs as shown below. The scores for each domain are then added together to give an mCPDAI score with a range of 0 to 12.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Not involved (0)</th>
<th>Mild (1)</th>
<th>Moderate (2)</th>
<th>Severe (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Arthritis</td>
<td>≤4 joints (swollen or tender); normal function (HAQ ≤0.5)*</td>
<td>≤4 joints but function impaired; or ≥5 joints, normal function</td>
<td>&gt;5 joints and function impaired</td>
<td></td>
</tr>
<tr>
<td>Skin Disease</td>
<td>PASI &lt;10 and DLI ≤0.5</td>
<td>PASI 10 but DLI &gt;0; or PASI &gt;10 and DLI ≤10</td>
<td>PASI &gt; 10 and DLI &gt; 10</td>
<td></td>
</tr>
<tr>
<td>Enthesitis</td>
<td>≤3 sites, normal function (HAQ ≤0.5)*</td>
<td>≤3 sites but function impaired; or &gt;2 sites but normal function</td>
<td>&gt;3 sites and function impaired</td>
<td></td>
</tr>
<tr>
<td>Dactylitis</td>
<td>≤3 digits; normal function (HAQ ≤0.5)*</td>
<td>≤3 digits but function impaired; or &gt;3 digits but normal function</td>
<td>&gt;3 digits and has function impaired</td>
<td></td>
</tr>
</tbody>
</table>

* HAQ only counted if clinical involvement of domain (joint/enthesis/dactylitis) present.

The DLQI (defined in section 5.5.2.1.2) score is based on the observed DLQI score and is not derived.

Change from baseline in mCPDAI score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

Subjects with low disease activity based on the mCPDAI score are those subjects who have a mCPDAI score less than or equal to 3.2.

5.5.1.1.10. DAPSA Related Endpoints

The Disease Activity Index for Psoriatic Arthritis (DAPSA) score is a derived score combining swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient’s Assessment of Pain (on a 10-unit VAS), and Patient’s Global Assessment of Disease Activity (arthritis, on a 10-unit VAS).

The DAPSA is a continuous parameter and is defined as follows:

\[ \text{DAPSA} = \text{STC}66 + \text{TJC}68 + \text{CRP (mg/dL)} + \text{PAIN} + \text{GDPT}, \]

where

- SJC66 and TJC68 are defined similarly as in DAS28 (CRP) (Section 5.4.8.1).
- CRP\text{mg/dL}: CRP in mg/dL. LLOQ rule specified in Appendix 1 will be applied to values < LLOQ.
- PAIN: Patient’s Assessment of Pain on a 10-unit VAS.
- GDPT: Patient’s Global Assessment of Disease Activity (arthritis) on a 10-unit VAS.

If any of the components required for computing the DAPSA score is missing, the DAPSA score will be set to missing.
**Change from baseline in DAPSA** measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

**Subjects in remission, or with low disease activity** based on the DAPSA score are those subjects who have a DAPSA score less than or equal to 4, or greater than 4 and less than or equal to 14, respectively.

### 5.5.1.1.11. Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA)

The PsA minimal disease activity (MDA) criteria are a composite of 7 outcome measures used in PsA. A subject is considered as having achieved the PsA MDA at a visit if the subject has fulfilled at least 5 of the following 7 criteria at that visit:

- Tender joint count (68 joints) \( \leq 1 \)
- Swollen joint count (66 joints) \( \leq 1 \)
- Psoriasis activity and severity index \( \leq 1 \)
- Patient’s Assessment of Pain \( \leq 15 \) on a 100-unit VAS
- Patient’s Global Assessment of Disease Activity (arthritis and psoriasis) \( \leq 20 \) on a 100-unit VAS
- HAQ-DI score \( \leq 0.5 \)
- Tender enthesal points \( \leq 1 \) (LEI index score \( \leq 1 \))

A subject is considered as having achieved VLDA at a visit if the subject has fulfilled all 7 criteria described above at that visit.

### 5.5.1.1.12. BASDAI Related Endpoints

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was developed as a subject self-assessment for ankylosing spondylitis and consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis. Only subjects with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA will complete the BASDAI using a 10-unit VAS to indicate the degree of their symptoms over the past week on the following criteria:

- A. Fatigue on a 10-unit VAS
- B. Spinal pain on a 10-unit VAS
- C. Joint pain on a 10-unit VAS
- D. Enthesitis on a 10-unit VAS
- E. Qualitative morning stiffness on a 10-unit VAS
- F. Quantitative morning stiffness on a 10-unit VAS

The BASDAI score = \( 0.2 \times (A + B + C + D + 0.5\times[E + F]) \). If any of the components required for computing the BASDAI score is missing, the BASDAI score will be set to missing.

Higher BASDAI scores indicate greater disease severity and a score decrease of 50% or 2 points is considered **clinically meaningful**.
Change from baseline in BASDAI score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

Note that change from baseline in BASDAI score, and ≥ 20%, ≥ 50%, ≥ 70 %, and ≥ 90% improvement from baseline in BASDAI score are only applicable to subjects with spondylitis and peripheral joint involvement as their primary arthritic presentation of PsA and BASDAI >0 at baseline.

5.5.1.2. Analysis Methods

Endpoints through Week 24 will be analyzed at Week 24 DBL based on FAS1 (Section 2.3.1.1) with the following exceptions:

**HAQ-DI response**, among the FAS1 subjects with HAQ-DI score ≥ 0.35 at baseline.

**BASDAI**: among FAS1 subjects with spondylitis and peripheral joint involvement as their primary arthritic presentation of PsA and BASDAI >0 at baseline.

Endpoints from Week 24 through Week 52 will be analyzed at Week 52 DBL based on FAS2 (Section 2.3.1.2); and endpoints from Week 52 through Week 100 will be analyzed at Final (Week 112) DBL based on FAS3 (Section 2.3.1.3).

All endpoints will be descriptively summarized by treatment groups. Treatment comparisons will be performed by visit through Week 24. Nominal p values and 95% CIs for the difference between each guselkumab group and placebo group will be provided. No treatment comparison will be performed after Week 24.

For **binary response endpoints**, treatment comparisons will be performed using a CMH test as described in Section 5.3.2.1. For **continuous endpoints**, treatment comparisons will be performed using an ANCOVA model on the MI data for HAQ-DI, DAS 28 (CRP), dactylitis, and enthesitis endpoints as described in Section 5.4.1.2, and an MMRM/eLDA model as described in Section 5.2.4.1.

All the analyses will be based on the Composite Estimand (Section 5.2.4.1).

Table 8 outlines the other efficacy endpoints related to reduction of signs and symptoms and physical function, the methods for analyses, and the data handling rules used.
<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Proportions of subjects who achieved an ACR 20, ACR 50, and ACR 70</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively • CMH test for p-value • Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>responses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 ACR components</td>
<td>NA</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td>Percent change from baseline in ACR components</td>
<td>NA</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td>4 Change from baseline in HAQ-DI score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>MI Section (5.2.3.3)</td>
<td>• Descriptive summary statistics • ANCOVA for each MI dataset and then analysis results across all MI datasets combined • LS mean (95% CI) for each treatment group and for differences between groups.  o P-values for treatment comparisons</td>
</tr>
<tr>
<td>5 Proportion of HAQ-DI responders (≥0.35 Improvement from baseline in</td>
<td>Composite (Section 5.2.4.1) whose baseline</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively • CMH test for p-value • Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>HAQ-DI score)</td>
<td>baseline HAQ-DI score ≥ 0.35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Proportions of subjects with DAS28 (CRP) responses</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively • CMH test for p-value • Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>7 Proportions of subjects with DAS28 remission</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively • CMH test for p-value • Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>8 Change from baseline in DAS28 (CRP)</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>MI (Section 5.2.3.3)</td>
<td>• Descriptive summary statistics • ANCOVA for each MI</td>
</tr>
</tbody>
</table>
### Table 8: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Endpoints of Signs & Symptoms and Physical Function

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>dataset and then analysis results across all MI datasets combined</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• LS mean (95% CI) for each treatment group and for differences between groups.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-values for treatment comparisons</td>
</tr>
<tr>
<td>9 Proportions of subjects with PsARC response</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>10 Proportions of subjects with resolution of enthesitis</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1 with enthesitis at baseline</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>11 Change from baseline in enthesitis score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1 with enthesitis at baseline</td>
<td>MI (Section 5.2.3.3)</td>
<td>• Descriptive summary statistics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ANCOVA for each MI dataset and then analysis results across all MI datasets combined</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• LS mean (95% CI) for each treatment group and for differences between groups.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-values for treatment comparisons</td>
</tr>
<tr>
<td>12 Proportions of subjects with resolution of dactylitis</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1 with dactylitis at baseline</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>13 Change from baseline in dactylitis score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1 with dactylitis at baseline</td>
<td>MI (Section 5.2.3.3)</td>
<td>• Descriptive summary statistics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ANCOVA for each MI dataset and then analysis results across all MI</td>
</tr>
</tbody>
</table>
Table 8: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Endpoints of Signs & Symptoms and Physical Function

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</td>
<td></td>
<td></td>
<td></td>
<td>datasets combined</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• LS mean (95% CI) for each treatment group and for differences between groups.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-values for treatment comparisons</td>
</tr>
<tr>
<td>14</td>
<td>Change from baseline in PASDAS</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>15</td>
<td>Change from baseline in GRACE index score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>16</td>
<td>Change from baseline in DAPSA score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>17</td>
<td>Proportions of subjects with minimal disease activity</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>18</td>
<td>Proportions of subjects with ≥20%, ≥50%, ≥70%, and ≥90% improvement from baseline in BASDAI score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1 with spondylitis and peripheral joint involvement as their primary arthritic presentation of PsA and</td>
<td>NRI (Section 5.2.3.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
</tbody>
</table>
Table 8: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Endpoints of Signs & Symptoms and Physical Function

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 19 | Change from baseline in BASDAI score | Composite (Section 5.2.4.1) | FAS1 with spondylitis and peripheral joint involvement as their primary arthritic presentation of PsA | BASDAI=0 at baseline | • Summarized descriptively  
• MMRM model for  
  o LS mean (SD)  
  o Treatment difference in LS mean (95% CI)  
  o P-value of comparing LS mean |
| 20 | Change from baseline in mCPDAI | Composite (Section 5.2.4.1) | FAS1 | - | • Summarized descriptively  
• MMRM model for  
  o LS mean (SD)  
  o Treatment difference in LS mean (95% CI)  
  • P-value of comparing LS mean |
| 21 | Proportion of subjects with low or very low disease activity based on PASDAS | Composite (Section 5.2.4.1) | FAS1 | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value |
| 22 | Proportion of subjects with low disease activity based on GRACE score | Composite (Section 5.2.4.1) | FAS1 | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value |
| 23 | Proportion of subjects with low disease activity or remission based on DAPSA | Composite (Section 5.2.4.1) | FAS1 | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value |
| 24 | Proportion of subjects with low disease activity based on mCPDAI | Composite (Section 5.2.4.1) | FAS1 | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value |
| 25 | Proportions of subjects with very low disease activity | Composite (Section 5.2.4.1) | FAS1 | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value  
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |

'NA' = Not Applicable; ‘-’ indicates Missing Data Rules not to be applied.

ENDPOINTS BY VISIT FROM WEEK 24 THROUGH WEEK 52 AT WEEK-52 DBL

- Subjects in FAS2 will be the analysis population.

Approved, Date: 21 March 2019
### Table 8: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Endpoints of Signs & Symptoms and Physical Function

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• All the endpoints will be descriptively summarized by visit.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• No treatment comparison will be performed.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• No data handling rules will be applied and all analyses will be based on observed data.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ENDPOINTS BY VISIT FROM WEEK 52 THROUGH WEEK 100 AT WEEK-112 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Subjects in FAS3 will be the analysis population.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• All the endpoints will be descriptively summarized by visit.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• No treatment comparison will be performed.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• No data handling rules will be applied and all analyses will be based on observed data.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 5.5.2. Efficacy Endpoints Related to Skin Disease

Other efficacy endpoints related to skin disease include:

- Proportions of subjects who achieve a PASI 75, 90 and 100 responses by visit through Week 100 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline. Proportion of subjects with an IGA score of 0 (cleared) by visit through Week 100 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

- Change from baseline in PASI score by visit through Week 100 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

- Proportion of subjects who achieve a DLQI score of 0 or 1 by visit through Week 100 among the subjects with baseline DLQI score > 1 and with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

- Proportion of subjects who achieve ≥5-point improvement from baseline in DLQI score by visit through Week 100 among the subjects with baseline DLQI score ≥5 and with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

- Change from baseline in DLQI score by visit through Week 100 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

- Proportion of subjects who achieve both PASI 75 and ACR 20 responses by visit through Week 100 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

- Proportion of subjects who achieve both PASI 75 and modified PsARC response by visit through Week 100 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

This section outlines the definitions and analyses for the above skin disease endpoints.
5.5.2.1. Definitions

5.5.2.1.1. PASI Related Endpoints

The Psoriasis Area and Severity Index (PASI) is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: neck and head, trunk (including axillae and groin), upper extremities, and lower extremities (including buttocks), which account for 10%, 30%, 20%, and 40% of the total BSA, respectively. Each of these 4 regions is assessed separately for erythema, induration and scaling on a scale of 0 - 4. The PASI score is a continuous endpoint calculated as follows:

\[
PASI = 0.1 \times (E_h + I_h + S_h) \times A_h + 0.3 \times (E_t + I_t + S_t) \times A_t + 0.2 \times (E_u + I_u + S_u) \times A_u + 0.4 \times (E_l + I_l + S_l) \times A_l
\]

- \(E, I, S\) are, respectively, the state of erythema (E), induration (I) and scaling (S) assessed on a scale of \(0 = \text{none}, 1 = \text{slight}, 2 = \text{moderate}, 3 = \text{severe}, \text{and} 4 = \text{very severe}\).
- \(h, t, u, l\) are the 4 body regions in the PASI system: neck and head (h), trunk (t), upper extremities (u), and lower extremities (l), respectively.
- \(A\) is the area of involvement for psoriatic lesions. The scale for estimating the area of involvement is outlined below:

0 = no involvement  
1 = 1% to 9% involvement  
2 = 10% to 29% involvement  
3 = 30% to 49% involvement  
4 = 50% to 69% involvement  
5 = 70% to 89% involvement  
6 = 90% to 100% involvement

- Coefficients 0.1, 0.3, 0.2, and 0.4 corresponds to that head (h), trunk (t), upper extremities (u) and lower extremities (l) account for 10%, 30%, 20%, and 40% of the total BSA, respectively.

If any of the components required for computing the PASI score is missing, the PASI score will be set to missing. The PASI score ranges from 0 to 72, with a higher score indicating a more severe disease.

Change from baseline in PASI scores measures the change in disease activity, where a negative change from baseline in PASI score indicates an improvement and a positive change indicates a worsening.

PASI 75 response is defined as ≥ 75% improvement from baseline in PASI scores.

PASI 90 response and PASI 100 response are defined similarly, with improvement threshold replaced by 90% and 100% respectively.
5.5.2.1.2. Endpoints Related to DLQI

The Dermatology Life Quality Index (DLQI) questionnaire is a dermatology-specific quality of life instrument designed to assess the impact of the disease on a subject’s HRQOL. It is a 10-item questionnaire that, in addition to evaluating overall quality of life, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. By summing the scores from each component item, a total DLQI score with a range of 0 to 30 and a sub-score for each of 6 related aspects are then derived, with a higher score indicating more severe disease. A score of ≤1 indicates no effect at all of disease on subject’s HRQOL, and a reduction of 5 points or more in total DLQI score is considered clinically meaningful improvement.

The endpoints related to DLQI include:

- Proportion of subjects with DLQI score of 0 or 1 among subjects with baseline DLQI score of ≥1, ≥3% BSA psoriatic involvement at baseline and an IGA score of ≥2 (mild) at baseline.
- Proportion of subjects who achieve ≥5 improvement from baseline in DLQI among subjects with baseline DLQI score of ≥5, ≥3% BSA psoriatic involvement at baseline and an IGA score of ≥2 (mild) at baseline.
- Change from baseline in DLQI score among subjects with ≥3% BSA psoriatic involvement at baseline and an IGA score of ≥2 (mild) at baseline.

Change from baseline in DLQI score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening.

5.5.2.2. Analysis Methods

All endpoints will be analyzed among subjects who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline.

All endpoints will be descriptively summarized by treatment groups. Treatment comparisons will be performed by visit through Week 24. Nominal p values and 95% CIs for the difference between each guselkumab group and placebo group will be provided. No treatment comparison will be performed after Week 24.

For binary response endpoints, treatment comparisons will be performed using a CMH test as described in Section 5.3.2.1. For continuous endpoints, treatment comparisons will be performed using an MMRM/cLDA model as described in Section 5.2.4.1.

All the analyses will be based on the Composite Estimand (Section 5.2.4.1).

Table 9 outlines the other efficacy endpoints related to skin disease, the methods for analyses, and the data handling rules used.
Table 9: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Endpoints of Skin Disease

<table>
<thead>
<tr>
<th>Endpoint Description</th>
<th>Estimand Description</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1. Proportions of subjects who achieve a PASI 75, 90, 100 responses                 | Composite (Section 5.2.4.1)                                                           | FAS1 who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | NRI (Section 5.2.3.1) | • Summarized descriptively
• CMH test for p-value
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |
| 2. Proportions of subjects who achieve who achieve both PASI 75 and ACR 20 responses | Composite (Section 5.2.4.1)                                                           | FAS1 who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | NRI (Section 5.2.3.1) | • Summarized descriptively
• CMH test for p-value
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |
| 3. Proportions of subjects who achieve who achieve both PASI 75 and modified PsARC responses | Composite (Section 5.2.4.1)                                                           | FAS1 who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | NRI (Section 5.2.3.1) | • Summarized descriptively
• CMH test for p-value
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |
| 4. Proportions of subjects with an IGA score of 0 (cleared)                          | Composite (Section 5.2.4.1)                                                           | FAS1 who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | NRI (Section 5.2.3.1) | • Summarized descriptively
• CMH test for p-value
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |
Table 9: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Endpoints of Skin Disease

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
</table>
| 5        | Change from baseline in PASI scores | Composite (Section 5.2.4.1) | FAS1 who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | - | • Summarized descriptively  
• MMRM model  
  o LS mean (SD)  
  o Treatment difference in LS mean (95%CI)  
  o P-value of comparing LS mean |
| 6        | Proportion of subjects with DLQI score of 0 or 1 | Composite (Section 5.2.4.1) | FAS1 who had DLQI score of >1, ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value  
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |
| 7        | Proportion of subjects who achieve ≥ 5 improvement from baseline in DLQI | Composite (Section 5.2.4.1) | FAS1 who had DLQI score of ≥5, ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | NRI (Section 5.2.3.1) | • Summarized descriptively  
• CMH test for p-value  
• Treatment difference in response rates and 95% CI calculated based on the Wald statistics |
| 8        | Change from baseline in DLQI score | Composite (Section 5.2.4.1) | FAS1 who had ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | - | • Summarized descriptively  
• MMRM model  
  o LS mean (SD)  
  o Treatment difference in LS mean (95%CI)  
  o P-value of comparing LS mean |

‘--’ indicates Missing Data Rules not to be applied.

ENDPOINTS BY VISIT FROM WEEK 24 THROUGH WEEK 52 AT WEEK-52 DBL

- Subjects in FAS2 will be the analysis population.
- All the endpoints will be descriptively summarized by visit.
- No treatment comparison will be performed.
- No data handling rules will be applied and all analyses will be based on observed data.

ENDPOINTS BY VISIT FROM WEEK 52 THROUGH WEEK 100 AT FINAL DBL

- Subjects in FAS3 will be the analysis population.
- All the endpoints will be descriptively summarized by visit.
- No treatment comparison will be performed.
- No data handling rules will be applied and all analyses will be based on observed data.

5.5.3. Other Radiographic Endpoints

Other efficacy endpoints related to joint structural damage include:

- Change from baseline in modified vdH-S score by visit through Week 100.
- Change in modified vdH-S score from Week 24 to Week 52, from Week 24 to Week 100, and from Week 52 to Week 100.
• Change from baseline in modified vdH-S erosion score by visit through Week 100.
• Change in modified vdH-S erosion score from Week 24 to Week 52, from Week 24 to Week 100, and from Week 52 to Week 100.
• Change from baseline in modified vdH-S joint space narrowing (JSN) score by visit through Week 100.
• Change in modified vdH-S JSN score from Week 24 to Week 52, from Week 24 to Week 100, and from Week 52 to Week 100.
• Change from baseline in modified vdH-S score by region and type of damage (ie, hand erosion, hand JSN, foot erosion, foot JSN subscores) by visit through Week 100.
• Proportion of subjects with a change of ≤0 from baseline and proportion of subjects with a change of ≤ 0.5 from baseline in modified vdH-S score by visit through Week 100.
• Proportion of subjects with a change of ≤0 from baseline and proportion of subjects with a change of ≤ 0.5 from baseline in modified vdH-S erosion score at by visit through Week 100.
• Proportion of subjects with a change of ≤0 from baseline and proportion of subjects with a change of ≤ 0.5 from baseline in modified vdH-S JSN score by visit through Week 100.
• Proportion of subjects without radiographic progression (based on the smallest detectable change [SDC]) from baseline by visit through Week 100.
• Proportion of subjects without radiographic joint erosion progression (based on SDC) from baseline by visit through Week 100.
• Proportion of subjects without radiographic JSN progression (based on the SDC) from baseline by visit through Week 100.
• Proportion of subjects with pencil in cup or gross osteolysis deformities by visit through Week 100.

This section outlines the definitions and analyses for the above radiographic endpoints.

5.5.3.1. Definition

Refer to Section 5.4.4.1 for definitions of erosion, JSN, hand, foot, and modified vdH-S scores.

For definition of change from baseline in modified vdH-S score, refer to Section 5.4.4.1.

Change from baseline in erosion score measures the change in progression of structural erosion, where a negative change indicates an improvement and a positive change indicates a worsening.

Change from baseline in JSN score measures the change in progression of structural joint space narrowing, where a negative change indicates an improvement and a positive change indicates a worsening.
The smallest detectable change (SDC) is the smallest change in score that is considered to be assessed correctly based on the limits of agreement (i.e., above the measurement error). The SDC for change from baseline in vdh-S score is determined as follows:

$$SDC = 1.96 \times \frac{SD}{\sqrt{\frac{2}{k}}}$$

- SD is the standard deviation of the difference between 2 readers in change from baseline in vdh-S score
- k is the number of readers (e.g., = 2 for this study)

Note that the SDC for change from baseline in erosion score and the SDC for change from baseline in JSN score are defined similarly.

Radiographic progression is defined as the change of modified vdh-S score > the SDC in modified vdh-S score.

Radiographic erosion progression is defined as the change of erosion score > the SDC in erosion score.

Radiographic JSN progression is defined as the change in JSN score > the SDC in JSN score.

5.5.3.2. Analysis Methods

Radiographic images will be read in 3 read campaigns. Endpoints through Week 24 (i.e., placebo controlled period) based on data generated from Read Campaign 1 will be analyzed at Week 24 DBL based on the FAS1-SD defined in Section 2.3.1; endpoints through Week 52 based on data generated from Read Campaign 2 will be analyzed at Week 52 DBL based on the FAS2-SD defined in Section 2.3.1; and endpoints from Week 52 through Week 100 based on data generated from Read Campaign 3 will be analyzed at Final (Week 112) DBL based on the FAS3-SD defined in Section 2.3.1. In all these analyses, data will be analyzed according to the randomized treatment groups.

All the radiographic endpoints will be summarized by treatment group. Treatment comparison will be performed at Week 24. No treatment comparison will be performed after Week 24.

Continuous endpoints, with missing data imputed by MI (Section 5.2.3.3), will be compared between a guselkumab group versus the placebo group similarly to the major secondary endpoint of change from baseline in modified vdh-S score at Week 24 as described in Section 5.4.4.2.

Response endpoints will be derived from the corresponding continuous endpoints for each imputation. The treatment difference between each guselkumab group versus the placebo group will be tested using a CMH test stratified by baseline use of non-biologic DMARD (yes, no) and most recent CRP value prior to randomization (<2.0 mg/dL, ≥2.0 mg/dL). The magnitude of the treatment difference will be estimated by the difference in proportion of subjects without progression between the guselkumab and placebo groups with a 95% CI calculated based on
Wald statistics. The analysis results from the N imputation datasets will be combined, according to Rubin\(^2\), and the p-value for testing the treatment difference will be obtained. When combining analysis results for CMH test, Wilson-Hilferty-transformation\(^2\) will be applied to the test statistics to achieve an approximate normal distribution.

For the Week 52 database lock, an exploratory analysis will be provided for subjects who remained on treatment to compare the change from Week 24 to Week 52 Gus arm with \(k\) (\(k=0, 0.2, 0.4, 0.8, 1.0\) and 1.2) times of change from baseline to Week 24 in placebo arm.

Table 10 outlines the efficacy endpoints related to joint structural damage, the methods for analyses, and the data handling rules used.

| Table 10: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Radiographic Endpoints |
|---|---|---|---|
| Endpoint | Estimand | Analysis Set | Missing Data Rules | Analysis Methods |
| ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL |
| 1 | Change from baseline in modified vdH-S scores \(^a\) | De Facto (Treatment Policy, Section 5.2.4.3) | FAS1-SD | MI | • Summarized descriptively  
• For each imputed dataset, treatment comparison using ANCOVA model  
• P-value by combining treatment differences from all MI imputed datasets |
| 2 | Change from baseline in modified vdH-S erosion scores \(^a\) | De Facto (Treatment Policy, Section 5.2.4.3) | FAS1-SD | MI | • Summarized descriptively  
• For each imputed dataset, treatment comparison using ANCOVA model  
• P-value by combining treatment differences from all MI imputed datasets |
| 3 | Change from baseline in modified vdH-S JSN scores \(^a\) | De Facto (Treatment Policy, Section 5.2.4.3) | FAS1-SD | MI | • Summarized descriptively  
• For each imputed dataset, treatment comparison using ANCOVA model  
• P-value by combining treatment differences from all MI imputed datasets |
| 4 | Change from baseline in modified vdH-S scores by region and damage type | NA | FAS1-SD | - | • Summarized descriptively |
| 5 | Proportion of subjects with a change of ≤ 0 from baseline in modified vdH-S scores | Treatment Policy, section 5.2.4.3 | FAS1-SD | MI | • Pooled response rates  
• Pooled p-values from CMH tests  
• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald
### Table 10: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Radiographic Endpoints

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6  Proportion of subjects with a change of $\leq 0$ from baseline in modified vdh-S erosion scores</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
<td>• Pooled response rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled p-values from CMH tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald statistics</td>
</tr>
<tr>
<td>7  Proportion of subjects with a change of $\leq 0$ from baseline in modified vdh-S JSN scores</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
<td>• Pooled response rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled p-values from CMH tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald statistics</td>
</tr>
<tr>
<td>8  Proportion of subjects with a change of $\leq 0.5$ from baseline in modified vdh-S scores</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
<td>• Pooled response rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled p-values from CMH tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald statistics</td>
</tr>
<tr>
<td>9  Proportion of subjects with a change of $\leq 0.5$ from baseline in modified modified vdh-S erosion scores</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
<td>• Pooled response rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled p-values from CMH tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald statistics</td>
</tr>
<tr>
<td>10 Proportion of subjects with a change of $\leq 0.5$ from baseline in modified vdh-S JSN scores</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
<td>• Pooled response rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled p-values from CMH tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald statistics</td>
</tr>
<tr>
<td>11 Proportion of subjects without radiographic progression (based on SDC) from baseline at Week 24</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
<td>• Pooled response rates</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled p-values from CMH tests</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pooled treatment difference in response rates and 95% CIs calculated based on the Wald statistics</td>
</tr>
</tbody>
</table>
Table 10: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for Radiographic Endpoints

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Proportion of subjects without radiographic erosion progression (based on SDC) from baseline at Week 24</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
</tr>
<tr>
<td>13</td>
<td>Proportion of subjects without radiographic JSN progression (based on SDC) from baseline at Week 24</td>
<td>Treatment Policy, section 5.2.4.3</td>
<td>FAS1-SD</td>
<td>MI</td>
</tr>
<tr>
<td>14</td>
<td>Proportion of subjects with pencil in cup or gross osteolysis deformities at Baseline and Week 24</td>
<td>NA</td>
<td>FAS1-SD</td>
<td>-</td>
</tr>
</tbody>
</table>

*NA* = Not Applicable; ‘–’ indicates no missing data rules to be applied.

ENDPOINTS BY VISIT FROM WEEK 24 THROUGH WEEK 52 AT WEEK-52 DBL
- Subjects in FAS2-SD will be the analysis population.
- All the endpoints will be descriptively summarized by visit.
- No treatment comparison will be performed.
- No data handling rules will be applied and all analyses will be based on observed data.
- For sensitivity analysis, missing vdH-S score at Week 52 will be imputed by MI.

*3* In addition to the change from baseline, change from Week 24 will also be calculated.

ENDPOINTS BY VISIT FROM WEEK 52 THROUGH WEEK 100 AT FINAL (WEEK-112) DBL
- Subjects in FAS3-SD will be the analysis population.
- All the endpoints will be descriptively summarized by visit.
- No treatment comparison will be performed.
- No data handling rules will be applied and all analyses will be based on observed data.
- For sensitivity analysis, missing vdH-S score at Week 100 will be imputed by MI.

*3* In addition to the change from baseline, change from Week 24, and change from Week 52 will also be calculated.

**5.5.3.2.1.1. Radiographic Reader’s Agreement**

The agreement between the 2 primary reader scores will be assessed at treatment group level, subject level, and individual joint level.

In order to assess intra-reader variability, images of 10% of subjects will be randomly selected and re-read by each of the 2 primary readers (Read Campaigns 1, 2, and 3). The scores from the re-read will be used for intra-class correlation analysis.
The readers’ agreement at treatment group level will be evaluated by descriptive summarization of each primary reader’s score by treatment group overtime.

The readers’ agreement at subject level will be evaluated using the methods of Bland and Altman, as applied by and referred to as the “limits of agreement” method by plots of the differences between the 2 primary readers’ vdH-S scores versus the mean of the 2 primary readers’ vdH-S scores.\textsuperscript{22}

In addition, intra-reader and inter-reader variability will be assessed. The scores from the re-read will be used for intra-class correlation analysis. The intra-class correlation for intra-reader and inter-reader variability will be calculated on modified vdH-S score at baseline, Week 24, Week 52, and Week 100, and modified vdH-S score change from baseline at Weeks 24, 52, and 100.

Data handling rules:

- No data handling rules will be applied for assessment based on data from all Read Campaigns.

5.5.4. Other Efficacy Endpoints Related to Health-Related Quality of Life and Health Economics

In this study, health related quality of life (HRQOL) measures include questionnaires of SF-36 health survey, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol five-dimension (EQ-5D), and Work Productivity and Activity Impairment (WPAI).

Other efficacy endpoints related to HRQOL include:

- Change from baseline in SF-36 PCS score by visit through Week 100.
- Change from baseline in SF-36 MCS score by visit through Week 100.
- Change from baseline in domain scores of SF-36 scales by visit through Week 100.
- Proportion of subjects who achieve $\geq$ 5-point improvement from baseline in SF-36 MCS score by visit through Week 100.
- Proportion of subjects who achieve $\geq$ 5-point improvement from baseline in SF-36 PCS score by visit through Week 100.
- Change from baseline in FACIT-Fatigue score by visit through Week 100.
- Proportion of subjects who achieve $\geq$ 4-point improvement from baseline in FACIT-Fatigue scores by visit through Week 100.
- Change from baseline in FACIT-fatigue score at Week 24 by ACR 20 response at Week 24.
- Proportion of subjects who achieve $\geq$ 4-point improvement from baseline in FACIT-fatigue score at Week 24 by ACR 20 response at Week 24.
- Change from baseline in EQ-5D VAS scores by visit through Week 100.
- Change from baseline in EQ-5D index scores by visit through Week 100.
Change from baseline in WPAI scores by visit through Week 100.

This section outlines the definitions and analyses for the above HRQOL endpoints.

5.5.4.1. Definition

5.5.4.1.1. SF-36 Questionnaire

The SF-36 questionnaire is defined in Section 5.4.7.1.

Change from baseline in SF scores measures the change in health-related quality of life, where a positive change indicates an improvement and a negative change indicates a worsening.

5.5.4.1.2. FACIT-Fatigue Questionnaire

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The questionnaire consists of 13 questions that assess a subject’s level of fatigue and tiredness over the last 7 days. Each question is graded on a 5-point scale (0 - 4); and accordingly, the total FACIT-Fatigue scores can range from 0 to 52, with lower score reflecting more fatigue and higher scores reflecting less fatigue. Note that, when at least 7 questions are answered, the score can be calculated and should be adjusted by the number of available questions.

Although not developed for PsA, the FACIT-Fatigue has been used to assess fatigue in clinical trials of subjects with RA and has demonstrated sensitivity to change in these subjects. In rheumatology, a change of 4 points is considered clinical meaningful and has been used as response definition in the RA population.

Change from baseline in FACIT-Fatigue scores measures the change in fatigue where a positive change indicates an improvement and a negative change indicates a worsening.

5.5.4.1.3. EQ-5D Questionnaire

The EQ-5D questionnaire is a standardized measure of health status developed by the EuroQoL Group to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D is applicable to a wide range of health conditions and treatments. EQ-5D essentially consists of 2 elements: The EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).

The EQ-5D descriptive system comprises the following 5 dimensions:

- Mobility
- Self-Care,
- Usual Activities,
- Pain/Discomfort
- Anxiety/Depression
The EQ-5D 5 level version (EQ-5D-5L) was used in this study. Each of these 5 dimensions has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent’s health state which can be converted into a single summary index (EQ-5D index) by applying a formula that attaches values (also called weights) to each of the levels in each dimension.

The EQ VAS records the respondent’s self-rated health on a vertical, visual analog scale where the endpoints are labeled “Best imaginable health state” and “Worst imaginable health state.” The EQ VAS is used as a quantitative measure of health outcome as judged by the individual respondent. The US/UK model will be used for analyses.

**Change from baseline in ED-5Q scores** measures the change in health status where a positive change indicates an improvement and a negative change indicates a worsening.

**5.5.4.1.4. WPAI Questionnaire**

The WPAI Questionnaire - Specific Health Problem (WPAI-SHP) is a validated instrument that has been used to study the impact of various diseases on patients’ ability to work and perform daily activities (http://www.reillyassociates.net/WPAI_General.html). The WPAI-PsA assesses the impact of PsA on work and other daily activities during the past 7 days. The WPAI-PsA consists of the following 6 questions:

- Q1: currently employed (working for pay)? (yes, no) **If No, skip to Q6.**
- Q2: hours missed from work in the past 7 days due to PsA? (hours)
- Q3: hours missed from work in the past 7 days due to other reasons? (hours)
- Q4: hours actually worked in the past 7 days? (hours)
- Q5: degree to which PsA affected work productivity while at work in the past 7 days? [0 (no effect) to 10 (completely prevented from working)]
- Q6: degree to which PsA affected regular activities outside of work in the past 7 days? [0 (no effect) to 10 (completely prevented from daily activities)]

Based on the answers to the above 6 questions, 4 types of scores (in percentage) are calculated, with higher scores indicating greater impairment and less productivity, i.e., worse outcomes, as follows. **Note** that for subjects with answer=’No’ to Q1, only the 4th score (ie., percent activity impairment outside work due to PsA) can be calculated.

1. **Percent work time missed** due to PsA (absenteeism): $100 \times \frac{Q2}{(Q2+Q4)}$
2. **Percent impairment while working** due to PsA (presenteeism): $100 \times \frac{Q5}{10}$
3. **Percent overall work impairment** due to PsA (combining absenteeism and presenteeism): \[100 \times \left\{ \frac{Q2}{Q2+Q4} + \left[ (1 - \frac{Q2}{Q2+Q4}) \times \frac{Q5}{10} \right] \right\}\]

4. **Percent activity impairment outside work** due to PsA: 100 * Q6/10

**Change from baseline in WPAI scores** measures the change in work productivity and/or activity impairment, where a positive change indicates a worsening and a negative change indicates an improvement.

### 5.5.4.2. Analysis Methods

All endpoints will be descriptively summarized by treatment groups using descriptive statistics, such as mean, median, standard deviation, interquartile range, minimum and maximum for continuous variables, and counts and percentages for categorical variables. Treatment comparisons will be performed by visit through Week 24. Nominal p-values and 95% CIs for the difference between each guselkumab group and placebo group will be provided.

For continuous endpoints, treatment comparisons will be performed using an MMRM model (Appendix 3: Description of statistical methods).

For **binary response endpoints**, treatment comparisons will be performed using a CMH test as described in Section 5.3.2.1. For **continuous endpoints**, treatment comparisons will be performed using ANCOVA on the MI data for MCS and PCS analyses as described in Section 5.4.1.2, and an MMRM/cLDA model as described in Section 5.1 for other continuous endpoints.

All the analyses will be based on the Composite Estimand (Section 5.2.4.1).

| Table 11: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for HRQOL Endpoints |
|---|---|---|---|---|
| **Endpoint** | **Estimand** | **Analysis Set** | **Missing Data Rules** | **Analysis Methods** |
| **ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL** | | | | |
| 1. Change from baseline in SF-36 PCS score | Composite (Section 5.2.4.1) | FAS1 | MI (Section 5.2.3.3) | - Descriptive summary statistics  
- ANCOVA for each MI dataset and then analysis results across all MI datasets combined  
- LS mean (95% CI) for each treatment group and for differences between groups.  
  o P-values for treatment comparisons |
| 2. Change from baseline in SF-36 MCS score | Composite (Section 5.2.4.1) | FAS1 | MI (Section 5.2.3.3) | - Descriptive summary statistics  
- ANCOVA for each MI dataset and then analysis results across all MI datasets combined  
- LS mean (95% CI) for each |
Table 11: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for HRQOL Endpoints

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</td>
<td></td>
<td></td>
<td></td>
<td>treatment group and for differences between groups.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-values for treatment comparisons</td>
</tr>
<tr>
<td>3 Change from baseline in SF-36 domain scores of SF-36 scale</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD) for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95%CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>4 Proportion of subjects who achieve ≥ 5-point improvement from baseline in SF-36 PCS</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>5 Proportion of subjects who achieve ≥ 5-point improvement from baseline in SF-36 MCS</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>6 Change from baseline in FACIT-Fatigue</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD) for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95%CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>7 Proportions of subjects who achieve ≥ 4-point improvement from baseline in FACIT-Fatigue score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
<tr>
<td>8 Change from baseline in EQ-5D VAS score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model for for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>9 Change from baseline in EQ-5D index score</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model for for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o P-value of comparing LS mean</td>
</tr>
<tr>
<td>10 Change from</td>
<td>Composite</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
</tbody>
</table>

Approved, Date: 21 March 2019
Table 11: Summary of Estimands, Analysis Sets, Data Handling Rules, and Analysis Methods for HRQOL Endpoints

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Estimand</th>
<th>Analysis Set</th>
<th>Missing Data Rules</th>
<th>Analysis Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENDPOINTS BY VISIT THROUGH WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>baseline in WPAI score</td>
<td>(Section 5.2.4.1)</td>
<td></td>
<td></td>
<td>• MMRM model for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• P-value of comparing LS mean</td>
</tr>
<tr>
<td><strong>ENDPOINTS AT WEEK 24 AT WEEK-24 DBL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Change from baseline in FACIT-Fatigue at Week 24 by ACR 20 response at Week 24</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>-</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• MMRM model</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o LS mean (SD) for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>o Treatment difference in LS mean (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• P-value of comparing LS mean</td>
</tr>
<tr>
<td>12 Proportions of subjects who achieve ≥ 4-point improvement from baseline in FACIT-Fatigue score at Week 24 by ACR 20 response at Week 24</td>
<td>Composite (Section 5.2.4.1)</td>
<td>FAS1</td>
<td>NRI (Section 5.2.3.1)</td>
<td>• Summarized descriptively</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• CMH test for p-value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treatment difference in response rates and 95% CI calculated based on the Wald statistics</td>
</tr>
</tbody>
</table>

‘-‘ indicates Missing Data Rules not to be applied.

**ENDPOINTS BY VISIT FROM WEEK 24 THROUGH WEEK 52 AT WEEK-52 DBL**

- Subjects in FAS2 will be the analysis population.
- All the endpoints will be descriptively summarized by visit.
- No treatment comparison will be performed.
- No data handling rules will be applied and all analyses will be based on observed data.

**ENDPOINTS BY VISIT FROM WEEK 52 THROUGH WEEK 100 AT FINAL DBL**

- Subjects in FAS3 will be the analysis population.
- All the endpoints will be descriptively summarized by visit.
- No treatment comparison will be performed.
- No data handling rules will be applied and all analyses will be based on observed data.

Additional Analyses for FACIT-Fatigue

Subgroup analysis comparing change in fatigue score between treatment and control will be conducted in ACR20 non-responder subgroup and ACR20 responder subgroup separately. Propensity score-based methods will be used to account for potential imbalances in baseline covariates. Covariates to be used in the propensity score models will include baseline fatigue score and selected demographics and disease related variables such as age, gender, BMI, PsA duration, physician global assessment, patient global...
assessment, HAQ-DI score, pain assessment, swollen joints 66 and tender joints 68. Logistic regression or Covariate Balancing Propensity Score (CBPS) models will be used to estimate the propensity score.

A mediation analysis will be performed to examine the mediating role of 24-week ACR20 response on change from baseline in fatigue score at week 24 provided both endpoints demonstrate a statistically significant difference between treatment arms (Appendix 3).

5.5.5. Other Tipping Point Analyses

Additional tipping point analyses aside from those for primary and major secondary endpoints will be performed to evaluate the impact when the missing data deviate from the MAR assumption and are summarized in the below Table 11a. The analysis methods used are the same as those described in Table 6a.

<table>
<thead>
<tr>
<th>Endpoints (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Analyses of Continuous Endpoints based on Treatment Policy Estimand, in which all observed data will be used, regardless of whether or not the subjects meet any TF criteria.</td>
<td>MI with FCS regression (Section 5.2.3.3.3, Table 12)</td>
<td>• Two-dimensional tipping point analysis</td>
</tr>
<tr>
<td>Change from baseline at Week 16 in: • HAQ-DI score (FAS1) • SF-36 PCS score (FAS1) • SF-36 MCS score (FAS1) • DAS28(CRP) (FAS1) • Enthesitis (LEI) among subjects with enthesitis (LEI) at baseline (FAS1) based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002 • Dactylitis among subjects with dactylitis at baseline (FAS1) based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002</td>
<td></td>
<td>• Treatment comparison using ANCOVA model • Analysis results to be presented graphically</td>
</tr>
</tbody>
</table>

Supplementary Analyses of Binary Endpoints based on Treatment Policy Estimand, in which all observed data will be used, regardless of whether or not the subjects meet any TF criteria.

• ACR 70 Response at Week 16 (FAS1) • IGA Response at Week 16 (FAS1 with \( \geq 3\) % BSA psoriatic involvement and an IGA score of \( \geq 2 \) at baseline) • Resolution of enthesitis (LEI) at Week 16 among subjects with enthesitis (LEI) at baseline based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002 • Resolution of dactylitis at Week 16 among subjects with dactylitis at baseline based on data combined from studies CNTO1959PSA3001 and CNTO1959PSA3002 | MI with FCS regression (Section 5.2.3.3.2, Table 12) | • Two-dimensional tipping point analysis. • The CMH\(^a\) test (stratified by randomization stratification factors) to compare treatment groups. • Analysis results to be presented graphically |
Statistical Analysis Plan | CNTO1959PSA3002 Amendment 3

**Table 11a: Summary of Tipping Point Analyses Other Than for Primary and Major Secondary Endpoints**

<table>
<thead>
<tr>
<th>Endpoints (Analysis Set)</th>
<th>Missing data</th>
<th>Analysis method</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNTO1959PSA3002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*When combining analysis results for the CMH test, the Wilson-Hilferty transformation will be applied to the test statistics to achieve an approximate normal distribution.*

6. **SAFETY**

Safety will be assessed by summarizing the occurrences and type of AEs, vital signs (pulse, blood pressure, and weight) and examining the changes in the laboratory parameters.

In all the safety analysis, subjects who were randomized and received at least 1 (partial or complete) dose of study agent administration will be included and analyzed according to the treatment they actually received, regardless of the treatments they are randomized to. No formal statistical comparison is planned.

6.1. **Safety Tables Presentation**

There are 3 DBLs in this study, respectively, at Week 24, Week 52, and End of Study (Week 112). Depending on the safety data categories, the cumulative safety data will be analyzed through different study periods which include, but are not limited to, through Week 24, through Week 52, and through end of study period. Tabular summaries of safety events for key study periods are in general presented as follows:

6.1.1. **Summaries Through Week 24**

Safety data through Week 24 will be analyzed according to the following treatment groups:

1. **Placebo**: Subjects who received placebo only and no guselkumab prior to Week 24.
2. **Guselkumab 100 mg at Weeks 0, 4, and then q8w**: Subjects who received guselkumab 100 mg q8w prior to Week 24 with an additional dose at Week 4.
3. **Guselkumab 100 mg q4w**: Subjects who received guselkumab 100 mg q4w prior to Week 24.
4. **Guselkumab Combined**: Subjects in Groups 2 and 3.

The above treatment groups 1-3 are **mutually exclusive**. This allows between-group comparisons of safety between a guselkumab group and the placebo group based on similar follow-up period in each group. The safety tables will have the column headings below:

<table>
<thead>
<tr>
<th>Analysis set: Safety Analysis Set</th>
<th>Placebo</th>
<th>100 mg q8w</th>
<th>100 mg q4w</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>#</td>
<td>#</td>
<td>#</td>
<td>#</td>
</tr>
</tbody>
</table>
For subjects who started treatment with placebo only but later received any amount of guselkumab prior to Week 24 inadvertently, the safety events/measurements on and after the first dose of guselkumab, will be excluded from the data summaries through Week 24. Only the safety events/measurements that occurred while the subjects had been receiving placebo only will be included in the data summaries through Week 24.

### 6.1.2. Summaries Through Week 52

Safety data through Week 52 will be analyzed according to the following treatment groups:

1. **Placebo**: Subjects who received placebo only. Follow-up will be based on the period that the subject was on placebo from the first dose up to Week 52.
   
   a. For subjects who started treatment with placebo and later received treatment with guselkumab (due to CO or inadvertently), follow-up will end at the first dose of guselkumab, and only the safety events/measurements that occurred prior to the first dose of guselkumab will be included in this group.

2. **Placebo → Guselkumab 100 mg q4w**: Subjects who started treatment with placebo and later received treatment with guselkumab (due to CO or inadvertently). Follow-up will start from the first dose of guselkumab up to Week 52. All the safety events/measurements that occurred on and after the first dose of guselkumab up to Week 52 will be included in this group.

3. **Guselkumab 100 mg at Weeks 0, 4, and then q8w**: Subjects who received guselkumab 100 mg q8w prior to Week 24 with an additional dose at Week 4. Follow-up will be from the first dose up to Week 52.

4. **Guselkumab 100 mg q4w**: Subjects who received guselkumab 100 mg q4w prior to Week 24. Follow-up will be from the first dose up to Week 52.

5. **Guselkumab 100 mg q4w Combined**: Subjects in Groups 2 and 4.

6. **All Guselkumab Combined**: Subjects in Groups 2, 3, and 4.

The above treatment groups 1-2 are **not mutually exclusive**. The safety tables will have the column headings below:

<table>
<thead>
<tr>
<th>Analysis set: Safety Analysis Set</th>
<th>Placebo</th>
<th>Guselkumab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100 mg q4w</td>
<td>100 mg q8w</td>
</tr>
</tbody>
</table>

### 6.1.3. Summaries Through End of Study

Safety data through End of Study (Week 112) will be analyzed according to the following treatment groups:
1. **Placebo → Guselkumab 100 mg q4w**: Subjects who started treatment with placebo and later received treatment with guselkumab (due to CO or inadvertently). Follow-up will start from the first dose of guselkumab up to end of study.

2. **Guselkumab 100 mg at Weeks 0, 4, and then q8w**: Subjects who received guselkumab 100 mg q8w prior to Week 24 with an additional dose at Week 4. Follow-up will be from the first dose up to end of study.

3. **Guselkumab 100 mg q4w**: Subjects who received guselkumab 100 mg q4w prior to Week 24. Follow-up will be from the first dose through end of study.

4. **Guselkumab 100 mg q4w Combined**: Subjects in Groups 1 and 3.

5. **All Guselkumab Combined**: Subjects in Groups 1, 2, and 3.

The safety tables will have the column headings below:

<table>
<thead>
<tr>
<th>Analysis set: Safety Analysis Set</th>
<th>Placebo → Guselkumab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100 mg q4w</td>
</tr>
<tr>
<td></td>
<td>100 mg q8w</td>
</tr>
<tr>
<td></td>
<td>100 mg q4w</td>
</tr>
<tr>
<td></td>
<td>100 mg q4w Combined</td>
</tr>
<tr>
<td></td>
<td>All Combined</td>
</tr>
</tbody>
</table>

### 6.2. Adverse Events

AEs that occurred any time over the study will be reported and coded using MedDRA. Analyses of AEs will be performed on those events that are considered treatment emergent. Treatment emergent AEs (TEAEs) are those AEs that occurred after the start of initial study agent administration and those AEs that were present at baseline but worsened in severity after the start of initial study agent administration.

TEAEs will be summarized by MedDRA system organ class, preferred term, and actual treatment group. The numbers of subjects reporting at least 1 event of the following AE categories will be summarized:

- Any TEAEs
- Treatment emergent serious AEs (SAEs)
- TEAEs with severe intensity
- TEAEs that led to permanent discontinuation of study agent administration
- Treatment emergent infections
- Treatment emergent serious infections
- Treatment emergent infections requiring oral or parenteral anti-microbial treatment
- Injection-site reactions
- Anaphylactic reactions or delayed hypersensitivity reactions
All AE summary tables will include average weeks of follow-up and average number of study agent administrations for each treatment group.

In addition to the summary tables, a by-subject listing will be provided for deaths that occurred during the study and, respectively, for the following TEAEs:

1. SAEs
2. AEs that led to permanent discontinuation of study agent administration
3. Anaphylactic reactions or serum sickness reactions
4. Malignancies
5. Serious infections including TB

6.3. **Clinical Laboratory Tests**

The clinical laboratory parameters to be evaluated by the central laboratory include but are not limited to:

- **Hematology**: bands, basophils, eosinophils, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, red blood cell (RBC) count and white blood cell (WBC) count

- **Clinical chemistry**: albumin, alkaline phosphatase, alanine aminotransferase (serum glutamate pyruvate transaminase) [ALT (SGPT)], aspartate aminotransferase (serum glutamic oxaloacetic transaminase) [AST (SGOT)], bicarbonate, blood urea nitrogen (BUN), calcium, chloride, creatinine, glucose, potassium, sodium, total bilirubin, total protein, uric acid

The following analyses will be performed as appropriate by actual treatment group:

- Plots of the observed values and changes from baseline over time for selected clinical laboratory parameters
- Number of subjects with post-baseline values by maximum toxicity grade according to National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) for parameters with NCI-CTCAE criteria defined
- Listings of subjects with any post-baseline lab value of NCI-CTCAE toxicity Grade 3 or higher

6.4. **Vital Signs and Physical Examination Findings**

Vital signs will be measured at visits as per the schedule of events in the protocol. Descriptive statistics of the observed value and change from baseline in each vital sign parameter will be summarized by treatment group; the numbers of subjects with any markedly abnormal post-baseline measurements will also be summarized over time by treatment group. The criteria for markedly abnormal vital signs are defined in the following table.

Abnormalities or changes in severity noted during physical examination will be reported as adverse events and are included in the analysis of adverse events.
6.5. Electrocardiogram

No analysis is planned.

6.6. Other Safety Parameters

6.6.1. Suicidal Ideation and Behavior

The electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) will be used as a screening tool to prospectively evaluate the potential of guselkumab to induce suicidal ideation and behavior. The eC-SSRS defines five subtypes of suicidal ideation and behavior in addition to self-injurious behavior with no suicidal intent, and is a fully-structured subject self-report questionnaire, including standardized questions, follow-up prompts, error handling routines, and scoring conventions.\textsuperscript{17,19} Two versions of the eC-SSRS will be used in this study, the Lifetime version and the Since Last Contact version. The Lifetime version will be conducted during the screening visit and the Since Last Contact version will be conducted at all other visits through Week 112.

Subjects will complete the eC-SSRS questionnaire using the Sponsor-provided electronic tablets (or through an Interactive Voice Response System, if available). Study site personnel will train the subjects on how to use the electronic device and/or a telephone system. The eC-SSRS will be provided in the local languages in accordance with local guidelines.

The eC-SSRS will be performed during each evaluation visit according to the Time and Events schedule. The eC-SSRS should be performed after the joint assessment at the screening visit (after signing informed consent). At Week 0/baseline and at all post-baseline visits, the eC-SSRS will be the first assessment/questionnaire that the subject completes prior to study agent administration.

At the conclusion of each assessment, the site will receive an eC-SSRS Findings Report from the eC-SSRS vendor. Positive reports are generated from the eC-SSRS vendor for ANY of the following findings:

- Ideation Level 4: Some intent to act, no plan
Ideation Level 5: Specific plan and intent
Behaviors: Actual Suicide Attempts
Behaviors: Interrupted Attempts
Behaviors: Aborted Attempts
Behaviors: Preparatory actions

Negative suicidality indication reports are generated from the eC-SSRS vendor when there are NO indications of the above.

Any eC-SSRS findings, which in the opinion of the investigator are new or considered to be a worsening and clinically significant, should be reported on the AE eCRF.

Suicidal ideation and behavior will be categorized as follows, with higher scores indicating greater severity:

**Suicidal Ideation (1-5)**
- 1 = Wish to be Dead
- 2 = Non-specific Active Suicidal Thoughts
- 3 = Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
- 4 = Active Suicidal Ideation with Some Intent to Act, without Specific Plan
- 5 = Active Suicidal Ideation with Specific Plan and Intent

**Suicidal Behavior (6-10)**
- 6 = Preparatory Acts or Behavior
- 7 = Aborted Attempt
- 8 = Interrupted Attempt
- 9 = Actual Attempt (non-fatal)
- 10 = Completed Suicide

The baseline is defined as the most severe/maximum score at screening and Week 0. Suicidal ideation and behavior will be analyzed by the most severe/maximum post baseline outcome. In addition, a shift table from baseline to post-baseline will also be provided. Subjects with positive (i.e., score >0) ideation and behavior will be presented in a data listing.

7. **PHARMACOKINETICS/PHARMACODYNAMICS**

7.1. **Pharmacokinetics**

Pharmacokinetics (PK) samples for measuring serum guselkumab concentrations will be collected from all subjects at the specified visits as shown in the schedule of events of the protocol. Serum samples will also be collected at the final visit from subjects who terminate study participation early. Samples must be collected before study agent administration at visits when a study agent administration is scheduled. A random venous blood sample for population
PK analysis will be collected from all subjects on any day between Weeks 4 to 12, except on the days of the scheduled study visit at Weeks 4, 8, and 12. Additionally, this blood sample must be collected at least 24 hours prior to or after the actual time of study agent administration at Weeks 4, 8, or 12 (ie, it cannot be collected within 24 hours before or after study agent administration).

All PK analyses will be based on the PK Analysis Set (Section 2.3.3). Subjects will be analyzed according to the treatment groups that they actually received. No imputation for missing concentration data will be performed.

For analysis on serum guselkumab concentrations, descriptive statistics, including arithmetic mean, SD, median, interquartile range, minimum and maximum will be calculated, where appropriate, by treatment group at each serum sampling time. PK data may be displayed graphically. The following analyses will be performed by treatment group as appropriate:

- Summary of serum guselkumab concentrations at each visit by treatment group
- Proportion of subjects without detectable serum guselkumab concentration at each visit by treatment group
- Summary of serum guselkumab concentrations at each visit by treatment group and body weight
- Summary of serum guselkumab concentrations at each visit by treatment group and baseline MTX use (Yes, No)
- Summary of serum guselkumab concentrations by baseline CRP levels
- Plot of median serum guselkumab concentrations over time by treatment group

In addition, the relationship between serum guselkumab concentrations and safety or efficacy may be explored.

For summary statistics of serum guselkumab concentrations, concentration values below the lower limit of quantification will be treated as zero. Once a subject meets one of the following dosing deviation criteria, the subject’s data will be excluded from the by-visit data analyses from that point onwards.

Dosing deviation criteria:

- Discontinue SC guselkumab administrations.
- Skipped an SC guselkumab administration.
- Received an incomplete/ incorrect SC dose.
- Received an incorrect SC study agent.
- Received an additional SC guselkumab dose.

In addition, if a subject has an administration outside of visit windows (Section 2.1.1), the concentration data collected at and after that visit will be excluded from the by-visit data analyses.
analyses. Additional exclusions for incongruous PK data to be implemented based on Janssen SOP-07948.

Population PK analyses will be performed to characterize the disposition characteristics of guselkumab based on the guselkumab concentration data from PsA studies. Data may be combined with other selected studies to support a relevant structural model. The population pharmacokinetic approach will also be used to identify significant covariates such as demographic characteristics (including but not limited to body weight, ethnic origin, sex, and age) and concomitant medications in subjects with PsA. A detailed analysis plan for population PK analysis will be developed separately, and a stand-alone technical report will be written to summarize the results of the population PK analysis.

**PK analyses presentation**

PK analyses will be summarized through the following time periods:

- Through Week 24
- Through Week 52
- Through End of Study (Week 112)

For the analyses, a subject is included in one and only one treatment group on the basis of the treatment regimen followed. The description of treatment groups are as follows:

1. **Placebo → Guselkumab 100 mg q4w**: Subjects randomized to placebo and were switched over to Guselkumab 100 mg q4w (due to CO) at Week 24.

2. **Guselkumab 100 mg at Week 0, Week 4, and then q8w**: Subjects randomized to guselkumab 100 mg at Week 0, Week 4, and then q8w and received guselkumab 100 mg q8w throughout with an additional dose at Week 4.

3. **Guselkumab 100 mg q4w**: Subjects randomized to guselkumab 100 mg q4w and received guselkumab 100 mg q4w throughout.

**7.2. Immunogenicity (Antibodies to Guselkumab)**

Blood samples will be collected to examine the formation of antibodies to guselkumab at the specified visits as shown in the schedule of events of the protocol. Serum samples will also be collected at the final visit from subjects who terminate study participation early.

The antibodies to guselkumab will be summarized based on Immunogenicity Analysis Set (Section 2.3.4). Subjects will be analyzed according to the treatment groups that they actually received. No imputation for missing concentration data will be performed.

The following analysis of antibodies to guselkumab will be performed by treatment group:

- Summary of antibodies to guselkumab status
- Summary of neutralizing antibodies to guselkumab status
• List of subjects positive for antibodies to guselkumab

In addition, to explore the relationship between antibodies to guselkumab status and serum guselkumab concentrations, efficacy and safety, the following analysis may be performed as appropriate:

• Summary of clinical response (e.g., ACR 20 and ACR50, PASI) by antibody to guselkumab status
• Summary of injection-site reactions by antibody to guselkumab status
• Summary of serum guselkumab concentrations by antibody to guselkumab status
• Plots of median trough serum guselkumab concentrations over time by antibody to guselkumab status

**Immunogenicity analyses presentation**

Immunogenicity analyses will be summarized through the following time periods:

• Through Week 24
• Through Week 52
• Through End of Study (Week 112)

For the immunogenicity analyses, the description of treatment groups is as follows:

1. **Placebo → Guselkumab 100 mg q4w**: Subjects randomized to placebo and were switched over to Guselkumab 100 mg (due to CO) at Week 24.
2. **Guselkumab 100 mg at Week 0, Week 4, and then q8w**: Subjects randomized to guselkumab 100 mg at Week 0, Week 4, and then q8w and received guselkumab 100 mg q8w throughout with an additional dose at Week 4.
3. **Guselkumab 100 mg q4w**: Subjects randomized to guselkumab 100 mg q4w and received guselkumab 100 mg q4w throughout.
4. **Guselkumab Combined**: all subjects who received guselkumab in groups 1, 2 and 3.

7.3. **Pharmacodynamics**

Samples for serum biomarkers will be collected for all subjects as indicated in the Time and Events Schedule of the protocol. The analyses on PD biomarkers are to better understand the biology of PsA, to provide a biological assessment of the subjects’ response to treatment with guselkumab, to analyze differences between responders and non-responders, and to determine if the markers can be used to classify subjects as potential responders prior to treatment.

All PD analyses will be based on the PD Analysis Set (Section 2.3.5). Subjects will be analyzed according to the treatment groups that they actually received. No imputation for missing concentration data will be performed. The PD analyses results will be provided in an independent technical report.
7.4. Pharmacokinetic/Pharmacodynamic Relationships

If data permit, the relationships between serum guselkumab concentration and efficacy may be analyzed graphically. If any visual trend is observed, a suitable population PK/PD model may be developed to describe the exposure-response relationship. Details will be given in a population PK/PD analysis plan and results of the population PK/PD analysis will be presented in a separate technical report.
REFERENCES


Approved, Date: 21 March 2019


APPENDICES

APPENDIX 1: RULES APPLIED IN DEFINITIONS OF ENDPOINTS

1. Joint Evaluability Rules for Sign and Symptom Data

For subjects having a joint injection(s)/surgical joint procedure(s) prior to the date of study entry (e.g., randomization) or during the study, the affected joint(s) will be valued according to the following rules:

- For subjects having a joint injection and/or surgical joint procedure prior to the date of randomization, the affected joints will be analyzed according to the impact of the joint injection and/or surgical joint procedure on the evaluability of the involved joints.
  - If a joint is considered un-evaluable at baseline due to certain procedure/injection performed prior to the date of randomization, the joint will be considered un-evaluable throughout the study.

- For subjects undergoing joint procedures for the treatment of PsA during the study, the affected joints will be considered as swollen and tender from the date of procedure onwards.

- For subjects undergoing joint procedures during the study for the treatment of non-PsA disease indication, the affected joints will be analyzed according to the impact of the surgical joint procedure on the evaluability of the involved joints.

- For subjects undergoing joint injections for PsA during the study, the affected joints will be considered as swollen and tender from the date of injection for the next 90 days.

- For subjects undergoing joint injections for non-PsA related reasons during the study, the affected joints will be considered as non-evaluable from the date of injection for the next 90 days.

2. Joint Count Adjustment Rule

For subjects who have an incomplete set of evaluable joints the joint count/score will be adjusted to the total number joints of interest (e.g., 68 joints for tenderness and 66 joints for swelling) by dividing the number of affected joints by the number of evaluable joints and multiplying by the total number joints of interest.

3. LLOQ rule

Any value < LLOQ is considered equal to half of the value of LLOQ for numerical calculations.

4. Joint Evaluability Rules for Radiographic Data

A joint may be not evaluable due to surgery/joint replacement or radiographically insufficient data for reading. Joints with surgery/joint replacement or with radiographically insufficient data for reading will be considered as not evaluable for joint erosion/JSN.
For a joint that is considered as not evaluable at a given time point, both the joint-level erosion score and the joint-level JSN score will be set to missing at the said time point.

5. **Erosion and JSN Score Adjustment Rules**

The regional erosion and JSN scores for hands and feet will be determined based on the evaluable joints. For subjects who have an incomplete set of evaluable joints at a given time point, each reader’s regional erosion and JSN scores at the said time point will be adjusted using the following rules:

### Rules for Adjustment of Erosion Scores by Region

<table>
<thead>
<tr>
<th>Region</th>
<th>Adjustment for the incomplete set of evaluable joints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hands/Wrists</td>
<td>• If total number of joints evaluable at the given time point is ≥ 20 (i.e., 50% of 40), then the erosion score for hands/wrists will be obtained by calculating the average erosion score for hands and wrists and multiplying with 40.</td>
</tr>
<tr>
<td></td>
<td>• If the total number of joints evaluable at the given time point is &lt; 20, then the erosion score for hands and wrists will be set to missing.</td>
</tr>
<tr>
<td>Feet (12 joints)</td>
<td>• If total number of joints evaluable at the given time point is ≥ 6 (i.e., 50% of 12), then the erosion score for feet will be obtained by calculating the average erosion score for feet and multiplying with 12.</td>
</tr>
<tr>
<td></td>
<td>• If the total number of joints evaluable at the given time point is &lt; 6, then the erosion score for feet will be set to missing.</td>
</tr>
</tbody>
</table>

### Rules for Adjustment of JSN Scores by Region

<table>
<thead>
<tr>
<th>Region</th>
<th>Adjustment for the incomplete set of evaluable joints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hands/Wrists</td>
<td>• If total number of joints evaluable at the given time point is ≥ 20 (i.e., 50% of 40), then the JSN score for hands/wrists will be obtained by calculating the average JSN score for hands and wrists and multiplying with 40.</td>
</tr>
<tr>
<td></td>
<td>• If the total number of joints evaluable at the given time point is &lt; 40, then the JSN score for hands and wrists will be set to missing.</td>
</tr>
<tr>
<td>Feet (12 joints)</td>
<td>• If total number of joints evaluable at the given time point is ≥ 6 (i.e., 50% of 12), then the JSN score for feet will be obtained by calculating the average JSN score for feet and multiplying with 12.</td>
</tr>
<tr>
<td></td>
<td>• If the total number of joints evaluable at the given time point is &lt; 6, then the JSN score for feet will be set to missing.</td>
</tr>
</tbody>
</table>
A reader’s vdH-S score is the sum of the reader’s erosion and JNS scores of both hands and feet. If a reader’s regional score is missing for any region of erosion or JSN, the reader’s vdH-S score will be set to missing.

6. **Reader Adjudication Rules**

For each subject, let $\Delta_1$ and $\Delta_2$ stand for the change from baseline in vdH-S score, respectively, of primary readers 1 and 2 at any post-baseline visit (i.e., Week 24 in Read Campaign 1, Week 24 or Week 52 in Read Campaign 2, and Week 24, Week 52 or Week 100 in Read Campaign 3). If the absolute difference between $\Delta_1$ and $\Delta_2$ is greater than 10 (i.e., $|\Delta_2 - \Delta_1| > 10$), or either $\Delta_1$ or $\Delta_2$ is missing (but not both $\Delta_1$ and $\Delta_2$ are missing), an adjudicator (a third reader) will then read all the radiographic images (including baseline and post-baseline images) in that given read campaign from that subject.

7. **Reader Selection Rules**

For subjects who require adjudication (i.e., there are readings from 3 readers), the scores from 2 selected readers will be used in the analysis.

Let $\Delta_1$, $\Delta_2$, and $\Delta_3$ stand for the change from baseline in vdH-S score at Week 24, respectively, of primary reader 1 (Reader 1), primary reader 2 (Reader 2), and the adjudicator (Reader 3). The 2 readers whose scores will be used in the analysis will be selected from the 3 readers based on the criteria specified in the table below.

<table>
<thead>
<tr>
<th>Rules for Selection of Readers Following Adjudication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scenarios based on change from baseline in vdH-S score at Week 24</td>
</tr>
<tr>
<td>$</td>
</tr>
<tr>
<td>$</td>
</tr>
<tr>
<td>$</td>
</tr>
<tr>
<td>$\Delta_1$ is missing but $\Delta_2$ and $\Delta_3$ are non-missing</td>
</tr>
<tr>
<td>$\Delta_2$ is missing but $\Delta_1$ and $\Delta_3$ are non-missing</td>
</tr>
<tr>
<td>$\Delta_3$ is missing but $\Delta_1$ and $\Delta_2$ are non-missing</td>
</tr>
<tr>
<td>Both $\Delta_1$ and $\Delta_3$ are missing, but $\Delta_2$ is non-missing</td>
</tr>
<tr>
<td>Both $\Delta_2$ and $\Delta_3$ are missing, but $\Delta_1$ is non-missing</td>
</tr>
</tbody>
</table>
8. **Smallest Detectable Change**

Smallest Detectable Change (SDC) is the smallest change in a score that is considered to be assessed correctly based on the limits of agreement (ie, above the measurement error) (Bruynesteyn et al 2005).

The SDC in score of interest is determined as follows:

\[
SDC = \frac{1.96 \times SD}{\sqrt{2} \times \sqrt{k}},
\]

- \(SD\) is the standard deviation of the difference between the 2 selected readers in change from baseline in the score of interest
- \(k = 2\), is the number of readers
### APPENDIX 2: STATISTICAL HYPOTHESIS

<table>
<thead>
<tr>
<th>Hypothesis</th>
<th>Global</th>
<th>US Specific</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H1. Guselkumab 100 mg q4w SC is superior to placebo as assessed by the proportion of subjects achieving an ACR 20 response at Week 24 <em>(primary hypothesis)</em></td>
<td>Controlled as in figure 3</td>
<td>Controlled as in figure 2</td>
</tr>
<tr>
<td>H2. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by the proportion of subjects achieving an ACR 20 response at Week 24</td>
<td>Controlled as in figure 3</td>
<td>Controlled as in figure 2</td>
</tr>
</tbody>
</table>

<p>| <strong>Major Secondary Endpoints</strong> | | |
| H3. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects who achieved a psoriasis IGA response at Week 24 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | Controlled as in figure 3 | Controlled as in figure 2 |
| H4. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects who achieved a psoriasis IGA response at Week 24 among the subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 (mild) at baseline | Controlled as in figure 3 | Controlled as in figure 2 |
| H5. Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in DAS28 (CRP) at Week 24 | Controlled as in figure 3 | Weakly-controlled |
| H6. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in DAS28 (CRP) at Week 24 | Controlled as in figure 3 | Weakly-controlled |
| H7. Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in HAQ-DI score at Week 24 | Controlled as in figure 3 | Controlled as in figure 2 |
| H8. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in HAQ-DI score at Week 24 | Controlled as in figure 3 | Controlled as in figure 2 |
| H9. Guselkumab 100 mg q4w SC is superior to treatment with placebo SC as measured by change from baseline in modified vdH-S score at Week 24 | Controlled as in figure 3 | Controlled as in figure 2 |
| H10. Guselkumab 100 mg at Week 0, Week 4, then q8w | Controlled as | Controlled as |</p>
<table>
<thead>
<tr>
<th>SC is superior to treatment with placebo SC as measured by change from baseline in modified vdH-S score at Week 24</th>
<th>in figure 3</th>
<th>in figure 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>H11. Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in SF-36 PCS at Week 24</td>
<td>Controlled as in figure 3</td>
<td>Controlled as in figure 2</td>
</tr>
<tr>
<td>H12. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in SF-36 PCS at Week 24</td>
<td>Controlled as in figure 3</td>
<td>Controlled as in figure 2</td>
</tr>
<tr>
<td>H13. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects who achieved an ACR 50 response at Week 24</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H14. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects who achieved an ACR 50 response at Week 24;</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H15. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects achieved an ACR 20 response at Week 16</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H16. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects achieved an ACR 20 response at Week 16</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H17. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects who achieve an ACR 70 response at Week 24</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H18. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects who achieve an ACR 70 response at Week 24</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H19. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects who achieve an ACR 50 response at Week 16</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H20. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects who achieve an ACR 50 response at Week 16</td>
<td>Controlled as in figure 3</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H21. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline</td>
<td>Nominal</td>
<td>Nominal</td>
</tr>
<tr>
<td>H22. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline</td>
<td>Nominal</td>
<td>Nominal</td>
</tr>
</tbody>
</table>
SC is superior to placebo as assessed by proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline

H23. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects with resolution of dactylitis at Week 24 among the subjects with dactylitis at baseline

Nominal  Nominal

H24. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects with resolution of dactylitis at Week 24 among the subjects with dactylitis at baseline

Nominal  Nominal

H25. Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in SF-36 MCS at Week 24

Controlled as in figure 3  Controlled as in figure 2

H26. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in SF-36 MCS at Week 24

Controlled as in figure 3  Controlled as in figure 2

H27. Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in enthesitis score (based on Leeds Enthesitis Index [LEI]) at Week 24 among the subjects with enthesitis at baseline

Nominal  Nominal

H28. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in enthesitis score (based on Leeds Enthesitis Index [LEI]) at Week 24 among the subjects with enthesitis at baseline

Nominal  Nominal

H29. Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in dactylitis scores at Week 24 among the subjects with dactylitis at baseline

Nominal  Nominal

H30. Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in dactylitis scores at Week 24 among the subjects with dactylitis at baseline

Nominal  Nominal

H31. Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline with combined data from 3001 and 3002

Controlled as in figure 3  Controlled as in figure 2

H32. Guselkumab 100 mg at Week 0, Week 4, then q8w Controlled as Controlled as
<table>
<thead>
<tr>
<th>Hypothesis</th>
<th>Description</th>
<th>Control</th>
<th>Multiplicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>H33.</td>
<td>Guselkumab 100 mg q4w SC is superior to placebo as assessed by proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline with combined data from 3001 and 3002</td>
<td>Controlled as in figure 3</td>
<td>Controlled as in figure 2</td>
</tr>
<tr>
<td>H34.</td>
<td>Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by proportion of subjects with resolution of dactylitis at Week 24 among the subjects with dactylitis at baseline with combined data from 3001 and 3002</td>
<td>Controlled as in figure 3</td>
<td>Controlled as in figure 2</td>
</tr>
<tr>
<td>H35.</td>
<td>Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in enthesitis score (based on Leeds Enthesitis Index [LEI]) at Week 24 among the subjects with enthesitis at baseline with combined data from 3001 and 3002</td>
<td>Nominal</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H36.</td>
<td>Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in enthesitis score (based on Leeds Enthesitis Index [LEI]) at Week 24 among the subjects with enthesitis at baseline with combined data from 3001 and 3002</td>
<td>Nominal</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H37.</td>
<td>Guselkumab 100 mg q4w SC is superior to placebo as assessed by change from baseline in dactylitis scores at Week 24 among the subjects with dactylitis at baseline with combined data from 3001 and 3002</td>
<td>Nominal</td>
<td>Weakly-controlled</td>
</tr>
<tr>
<td>H38.</td>
<td>Guselkumab 100 mg at Week 0, Week 4, then q8w SC is superior to placebo as assessed by change from baseline in dactylitis scores at Week 24 among the subjects with dactylitis at baseline with combined data from 3001 and 3002</td>
<td>Nominal</td>
<td>Weakly-controlled</td>
</tr>
</tbody>
</table>

For hypothesis testing order and multiplicity adjustment, refer to Section 5.2.2.
APPENDIX 3: DESCRIPTION OF STATISTICAL MODELS

1. MIXED-EFFECT MODEL REPEATED MEASURES (MMRM)

To account for the missing data for continuous endpoints, a Mixed-Effect Model Repeat Measures (MMRM) will be used on the change from baseline, under the assumption of MAR, to test the difference between a guselkumab group and the placebo group. The model will include treatment group, the interaction terms of visit with treatment group, randomization stratification factors (baseline use of non-biologic DMARDs (yes, no), and most recent CRP value prior to randomization (<2.0 mg/dL, ≥2.0 mg/dL), and baseline score as explanatory variables. An unstructured covariance matrix for repeated measure within a subject will be used. The F-test will use Kenward-Roger’s approximating for degree of freedom. In case of lack of convergence, empirical structured covariances will be used in the following order until convergence is reached: 1) Toeplitz 2) first order Autoregressive Moving Average. The model will include data from all 3 treatment groups through Week 24. The treatment difference between a guselkumab group and the placebo group will be estimated by the difference in the least squares means (LSmeans). The 95% confidence interval (CI) for the differences in LSmeans and p-values will be calculated based on the MMRM.

2. CONSTRAINED LONGITUDINAL DATA ANALYSIS (CLDA) MODEL

To account for the missing data for continuous endpoints when 2% or more subjects have baseline score missing, a Constrained Longitudinal Data Analysis (cLDA) model may be performed on the measurement instead of the change, under the assumption of MAR, to test the difference between a guselkumab group and the placebo group. The model will include treatment group, the interaction terms of visit with treatment group, and randomization stratification factors (baseline use of non-biologic DMARDs (yes, no), and most recent CRP value prior to randomization (<2.0 mg/dL, ≥2.0 mg/dL). An unstructured covariance matrix for repeated measure within a subject will be used. The F-test will use Kenward-Roger’s approximating for degree of freedom. In case of lack of convergence, empirical structured covariances will be used in the following order until convergence is reached: 1) Toeplitz 2) first order Autoregressive Moving Average. The model will include data from all 3 treatment groups through Week 24. The treatment difference between a guselkumab group and the placebo group will be estimated by the difference in the LS means. The 95% CIs for the differences in LS means and p-values will be calculated based on the cLDA model.

3. MIXED EFFECT LINEAR GROWTH CURVE MODEL

Due to the slow progression in structural damage and over a short period of time, the assumption that progression follows a linear trend seems to be reasonable. To use all available post-treatment data that are collected out-side of the analytical window for Week 24, a mixed effect linear growth model will be fitted to the change from baseline in vdH-S score where, effect of treatment on the change from baseline in vdH-S score through Week 24 will be estimated by the slope. The fixed effects in the model include the interaction of time with treatment group, and the interaction of time with randomization stratification factors. The model will include a random coefficient for time. Additionally, an intercept term will not be included in the model. Time will
be included as a continuous variable. All observed data post treatment in the placebo controlled period will be used.

4. **MEDIATION ANALYSIS**

Mediation analysis will be performed to examine the mediating role of 24-week ACR20 response on change from baseline in fatigue score at week 24 provided both endpoints demonstrate a statistically significant difference between treatment arms. In the mediation analysis framework, natural direct effect can be conceived of as independent treatment effect on the outcome (i.e. change in fatigue score) that is above and beyond its effect on the mediator (i.e. ACR20 response); controlled direct effect can be conceived of as the independent treatment effect on the outcome controlling the mediator at a fixed level; and the natural indirect effect can be conceived of as a treatment effect on the outcome that is mediated by its effect on the mediator.

The parametric counterfactual approach implemented by Valeri and VanderWeele (2013)\(^{35}\) will be used to estimate the controlled direct effect (CDE), natural direct effect (NDE) and natural indirect effect (NIE). Let \( Y_\alpha \) and \( M_\alpha \) denote the values of the outcome and mediator that would have been observed had the exposure A been set to level \( \alpha \) and let \( Y_\alpha m \) denote the value of the outcome that would have been observed had the exposure A and mediator M been set to levels \( \alpha \) and \( m \) respectively. In the analysis of binary exposure, we will set \( \alpha = 1 \) for treated arm and \( \alpha = 0 \) for controlled arm. The average controlled direct effect (CDE) comparing treated (\( \alpha = 1 \)) to control (\( \alpha = 0 \)) given the mediator fixing to level \( m \) is defined by \( CDE(m) = E(Y_{1m} - Y_{0m}) \). The average natural direct effect (NDE) is defined by \( NDE = E(Y_{1M_0} - Y_{0M_0}) \). The average natural indirect effect is defined by \( NIE = E(Y_{1M_1} - Y_{1M_0}) \).

Covariates considered in this mediation analysis will include baseline fatigue score and demographics parameters and disease related parameters such as age, gender, BMI, PsA duration, physician Global Assessment (GDEV), patient global assessment (GDPT), HAQ-DI score, pain assessment (PAIN), Swollen Joints 66 (SJC66) and tender joints 68 (TJC68). We will also allow exposure-mediator interaction in this analysis.

Bootstrap will be used to obtain final effect estimates and their corresponding confidence intervals and P values. Model and variable selection may be conducted as sensitivity analysis. Alternative implementations of mediation analysis may also be explored as part of sensitivity analysis.
### APPENDIX 4: SUMMARY OF ANALYSES BASED ON MULTIPLE IMPUTATION

#### Table 12: Summary of Multiple Imputation Method

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>MI specification</th>
<th>Analysis method/Summary statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR20 Supplementary analysis 1</td>
<td>Multiple imputation with FCS regression of component scores</td>
<td>MIdataset1 (N=200, Seed(d)=4362478)</td>
</tr>
<tr>
<td>ACR20 Supplementary analysis 2</td>
<td>Multiple imputation with FCS regression of component scores</td>
<td>MIdataset2 (N=200, Seed(d)=4237590)</td>
</tr>
<tr>
<td>Change from baseline through Week 24 in:</td>
<td></td>
<td>Note: The MI is done only for the subset of subjects who have enthesitis at baseline and not all subjects in the study population.</td>
</tr>
<tr>
<td>- HAQ-DI Score</td>
<td>Multiple imputation with FCS regression of enthesitis scores</td>
<td>MIdataset3 (N=200, Seed(d)=6509723)</td>
</tr>
<tr>
<td>- DAS28(CRP) Score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline through Week 24 in: Dactylitis change from baseline through Week 24 among subjects with dactylitis</td>
<td>Multiple imputation with FCS regression of dactylitis scores</td>
<td>MIdataset4 (N=200, Seed(d)=1284097)</td>
</tr>
<tr>
<td>Change from baseline through Week 24 in:</td>
<td></td>
<td>Note: The MI is done only for the subset of subjects who have dactylitis at baseline and not all subjects in the study population.</td>
</tr>
<tr>
<td>- PCS score</td>
<td>Multiple imputation with FCS regression of PCS, MCS scores</td>
<td>MIdataset5 (N=200, Seed(d)=890473)</td>
</tr>
<tr>
<td>- MCS score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGA change from baseline through Week 24 among subjects with ≥3% BSA psoriatic involvement and an IGA score of ≥2 at baseline</td>
<td>Multiple imputation with FCS regression of IGA scores</td>
<td>MIdataset6 (N=200, Seed(d)=413249)</td>
</tr>
<tr>
<td>Change from baseline at Week 24 in vDHS score Main analysis</td>
<td>Multiple imputation with FCS regression of component scores</td>
<td>MIXdata1 (N=200, Seed(d)=4362478)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Note: The MI is done only for the subset of subjects who have hand erosion, foot erosion, hand JSN, and foot JSN at Week 24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: The MI is done only for the subset of subjects who have hand erosion, foot erosion, hand JSN, and foot JSN at Week 24.*
### Table 12: Summary of Multiple Imputation Method

<table>
<thead>
<tr>
<th>Change from baseline at Week 24 in vDHS score</th>
<th>2-step MI</th>
<th>1. MI through MLGC model (N=200, starting seed(^e) =46238)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main analysis</td>
<td>1. MI with Mixed effect linear growth model (MLGC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. MI with FCS regression on vDHS score</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. MI through MLGC model (N=200, starting seed(^e) =46238)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• All subjects with a postbaseline data will be included</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Imputed variables: vDHS score at Week 24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. MIXdata2 (N=1 by each of 200 imputations from step 1, Seed =94764732)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Imputation variables: vDHS score at Week 24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ancillary variables: vDHS score at baseline, treatment group, randomization stratification factors, and 7 ACR component overtime through Week 24</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) MIdataset2 is different from MIdataset1 as the joint scores used in DAS 28 (CRP) are different from those used in ACR.

\(^b\) An ancillary variable may be removed if its correlation with an indicator variable that determines missingsness of the variable to be imputed is low or, there are too many missing values for the ancillary variable within the subgroup of incomplete cases for the variable to be imputed. All the 7 ACR components (including all measurements from baseline through week 24) are in the list of the ancillary variables since they may be related to the mechanism leading to missing data.

\(^c\) Enthesitis-4 is the tender entheses count based on 4 sites (left and right achilles tendon insertion, and left and right humeral epicondyle lateral) instead of 6 sites. Only baseline, Week 2, Week 4 are included as ancillary variables.

\(^d\) The starting seed for FCS regression MI is used to generate a series of imputation seeds using the algorithm: INT((2\(^*\)31-2)*RANUNI(starting seed)), where each imputation seed will be used for a single imputation. To account for the possibility that some imputations may fail to complete due to out-of-range issues, 200+ initial imputation seeds will be prepared, and the first 200 successful imputations will be used for analysis.

\(^e\) The starting seed for the initial step of the 2-step MI is used to generate 200+ sets of random numbers from the normal distribution with mean 0 and standard deviation from the error of the predicted value at Week 24 taken from the MLGC model, which are then added to the predicted value get the imputed value.